METABOLISM, SEIZURES, AND BLOOD FLOW IN BRAIN FOLLOWING ORGANOPHOSPHATE EXPOSURE: MECHANISMS OF ACTION AND POSSIBLE THERAPEUTIC AGENTS

Final Summary Report

Lester R. Drewes, Ph. D.
Professor of Biochemistry

January 31, 1991

Supported by

U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
Fort Detrick, Frederick, Maryland 21702-5012

Contract No. DAMD17-86-C-6036

Department of Biochemistry and Molecular Biology
School of Medicine
University of Minnesota
Duluth, Minnesota 55812

Approved for public release; distribution unlimited.

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.
# Acute Neurotoxicity of the Organophosphorus (OP) Compounds Soman and Sarin: Mechanisms of Action and Possible Therapeutic Agents

Acute neurotoxicity of the organophosphorus (OP) compounds soman and sarin was investigated using the isolated, perfused canine brain preparation under constant perfusion pressure conditions. This model allows comprehensive study of metabolic (biochemical) and physiologic (vascular, electrical) responses to neurotoxicants. Intracarotid administration of soman (100 µg) or sarin (400 µg) produced cerebral vasodilation and synchronization of brain electrical activity prior to seizure genesis. OP-induced changes in cerebral blood flow and vasodilation were extensive. Increased neuronal discharge is associated with dramatic increases in cerebral oxygen and glucose metabolism. Regional autoradiography using D-[6-14C]glucose showed increased glucose metabolism in all brain regions. Metabolite transport systems of brain microvasculature were uninhibited by OP exposure. Studies using L-[1-14C]leucine and autoradiography showed protein synthesis that was greatest in cortical gray
matter, hippocampus, cerebellar gray matter, and some regions of brain stem was reduced by an average of ~60% after OP exposure. Based on results with cholinergic antagonists, the development of seizure activity and OP-induced vasodilation are separate, independent responses; simple involvement of cholinergic nicotinic, dopaminergic, or adrenergic mechanisms in OP-induced vasodilation is excluded. Nitric oxide, a recently identified endothelium-derived vasodilator, is a potent cerebrovasodilator, and OP compounds may cause vasodilation by mechanisms of its action on smooth muscle cells or stimulation of nitric oxide formation. Brain choline (Ch) levels rise following exposure to acetylcholinesterase inhibitors. Increased Ch levels during OP exposure, despite inhibition of acetylcholine (ACh) hydrolysis, suggest another means of Ch production. Blood-brain transport of lysophosphatidylcholine is not a significant source of Ch or phospholipid precursors. A phospholipase D capable of hydrolyzing phosphatidylcholine (PC) to free Ch was detected and characterized. It was discovered that a muscarinic ACh receptor is coupled to PC phospholipase D via a cholera toxin-sensitive G protein and this mechanism couples the neuronal muscarinic receptor to cellular responses.
METABOLISM, SEIZURES, AND BLOOD FLOW IN BRAIN FOLLOWING ORGANOPHOSPHATE EXPOSURE: MECHANISMS OF ACTION AND POSSIBLE THERAPEUTIC AGENTS

Final Summary Report

Lester R. Drewes, Ph. D.
Professor of Biochemistry

January 31, 1991

Supported by

U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
Fort Detrick, Frederick, Maryland 21702-5012

Contract No. DAMD17-86-C-6038

Department of Biochemistry and Molecular Biology
School of Medicine
University of Minnesota
Duluth, Minnesota 55812

Approved for public release; distribution unlimited.

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.
SUMMARY

The acute neurotoxicity of the organophosphorus (OP) compounds soman and sarin was investigated using the isolated, perfused canine brain preparation. This experiment model allows a comprehensive study of the metabolic (biochemical) and physiologic (vascular and electrical) responses to neurotoxicants because extracerebral tissues and influences are absent, biochemical and physiological parameters without significant alterations in baseline data may be determined for experimental periods (≤120 min), and blood and tissue samples may be readily collected for quantitative biochemical analyses.

Administration of soman (100 μg) or sarin (400 μg) produced cerebral vasodilation and synchronization of brain electrical activity (measured by electroencephalogram) for 4-6 min prior to seizure onset. OP-induced changes in cerebral blood flow and vasodilation were determined by regional distribution of the radiolabeled blood flow tracer iodoantipyrine. Increases were manifested extensively and, with the exception of the caudate nucleus, white matter, and pituitary, were approximately doubled. Variations observed may reflect either a region-specific dilation response or a variable, maximal blood flow capacity of contributing vessels. Increased brain electrical activity (seizure) is associated with rapid, large increases in cerebral metabolic rates for glucose, oxygen, lactate, and carbon dioxide. The regional autoradiographic method using D-[6-14C]glucose showed glucose metabolism to be increased in all brain regions. Infusion of L-[1-14C]leucine and subsequent autoradiography of brain sections clearly revealed brain regions with active protein synthesis, with the greatest rates occurring in cortical gray matter, hippocampus, cerebellar gray matter, and some regions of the brain stem. OP exposure reduced brain protein synthesis by 40-60% in all brain regions examined.

Previous experiments with cholinergic antagonists atropine and scopolamine and with cholinergic agonists oxotremorine and arecoline have established the involvement of a cholinergic muscarinic mechanism in OP-induced seizure, but not in OP-induced vasodilation. To evaluate the possible involvement of other transmitter mechanisms in these events, experiments were conducted with specific antagonists: scopolamine, mecamylamine, propranolol, pimozide, and cimetidine. It was concluded that the development of seizure activity and the vasodilation induced by OP agents are separate and independent responses. Consequently, independent mechanisms must exist for OP-induced cerebral vasodilation.

Blood-brain transport studies indicated that a small increase in metabolite (glucose, leucine, glycine, and choline [Ch]) influx occurred during the first 20 min of OP exposure. This may result from the increase in vasodilation (increased vascular surface area) or from direct activation of transporters by a regulatory mechanism. Blood-brain transport studies also indicated that influx of [3H]lysophosphatidylcholine (lysoPC) into all areas of the brain investigated was low when compared to blood-borne metabolic substrates, such as glucose and amino acids. It is concluded that blood-brain transport of lysoPC does not serve as a significant source of brain Ch or brain phospholipid precursors.

The permeability of the brain vasculature to palmitate and oleate was relatively low (2-43 ml/g sec·105; pituitary, 71 ml/g sec·105), but varied significantly among regions, with white matter being least permeable and cerebrum most permeable. Transport of oleic acid into brain was significantly greater (threefold) than palmitic acid transport. Following soman exposure, blood-brain transport of palmitate, but not oleate, increased two- to threefold. The metabolic fate of the free fatty acids after they entered the brain were determined by regional analysis of brain lipids. In control experiments, 40-60% of the radioactive palmitic acid was recovered in phosphatidyicholine (PC), with the remainder distributed in the free fatty acid fraction and in other phospholipid fractions. Following soman exposure, the pattern of [3H]palmitate labeling, but not [3H]oleate, was dramatically changed. The total radioactivity of the extracted lipid was significantly increased and resulted from a two- to eightfold increase in the radioactivity of the free fatty acid fraction. This increase was at the expense of incorporation into all the other lipids, which consistently had decreased amounts of labeled fatty acids. These results indicate that the metabolism, but not transport, of palmitate is drastically altered by soman exposure and during soman-induced seizure. The data further suggest that the rate of
phospholipid synthesis is decreased, or the rate of phospholipid degradation is increased, or both. The pathway and mechanism for breakdown of phospholipids and production of unesterified Ch during OP intoxication were investigated with brain enzyme preparations (microsomal and synaptosomal) and radioactive substrates. The hydrolytic activity of microsomal phospholipase D from canine cerebral cortex was measured by a radiochemical assay using 1,2-dipalmitoyl-sn-glycerol-3-phosphoryl[3H]choline and analysis of released [3H]Ch. Of several detergents tested, Triton X-100 was found to be the most effective in allowing expression of phospholipase D hydrolytic activity. The microsomal phospholipase D does not require any metal ion for its hydrolytic activity. Calcium and magnesium were slightly inhibitory, causing a loss of more than 90% activity at the 4 mM concentration. Nonhydrolyzable guanine nucleotide analogues, such as GTPγS and GMPPCP, but not GDPβS, at micromolar concentrations, were persistently able to stimulate phospholipase D hydrolytic activity. GDPβS was capable of partially blocking GTPγS stimulation of phospholipase D.

Aluminum fluoride was also able to cause a two- to threefold increase in hydrolytic activity of phospholipase D. Cholera toxin had a stimulatory effect on hydrolytic activity of phospholipase D, whereas islet-activating protein pertussis toxin had no effect. These studies with canine cerebral cortex synaptosomes demonstrate that the guanine-nucleotide-binding protein- (G protein) regulated phospholipase D is directly linked to a muscarinic acetylcholine (ACh) receptor and that this pathway may be responsible for the rapid accumulation of phosphatidic acid and Ch in the central nervous system during OP intoxication. Our evidence demonstrates that a muscarinic ACh receptor is coupled to PC phospholipase D via a cholera toxin-sensitive G protein and that this mechanism is a novel signal transduction process coupling the neuronal muscarinic receptor to cellular responses. Furthermore, it is suggested that this pathway plays an important role in brain Ch metabolism and that these enzymes and regulatory proteins may be important targets of OP agents. The significance of this regulated process for supplying free Ch in the brain is especially evident when hydrolysis of ACh to Ch is blocked by acetylcholinesterase inhibitors. Further investigations of this newly discovered phospholipase D pathway will be of great benefit to our understanding of mechanisms of signal transduction and regulation of Ch and phospholipid metabolism in the central nervous system and the roles that these pathways play during periods of OP intoxication and therapeutic recovery. It is also believed that activation of phospholipases may be responsible for membrane degradation and eventually cell death. Soman, physostigmine, and diisopropylfluorophosphate were used to examine the direct effects of inhibitors on the hydrolysis of exogenous [3H]PC by synaptosomes prepared from canine cerebral cortex. Soman and physostigmine had slight stimulatory effects on hydrolysis, but diisopropylfluorophosphate did not.

To evaluate the possible involvement of neurotransmitter systems other than the cholinergic muscarinic type in seizure genesis, experiments were conducted with specific receptor antagonists. None of the selected antagonists prevented the characteristic responses to soman exposure. Results indicate that simple involvement of cholinergic nicotinic, dopaminergic, adrenergic, or histaminergic mechanisms in OP-induced vasodilation and seizure may be excluded. In addition, pretreatment with the anticonvulsant valproic acid was ineffective in inhibiting soman-induced responses. Neither pyridostigmine nor HI-6 altered cerebral metabolism or, when administered prior to OP, prevented OP-induced convulsions, presumably because of their inability to cross the blood-brain barrier. Physostigmine, which is more lipid soluble, penetrated the blood-brain barrier, and its acute effects (vasodilation and seizure) were similar to the effects of soman. However, cholinergic antagonists blocked physostigmine responses; OP responses were not blocked. This is the clear distinction between the actions of OP compounds and carbamate anticholinesterases. However, when the brain was pretreated with scopolamine and physostigmine and then exposed to OP compounds, the vasodilation was blocked. This blocking of OP-induced vasodilation by the combination of physostigmine and scopolamine represents to our knowledge the first demonstration of the antagonism of this pathophysiological effect of OP agents. Neostigmine was able to prevent OP-induced vasodilation, but its presence precipitated seizure genesis. We tested the vasodilator activity of nitric oxide, proposed to be an endothelium-dependent relaxing factor in several tissues, on the cerebral vasculature and found it to be a potent dilator. Nitro blue tetrazolium, an inhibitor of nitric oxide, when present in the perfusate, blocked soman-induced vasorelaxation. This suggests that OP compounds may cause vasodilation by stimulating the formation of nitric oxide, and the pathway and mechanism may be targets for therapeutic intervention.
This report describes the progress and results during a five-year research project. Appropriate comments are made by the principal investigator on the significance of the results and on their relevance to the comprehensive study. These comments are provided in the context of the overall goal of suggesting methods for preventing organophosphorus effects on human health.

In conducting the research described in this report, the investigators adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee of the Institute of Laboratory Animal Resources on Care and Use of Laboratory Animals, National Research Council (DHEW Publication No. (NIH) 86-23, Revised 1985).

Citation of commercial organizations and trade names in this report does not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Summary</td>
</tr>
<tr>
<td>Foreword</td>
</tr>
<tr>
<td>List of Tables</td>
</tr>
<tr>
<td>List of Figures</td>
</tr>
<tr>
<td>Introduction</td>
</tr>
<tr>
<td>Background</td>
</tr>
<tr>
<td>Specific Aims</td>
</tr>
<tr>
<td>Methods</td>
</tr>
</tbody>
</table>

Experiments:

**Specific Aim 1.** Monitor changes in brain electrical activity, blood flow, and cerebral metabolism in isolated brain under constant pressure, control conditions and after organophosphate exposure ....................... 15

**Specific Aim 2.** Determine regional distribution of cerebral blood flow after organophosphate exposure ..... 18

**Specific Aim 3.** Determine regional utilization of glucose in control and in organophosphate-exposed brain ................................. 19

**Specific Aim 4.** Determine regional protein synthesis in control and in organophosphate-exposed brain ................................. 20

**Specific Aim 5.** Investigate the blood-brain transport of various metabolites in control and in organophosphate-exposed brain ................................. 22

**Specific Aim 6.** Examine the cerebral metabolism of acetylcholine, choline, and choline depots (choline-containing lipids) after organophosphate exposure .... 23

**Specific Aim 7.** Identify the source and mechanism of choline production in organophosphate-exposed brain and determine phospholipase activity, phospholipid content, and the identity of choline-labeled phospholipid products .... 27

**Specific Aim 8.** Determine the kinetics of labeling of choline in phospholipids of various cellular fractions. Determine the regional blood-brain transport of the fatty acid palmitate (C16) and determine the kinetics of fatty acid incorporation into choline-containing brain phospholipids .................................... 29

**Specific Aim 9.** Examine the effects of organophosphorus compounds on labeling of phosphatidylcholine and on receptor-mediated choline turnover .... 31

**Specific Aim 10.** Determine changes in catecholamines and other neurotransmitters in organophosphate-exposed brain .................................................................................................................. 33

**Specific Aim 11.** Examine the effects of α-methyl-p-tyrosine on cerebral blood flow, brain electrical activity, cerebral metabolism, and turnover of biogenic amines in control and in organophosphate-exposed brain .............................................. 35

**Specific Aim 12.** Examine the effects of receptor family antagonists on cerebral blood flow, brain electrical activity, and cerebral metabolism in control and in organophosphate-exposed brain .................................................................................................. 36

**Specific Aim 13.** Examine the effects of a nicotinic agonist on receptor-mediated release of choline from phospholipids. Test the hypothesis that the muscarinic receptor-regulated phosphatidylcholine phospholipase D and phosphatidic acid phosphatase pathway is important in signal transduction for generation of diacylglycerol from phosphatidylcholine in brain ... 38
Specific Aim 14. Examine the efficacy of scopolamine and valproate as protective agents against cerebral damage caused by organophosphate-induced seizure .......................................................... 40

Specific Aim 15. Examine the effects of HI-6 and pyridostigmine (and physostigmine and neostigmine), alone or in combination with other drugs, in control and in organophosphate-exposed brain ........................................... 42

Specific Aim 16. Determine the effects of nitric oxide and nitro blue tetrazolium on blood flow, cerebral metabolism, and brain electrical activity in control and in organophosphate-exposed brain ........................................... 44

Tables ..................................................................................................................... 45-67
Figures ................................................................................................................. 69-98
References ........................................................................................................... 99-109
List of Contract-supported Publications .............................................................. 111
List of Contract-supported Personnel ................................................................. 112
Distribution List ................................................................................................. 113
| Table 1: | Regional Cerebral Blood Flow in Perfused Canine Brain and the Effect of Soman Exposure | 45 |
| Table 2: | Effects of Soman on Regional Utilization of Glucose | 46 |
| Table 3: | L-[1-14C]Leucine Incorporation into Brain | 47 |
| Table 4: | Uptake of L-[1-14C]Leucine by Perfused Canine Brain Under Control Conditions | 48 |
| Table 5: | Uptake of L-[1-14C]Leucine by Perfused Canine Brain During Soman-Induced Seizure | 49 |
| Table 6: | Regional Protein Synthesis in Perfused Canine Brain After Soman Exposure | 50 |
| Table 7: | Unidirectional Influx of Glucose | 51 |
| Table 8: | Unidirectional Influx of Leucine | 52 |
| Table 9: | Unidirectional Influx of Glycine | 53 |
| Table 10: | Unidirectional Influx of Choline | 54 |
| Table 11: | Levels of Choline (Ch) and Acetylcholine (ACh) (nmol/g) in Tissue From Various Regions of Canine Brain | 55 |
| Table 12: | Cerebral Metabolism Rates for Choline (CMRCh) | 56 |
| Table 13: | Unidirectional Influx of Choline (Ch) | 56 |
| Table 14: | Effects of Soman and Sarin on Acetylcholine (ACh) Levels (nmol/g) in Various Regions of Isolated, Perfused Canine Brain | 57 |
| Table 15: | Effects of Soman and Sarin on Choline (Ch) Levels (nmol/g) in Various Regions of Isolated, Perfused Canine Brain | 57 |
| Table 16: | Phospholipase D Activity and the Effects of Diisopropylflurophosphate (DFP) on Hydrolysis of 1,2-Dipalmitoyl-sn-glycerol-3-phosphoryl[3H]choline by Phospholipase D Activity in the Subcellular Fractions from Canine Brain | 58 |
| Table 17: | Effects of Detergents on the Hydrolysis of 1,2-Dipalmitoyl-sn-glycerol-3-phosphoryl[3H]choline by Microsomal Phospholipase D | 59 |
| Table 18: | Effects of EDTA and Cations on the Hydrolysis of 1,2-Dipalmitoyl-sn-glycerol-3-phosphoryl[3H]choline by Microsomal Phospholipase D | 60 |
| Table 19: | Blood-brain Transport of [3H]Palmitic Acid | 61 |
| Table 20: | Blood-brain Transport of [3H]Oleic Acid | 62 |
| Table 21: | Free Fatty Acid Concentrations in Perfusate | 63 |
| Table 22: | [3H]Palmitate Incorporated into Lipids | 64 |
| Table 23: | Effects of Soman on [3H]Palmitate Incorporated into Lipids | 64 |
| Table 24: | [3H]Oleate Incorporated into Lipids | 65 |
| Table 25: | Effects of Soman on [3H]Oleate Incorporated into Lipids | 65 |
| Table 26: | Biogenic Amine Levels in Canine Brain | 66 |
| Table 27: | Biogenic Amine and Metabolite Levels in Canine Brain | 67 |
FIGURES

Figure 1: Diagram of Brain Perfusion System .......................................................... 69
Figure 2: Cerebral Vascular Resistance (CVR) and Cerebral Blood Flow (CBF) in Perfused Brain Under Constant Pressure Conditions After OP Treatment .......................................................... 70
Figure 3: Cerebral Glucose Metabolism (CMR-G) Under Constant Pressure Conditions After OP Treatment .......................................................... 71
Figure 4: Cerebral Oxygen Metabolism (CMR-O2) Under Constant Pressure Conditions After OP Treatment .......................................................... 72
Figure 5: Cerebral Carbon Dioxide Production (CMR-CO2) Under Constant Pressure Conditions After OP Exposure .......................................................... 73
Figure 6: Lactate Efflux from Brain Under Constant Pressure Conditions After OP Exposure .......................................................... 74
Figure 7: EEG and Soma Exposure During Constant Pressure Conditions .............. 75
Figure 8: EEG and Sarin Exposure During Constant Pressure Conditions .............. 76
Figure 9: Regional Cerebral Blood Flow in the Isolated Canine Brain as Determined by [14C]-iodoantipyrine Infusion and Autoradiography ...................... 77
Figure 10: Regional Glucose Metabolism in the Isolated Canine Brain .............. 78
Figure 11: Relative Protein Synthesis in Brain Regions ............................................ 79
Figure 12: Effects of Oligemia on Relative Protein Synthesis in Brain Regions .............. 79
Figure 13: Autoradiography of L-[1-14C]leucine Uptake and Protein Synthesis in Brain Under Control Perfusion Conditions ............................................. 80
Figure 14: Autoradiography of L-[1-14C]leucine Uptake and Protein Synthesis in Brain Following OP (100 mg) Exposure ............................................. 81
Figure 15: Choline (Ch) Efflux From A) Soma- and B) Sarin-treated, Perfused Canine Brain .......................................................... 82
Figure 16: Brain Choline (Ch) Metabolism .............................................................. 83
Figure 17: Possible Pathways and Enzymes Involved in Choline Production .............. 84
Figure 18: Effects of Triton X-100 on the Hydrolytic Activity of Dog Brain Microsomal Phospholipase D .......................................................... 85
Figure 19: Positional Distribution of Labeled Fatty Acids Incorporated into Phosphatidylcholine .......................................................... 86
Figure 20: Comparison of the Amounts of Choline (Ch) and Phosphocholine Released by Cerebral Cortex Synaptosomes Prepared from Control Dog Brains with the Amounts Released by Synaptosomes from Organophospho-treated Brains .......................................................... 87
Figure 21: Effects of In Vitro Addition of Soma on Choline (Ch) and Phosphocholine Release by Control Cerebral Cortex Synaptosomes .............. 88
Figure 22: Effects of Physostigmine on Choline (Ch) and Phosphocholine Release by Synaptosomes .......................................................... 89
Figure 23: Effects of a-Methyl-tyrosine on Cerebral Metabolism Rates (CMRs) .............. 90
Figure 24: Effects of Soma on Cerebrovascular Resistance (CVR) in Brains Pretreated with Specific Antagonists .......................................................... 91
Figure 25: Effects of Soma on Cerebral Metabolism Rates (CMRs) in Brains Pretreated with Specific Antagonists .......................................................... 92
Figure 26: Properties of Phosphatidyl Acid (PA) Phosphatase in Synaptic Membranes of Canine Cerebral Cortex .......................................................... 93
Figure 27: Cholinergic Stimulation of [3H]Phosphatidic Acid (PA) and [3H]Diacylglycerol (DAG) Generation in Synaptic Membranes of Canine Cerebral Cortex .......................................................... 94
FIGURES, continued

Figure 28: Effects of Various Compounds on Muscarinic Stimulation of 
[3H]Phosphatidic Acid (PA) and [3H]Diacylglycerol (DAG) Generation 
in Synaptic Membranes.................................................................95
Figure 29: Brain Vascular Response After Acetylcholinesterase Inhibition..........................96
Figure 30: Effects of Physostigmine on Cerebral Metabolism Rates (CMRs) 
in Brains Pretreated with Scopolamine...........................................97
Figure 31: Cerebrovascular Resistance (CVR) After Soman Treatment and 
After Soman Preceded by Nitro Blue Tetrazolium..............................98
INTRODUCTION

Organophosphate (OP) compounds comprise a major class of chemicals used as insecticides, primarily by agricultural workers and in chemical warfare. These compounds are highly toxic, and an accidental overdose can result in confusion, loss of reflexes, seizure, coma, and, ultimately, death (1). The development of effective prophylactic or therapeutic intervention methods requires the thorough understanding of the mechanism(s) of action and the sequential events leading to the pathophysiological state. Because OP compounds are potent inhibitors of acetylcholinesterase (AChE), most previous work has focused on their actions at the neuromuscular junctions. In recent years, evidence has been growing to suggest that OP toxicity is not exclusively the result of inhibition of AChE, but also of a number of pathophysiological alterations occurring in the central nervous system (CNS) (2). In this report, we present studies using the isolated canine brain perfused at constant pressure to allow cerebral blood flow to vary freely in response to changes in vascular resistance. These studies are the conclusion of a research project designed to examine the effects of OP exposure on brain metabolism and blood flow with the goals of understanding the underlying mechanisms of OP intoxication and suggesting means of therapeutic intervention.

BACKGROUND

The isolated, perfused canine brain is an important tool for studying cerebral metabolism and blood-brain transport, and several reasons exist for using it in toxicity studies. Traditionally, investigations of neurotoxicants have centered on either *in vitro* studies with simple systems or *in vivo* studies using whole animal systems. *In vitro* systems, many membrane barriers are demolished and enzymes are exposed to unfamiliar substrates and unusual concentrations of natural substrates. In addition, the methods of preparing brain slices, homogenates, or various cell organelles involve periods of anoxia or ischemia that may result in adverse and irreversible changes. After obtaining data from such systems and making appropriate corrections for artifacts resulting from preparation, one is confronted with the task of relating experimental results to the naturally occurring processes of the intact organ. *In vivo* preparations would simplify this task were it not for physiologic and metabolic interference from other tissues. A properly prepared isolated organ overcomes the stated disadvantages of both *in vitro* and *in vivo* systems. When care is taken to maintain the brain in a physiologic environment before and after isolation, it serves as an excellent tool for the comprehensive study of the metabolic and physiologic responses to neurotoxicants, such as the OPs. A closed, extracorporeal perfusion system permits the control of perfusate composition and flow rate, and constant arterial pressure can be sustained. Both arterial and venous blood samples may be obtained without contamination from other organs. Quantification of solute uptake is permitted because both flow rate and brain weight can be measured directly. Metabolic and physiologic studies can be readily related to *in vivo* processes because the brain is maintained in an active, functioning state, and the blood-brain barrier remains intact. At any time during an experiment, frozen tissue samples are easily obtained from the brain through a craniotomy. A final, but important, feature of the isolated canine brain is the economy that results from the ability to collect a large quantity of data and perform more than one experiment using a single preparation.

SPECIFIC AIMS

1. Monitor changes in brain electrical activity, blood flow, and cerebral metabolism in isolated brain under constant-pressure, control conditions and after organophosphate exposure.

2. Determine regional distribution of cerebral blood flow after organophosphate exposure.

3. Determine regional utilization of glucose in control and in organophosphate-exposed brain.
4. Determine regional protein synthesis in control and in organophosphate-exposed brain.

5. Investigate the blood-brain transport of various metabolites in control and in organophosphate-exposed brain.

6. Examine the cerebral metabolism of acetylcholine, choline, and choline deposits (choline-containing lipids) after organophosphate exposure.

7. Identify the source and mechanism of choline production in organophosphate-exposed brain and determine phospholipase activity, phospholipid content, and the identity of choline-labeled phospholipid products.

8. Determine the kinetics of labeling of choline in phospholipids of various cellular fractions. Determine the regional blood-brain transport of the fatty acid palmitate (C16) and determine the kinetics of fatty acid incorporation into choline-containing brain phospholipids.

9. Examine the effects of organophosphorus compounds on labeling of phosphatidylcholine and on receptor-mediated choline turnover.

10. Determine changes in catecholamines and other neurotransmitters in organophosphate-exposed brain.

11. Examine the effects of α-methyl-p-tyrosine on cerebral blood flow, brain electrical activity, cerebral metabolism, and turnover of biogenic amines in control and in organophosphate-exposed brain.

12. Examine the effects of receptor family antagonists on cerebral blood flow, brain electrical activity, and cerebral metabolism in control and in organophosphate-exposed brain.

13. Examine the effects of a nicotinic agonist on receptor-mediated release of choline from phospholipids. Test the hypothesis that the muscarinic receptor-regulated phosphatidylcholine phospholipase D and phosphatidic acid phosphatase pathway is important in signal transduction for generation of diacylglycerol from phosphatidylcholine in brain.

14. Examine the efficacy of scopolamine and valproate as protective agents against cerebral damage caused by organophosphate-induced seizure.

15. Examine the effects of HI-6 and pyridostigmine (and physostigmine and neostigmine), alone or in combination with other drugs, in control and in organophosphate-exposed brain.

16. Determine the effects of nitric oxide and nitro blue tetrazolium on blood flow, cerebral metabolism, and brain electrical activity in control and in organophosphate-exposed brain.

METHODS

Canine brain isolation and perfusion. The procedure for canine brain isolation (3) involves removal of the mandible, the snout, and all extracranial soft tissue, leaving only the brain case intact. A laminectomy at the level of the second cervical vertebra permits ligation and transection of the spinal cord, dura, and vertebral sinuses. Blood is supplied to the brain through the internal carotid arteries and the anastomotic branch of the internal maxillary segments of the external carotid arteries (4). A Luer connector, placed through the occipital bone into the confluence of sinuses, permits the return of venous blood to the oxygenator. All these procedures are conducted without interruption of blood or perfusate supply to the brain. Thus, at no time is the brain subject to anoxia or ischemia.
Arterial blood—hematocrit adjusted to 33% with high-molecular-weight dextran (Rheomacrodex, Pharmacia Laboratories, Piscataway, NJ)—is drawn from a reservoir (Fig. 1) by a variable speed roller pump and is propelled sequentially through a heat exchanger, bubble trap, and T-tubes placed into the common carotid arteries near the bifurcation of the internal and external carotid arteries. At the time of isolation, the pump is adjusted to deliver blood to the brain at a flow rate of approximately 65 ml/100 g/min. Perfusion pressure is held constant during experiments by adjusting the roller pump speed manually, maintaining the mean arterial pressure at 102 ± 20 mm Hg, and the average control cerebrovascular resistance (CVR) at 169 ± 7 torr-g-min/ml. CVR is determined by the equation: CVR = mm Hg-W/F, in which W is the brain weight (g), and F is the blood flow rate (ml/min). Under these conditions, the perfusion pressure provides adequate perfusion to the brain stem and to other posterior brain regions. Blood in the reservoir is continuously recirculated through a dacron wool filter (Abbott Laboratories, North Chicago, IL) and membrane oxygenator at a rate of 20 ml/min (Sci-Med Products, Minneapolis, MN) (4).

Arterial blood is frequently sampled, and the pH, pCO₂, and pO₂ are determined using a pH/blood gas analyzer (model 170, Corning Medical, Medfield, MA) and appropriately standardized electrodes. Blood in the reservoir is maintained at pH 7.40 and at a pCO₂ of 40 torr with sodium bicarbonate or by adjusting the oxygenator gas mixture (97% air and 3% CO₂). Blood glucose concentration is measured using a glucose analyzer (model 27, Yellow Springs Instruments, Inc., Yellow Springs, OH) and maintained at 5-6 mM (90-108 mg/dl) with addition of concentrated glucose solution. Blood temperature is maintained at 38°C. Total oxygen content is determined with a calibrated Lex-O₂-Con analyzer (Hospex Fiberoptics, Chestnut Hill, MA). Continuous monitoring of venous oxygen content is achieved by drawing a portion of the venous effluent from the confluence of sinuses through the flow cell of an oximeter (Waters Instruments, Rochester, MN). The oximeter, which measures O₂ saturation of hemoglobin, is calibrated with the Lex-O₂-Con analyzer. The cerebral metabolic rate (CMR) for oxygen consumption (CMR-O₂) is then calculated with the equation: \[ \text{CMR-O}_2 = (A-V) \times F/W, \] in which A-V is the arteriovenous difference (μmol/ml). When A, F, and W are constant, the venous oxygen content directly reflects oxygen consumption by the brain. The cerebral blood flow (CBF) rate is determined by measuring the volume of venous blood collected in a 1-min interval. Arterial perfusion pressure is measured by placing a cannula connected to a pressure transducer into the infraorbital branch of the carotid artery near the base of the Circle of Willis. Intracranial pressure is measured by insertion of a needle cannula into the cisterna magna. Silver electrodes are attached to the skull at temporal and occipital locations for monitoring electroencephalograph (EEG) activity. Heparinized blood is collected from an appropriate donor dog immediately prior to use in the brain perfusion experiments. Centrifugation of the blood from the donor and aspiration of the buffy coat (platelets, lymphocytes, and macrophages) have eliminated the frequent and variable rise in vascular resistance during perfusion periods of 0.5-5 hr. We suspect that vasoconstrictor substances are released by cells of this layer, and, therefore, removal of these cells is included in routine preparation of the perfusate.

Data analysis. Appropriate statistical tests were applied to determine the statistical significance of the results. Experimental results are reported as means ± S.D. or S.E.M. In most cases the results were evaluated by Student's unpaired, two-tailed t-test. A p value of <0.05 was usually required to establish statistical differences between means of two groups. When appropriate with additional groups of data, analysis of variance was applied.

Specific Aim 1. Monitor changes in brain electrical activity, blood flow, and cerebral metabolism in isolated brain under constant-pressure, control conditions and after organophosphate exposure.

Background. A major feature of OP toxicity is the immediate alteration in the EEG pattern (2, 5, 6). In acute high-dose exposures, the resulting EEG pattern is comparable to status epilepticus and is indicative of excessive neuronal activity. We have found in studies with the isolated perfused canine brain (7, 8) that a significant delay occurs between the time of OP exposure and the onset of brain seizure. This contrasts other seizure-inducing chemicals such as bicuculline, pentylenetetrazole (9, 10), and others that produce seizure simultaneously with their arrival at the brain. The delayed, predictable seizure onset (4 min for 100 μg of soman and 6 min for 400 μg of sarin under the...
conditions of our experiments) provides the opportunity to study biochemical changes present pre-
ictally, thus related to seizure genesis and cellular damage, and to differentiate them from those
resulting from prolonged convulsions and concomitant metabolic derangements. In this study, EEG
activity was monitored to provide the most sensitive indicator of altered neuronal activity or
physiologically related function.

Our earlier studies have shown that administration of OP compounds to the isolated, perfused
canine brain reduced the CVR, indicating vasodilation (11). Because of the potential significant
pathological consequence of CBF alterations during OP intoxications, total and regional CBF were
investigated in this study and reported in this aim and in Specific Aims 2, 11, 12, and 14-16. Other
researchers have reported that cholinesterase inhibition (by physostigmine) increases CBF and
causes vasodilation (12). The mechanism by which the anticholinesterase compounds altered CBF is
not known. Many authors have interpreted changes in CVR to be a direct consequence of the
increased CMR (13, 14). Howse et al. (15) proposed tissue pH as an important sampling factor with
regard to cerebral metabolism and blood flow. Metabolic control of CVR by means of the vasodilator
action of adenosine has been proposed by Rubio and Berne (16). Despite this evidence for the
metabolic regulation of decrease in CVR, several workers failed to find direct correlation between
CMR and CBF (17). In our studies, also, we did not find any relationship between OP-induced
change in CVR and OP-induced seizure or change in CMR. This issue is addressed further in
Specific Aims 2, 11, 12, and 14-16.

Cerebral oxygen and glucose consumption are reportedly elevated during epileptic-like seizure
induced with chemicals or electroshock (9, 10, 17-19). This also now appears to be the case with the
OP compounds soman and sarin (7, 8, 20-22). It has been suggested that brain lactate may play a
role in the development of OP-induced neuropathological changes. It is known that brain lactate
becomes elevated during seizure induced by OP or by other chemical convulsants. This is probably a
result of increased metabolic activity of the glycolytic pathway or an increase in the NADH/NAD+
ratio. Both of these effects will occur if the metabolic demands of the brain exceed the oxygen supply.
Lactate accumulation in brain may be enhanced by hyperglycemia because elevated blood glucose
provides additional substrate for brain glycolysis (23). The inability of the brain to remove lactate by
transport into the blood is also an important factor in elevation of brain lactate.

One response to acute OP intoxication in experimental animals is hyperglycemia (24, 25). Thus, if
respiratory distress is sufficient to produce hypoxia and if brain glucose supplies from hyperglycemia
are in excess, then brain lactic acidosis would be expected. If the brain acidosis reaches an excessive
level, then it would further be expected that the metabolic processes of the brain cells would be irreversibly damaged, and cell death would result. There is some evidence that this can occur under
some circumstances because normoglycemic or hypoglycemic animals recover from severe hypoxia,
but similarly treated animals made hyperglycemic do not (26). Brain lactate in the normoglycemic and
hyperglycemic animals reaches about 15 μmol/g and 35 μmol/g, respectively. However, the elevation
of brain lactate after OP intoxication has not been observed to reach these concentration levels. In
addition, when blood flow and oxygenation are not compromised, evidence indicates that during
seizure the supply of oxygen is not limiting for cerebral metabolism (27). The experiments included in
this specific aim were designed to characterize some of the basic metabolic processes that occur in
the CNS during acute OP exposure and to relate them to physiological functions such as EEG and
CBF in order to identify the key events leading to the neuropathological consequences of OP
exposure.

Method. Canine brains were isolated and perfused for 90 min as described in METHODS (Fig. 1).
EEG tracings monitored the brain electrical activity continuously, and pressure tracings indicated
variations in blood pressure. Arterial and venous samples (1 ml each) were taken at 10-min intervals or
more frequently when appropriate and analyzed to determine the CMRs for oxygen, glucose (CMR-
G), lactate (CMR-L), and carbon dioxide (CMR-CO2).

After a control perfusion period of 30-40 min to establish steady-state conditions and to obtain
baseline data, soman (100 μg) or sarin (400 μg) (28) was injected directly into an arterial cannula.
Arterial and venous samples were taken every minute up to 10 min, at 5-min intervals up to 30 min.
and then at 10-min intervals up to 60 min. CMRs were measured, and pressure and EEG tracings were observed throughout the perfusion period.

**Results.** The data on total brain blood flow (Fig. 2) and CMRs (Figs. 3-6) are expressed as percents of control, with the control value considered to be 100%. When soman was injected, CBF increased slowly in the first minute and then rapidly in the second minute (Fig. 2A). The CBF remained steadily high at about 150% up to 20 min and then slowly returned to near control values after 40 min. The CVR decreased to 60% of control values within 2 min, remained low up to 15 min, and then gradually increased to near control values after 40 min. The CBF increased rapidly to 150% within 1 min after sarin injection (Fig. 2B) and reached a maximum of 155% in 3 min. The rate remained high up to 15 min and then gradually returned to near control levels after 40 min. CVR, calculated as a ratio of pressure to flow, showed corresponding rapid decreases within 1 min after OP injection, indicating the vasodilatory action of OP.

Patterns of brain electrical activity (measured by EEG) after OP treatment under constant pressure conditions are similar to those observed under constant flow (8) (Figs. 7, 8). As the OP reached the cerebral vasculature, the EEG was rapidly altered. The maximum amplitude decreased by half to about 35 μV, and the frequency increased. These ictal periods occurred after about 4 min for soman and after 5.6 min for sarin. The ictal periods lasted 30-60 sec and were repeated several times before becoming continuous. By 60 min after OP, higher and lower frequency waves appeared in the pattern.

The altered blood flow and EEG are associated with increased substrate (glucose, O₂) utilization. Soman administration (Fig. 3A) caused an increase in glucose utilization with a maximal value of 165% of control after 6 min and remained steady up to 20 min. After sarin administration, the CMR-G increased rapidly and linearly for 3 min and plateaued at 160% of control by 10 min (Fig. 3B). The CMR-G was then steady up to 20 min before declining. Oxygen consumption increased rapidly after OP exposure. Administration of soman (Fig. 4A) caused a steady increase in O₂ consumption, reaching a maximal value of 150% of control in about 7 min and remaining at that value up to 15 min. The CMR-O₂ gradually decreased toward control levels by 50 min. The CMR-O₂ increased to 160% of control within 5 min after sarin administration (Fig. 4B). It remained high up to 30 min and then declined to near control values by 50 min. Soman administration (Fig. 5A) caused increases in CO₂ production to approximately 160% of control in about 3 min, and production remained at that level for 15 min and then declined to control values by 50 min. Administration of sarin (Fig. 5B) resulted in a similar metabolism pattern. Lactate efflux after OP exposure is shown in Fig. 6, and a net increase can be noted during the 10- to 15-min period after soman injection (Fig. 6A) and during the 3- to 7-min period after sarin injection (Fig. 6B).

**Comment.** The results of these experiments demonstrated that isolation and perfusion procedures for canine brain under constant pressure conditions were standardized (4) and that the perfusion system was validated for measurement of metabolic and physiologic parameters for prolonged periods (≤ 90 min), with no significant alterations or drift in baseline data.

Experiments under constant pressure conditions, when compared to experiments with constant flow, had longer periods of seizure activity with fewer silent periods. OP exposure caused significant cerebrovasodilation and an increase in CBF. Differences in the length of seizure activity and the frequency of silent periods were probably the results of variation of blood flow. Greater blood flow in experiments with constant pressure allowed a larger supply of substrates (oxygen and glucose) for brain metabolism, which led to longer periods of neuronal hyperactivity (seizure activity). EEG patterns in experiments with soman or sarin were qualitatively similar.

Development of seizure was coupled to a significant increase in metabolism. The CMR-O₂ was slightly increased during the first several minutes, but was rapidly elevated during a concomitant epileptic-like seizure, which initiated after 4-6 min. The higher CMR-G after OP (160% of control) compared to CMR-O₂ (150% of control) indicates that all the glucose utilized may not be oxidized completely to CO₂ and H₂O. It is interesting to note that at about 20-30 min after OP there was a noticeable drop in CMR-G and CMR-O₂, followed by a rise at 30 min. The cause for this alteration is unknown. After 30 min, the CMR-CO₂ consistently increased again to reach a peak at 35 min and
then decreased to control values at 50 min. The overall pattern of CO₂ production is similar to that of glucose utilization; however, the initial burst of CO₂ production after sarin exposure (210% of control) far exceeded O₂ consumption and glucose utilization, indicating that the brain may metabolize some substrate(s) other than glucose. Small quantities of glucose may be metabolized to lactate via anaerobic glycolysis after OP exposure. High variability in the values does not allow a conclusion to be made about the lactate metabolism.

In contrast to cerebral oxidative metabolism, CBF and the associated vascular resistance both respond immediately to OP and do not change appreciably during the seizure phase of the response. Maximal CBF is reached about 1-3 min after OP exposure, and acceleration of metabolic activities occurs subsequently. Thus, CBF and metabolism become uncoupled during OP exposure. The significance of this observation is that OP-induced cerebrovasodilation, which permits increased delivery of blood-borne OP agents to the brain, is, therefore, a prime target of therapeutic strategies for preventing OP-induced injury.

Specific Aim 2. Determine regional distribution of cerebral blood flow after organophosphate exposure.

Background. The influence of OP compounds on CBF is only now becoming appreciated. It is well known that CBF is tightly coupled to metabolism in the normal physiological state. Under many circumstances, an increase in nutrient demand is accompanied by an increase in delivery; thus, increased regional blood flow parallels increased metabolism. During status epilepticus, large increases in CBF and metabolism have been reported (10), but this is generally believed to be associated with the increased metabolic demand (10). In studies with the isolated canine brain perfused at constant flow, we found that marked vasodilation occurred within seconds of the administration of soman or sarin into the arterial perfusate (7, 8). This decrease in CVR was maximal during the pre-ictal period and increased during during the 60 min following the onset of seizure. In the studies of this project, perfusion was conducted at constant pressure. Thus, both total and regional CBF were allowed to increase in response to OP-induced vasodilation similarly to the in vivo condition in which systemic blood pressure remains constant or increases. Although an increase in total CBF was observed, no information on regional changes was previously available. Such changes could be important, particularly if some areas of the brain were favored to receive the bulk of the increased flow and other areas received no or even reduced and compromising flows. The purposes of these studies were first to apply the regional autoradiographic methods to the perfused preparation and second to determine the regional distribution of CBF during the maximal OP-induced vasodilation and then to compare these flows to the control situation.

Method. A series of perfusion experiments were conducted to determine regional CBF under control conditions and after OP-induced vasodilation. These experiments were conducted under constant perfusion pressure conditions that allow CBF to increase when vasodilation occurs.

The autoradiographic methods for determining regional blood flow were applied to the perfused brain model. These methods are based on the principle originally developed by Kety (29). Radioactive tracer compounds are infused into the arterial perfusate, and the distribution in brain is evaluated by autoradiography of frozen tissue sections. Rates of blood flow are then calculated using appropriate mathematical models of transport and blood-tissue exchange.

Arterial and venous blood was sampled for blood gas/pH analyses and glucose and lactate determinations during the 30-min control perfusion period. Experiments were conducted under control conditions and after OP, and, in the experiments using OP, soman (100 μg) was injected to induce seizure. Immediately after the onset of high frequency and amplitude in the EEG tracing, characteristic of seizure, the [14C]iodoantipyrine (IAP) tracer (25 μCi) in 250 μl of isotonic saline was infused over a 30-sec period, using a constant-rate infusion pump (Harvard Apparatus, South Natick, MA) at a constant rate without recirculation of the venous perfusate. Perfusion was stopped instantly; the brain was then removed, frozen (liquid nitrogen-cooled isopentane, -100°C to -150°C), and
prepared for autoradiography and tissue sampling. Samples of arterial perfusate and aliquots of the injectate were analyzed for levels of radioactivity. Regional CBF was calculated using the equation

$$\text{CBF} = \frac{\int C^* \, dt}{C^*}$$

in which $C^*$ is the amount of radioactivity in brain (dpm/g), and the denominator is the amount of radioactivity injected (dpm) divided by the blood flow rate (mI/min). The application of this tracer to regional CBF studies in perfused dog brain was demonstrated previously (30).

**Results.** Regional CBF in the isolated canine brain appears to be distributed among the various brain regions in a physiological pattern (Fig. 9). No significant differences were observed between the left and right hemispheres. Those structures normally receiving high flows, such as the cerebral and cerebellar cortex, or low flows, such as the white matter, exhibited high and low flows, respectively. In addition, within the level of autoradiographic resolution there were no detectable focal areas of ischemia, as might be expected if microemboli had occurred in the perfusate and disrupted flow patterns. It was concluded that the method was successfully adapted and that reliable, reproducible, and excellent quality regional flow data were determined.

CBF in perfused brain was regionally variable with rates from 0.17 ml/g/min in cortical white matter to 1.14 ml/g/min in gray matter of parietal cortex (Table 1). The total blood flow rate in these experiments averaged 0.66 ml/g/min. The flow rates for specific regions were consistent and reproducible, as indicated by standard errors of less than 8% for most structures. After maximal vasodilation was induced by soman exposure, CBF increased by approximately 54%. Although in cortical gray matter structures the increase was more than 110%, in caudate nucleus, white matter, and pituitary, no significant increases occurred (Table 1). The CBF in the hippocampus increased after soman exposure, but to a lesser extent than in cortical regions.

**Comment.** The mechanisms involved in OP-induced vasodilation are manifested extensively in the brain and, with the exception of caudate nucleus, white matter, and pituitary, are uniformly activated in response to soman. Some regional variation was observed, which may reflect either the regional dilation response or the blood flow capacity of the contributing vessels.

Specific Aim 3. Determine regional utilization of glucose in control and in organophosphate-exposed brain.

**Background.** The use of $^{14}$C-labeled D-glucose for regional glucose utilization studies has been proposed (31) and applied to experimental conditions in which the 2-deoxyglucose method is not applicable or is less reliable. There appears to be some question about the regional rates of glucose metabolism determined by the $^{14}$C2-deoxyglucose method of Sokoloff (32) because the plasma glucose concentration increases considerably and the tissue glucose concentration is not known during the 45-min experimental period (20-22). Both these factors influence the value of the "lumped constant" and should be considered carefully or reevaluated before interpreting the results of the Sokoloff method (33, 34). We have observed a small, significant increase in cerebral oxygen consumption of OP-exposed brain during the pre-ictal period (7, 8), but the consumption increases greatly during each seizure and decreases during each post-ictal silent period. In the studies of this project, regional glucose-use rates were determined with D-$^{14}$Cglucose and a method developed by the principal investigator (8). Of consideration during studies with D-$^{14}$Cglucose is the possible loss of radioactive label to the blood. D-$^{[6-14]}$Cglucose was used in the present experiments because, in the brain, carbon in the 6th position is believed to be more stable when compared with the other positions (31), and the amount of $^{14}$CO$_2$ lost to the blood is small.
Method. Experiments were performed to study regional CMR-G. In the control experiments, to keep the specific activity of the arterial glucose constant, D-[6-14C]glucose was infused intra-arterially at a constant rate for 10 min without recirculation of the venous perfusate. In the experiments using OP, soman (100 μg) was injected to induce seizure. Immediately after the onset of high frequency and amplitude in the EEG tracing, characteristic of seizure, D-[6-14C]glucose was infused, again at a constant rate, without recirculation of the venous perfusate. Arterial and venous blood was sampled for blood gas/pH analyses and glucose and lactate determinations. After 10 min of isotope infusion, brains were quickly frozen in liquid nitrogen-cooled isopentane and stored at -70°C for later analysis of tissue samples and for the preparation of sections for autoradiography. CMR-G was measured in seven brain regions. Amino acids and lactate in the venous blood were separated by high-pressure liquid chromatography with electrochemical detection (HPLC-EC) and analyzed for radioactivity levels and for their rates of synthesis from D-[6-14C]glucose.

Results. Regional cerebral glucose metabolism as visualized by autoradiography is shown in Fig. 10. The metabolic rates for glucose in the corpus callosum, the cerebellar cortex, and in five gray matter structures from control and OP-exposed brains are listed in Table 2. The CMR-G values dramatically increased during OP-induced seizure in all areas examined and were particularly significant in the gyrus cinguli and corpus callosum. During the infusion of D-[6-14C]glucose, 14CO2 released amounted to only 3% of the total activity taken up by the brain and was similar in control and OP-exposed tissues. [14C]Lactate was the major metabolic product detected in the venous perfusate, and it accounted for about 5% of the total activity taken up by the brain. No detectable radioactivity was lost in the form of amino acids.

Comment. These results suggest that OP compounds increase the CMR-G in all brain regions and that D-[6-14C]glucose appears to be a suitable tracer for regional CMR-G studies because the loss of radioactivity through other products was less than 10%. Because the accumulation of glucose metabolic products does not distinguish between lactate and Krebs cycle intermediates, the relative flux of glucose through anaerobic glycolysis and aerobic pathways cannot be determined.

Specific Aim 4. Determine regional protein synthesis in control and in organophosphate-exposed brain.

Background. Acute exposure to OP agents in mammals causes excessive neuronal discharges mimicking an epileptic seizure. Associated with these convulsions is increased cerebral energy metabolism, principally in the form of increased glucose and oxygen consumption (see Specific Aim 1). Although cerebral energy metabolism may return to control levels during periods following OP-induced seizure, sustained biochemical alterations also are believed to occur. This may include irreversible changes leading to cell death, especially in selected or regional cell populations. It remains unclear whether the pathophysiological results are related to all energy metabolism or are related to other complex cellular processes such as protein synthesis or phospholipid metabolism. In this series of experiments, regional protein synthesis was examined in the isolated canine brain during control and during OP exposure using L-[1-14C]leucine in the arterial perfusate followed by autoradiography of coronal tissue sections. It was observed that OP-induced seizure dramatically reduced brain protein synthesis in all brain regions examined.

The autoradiographic techniques for evaluating regional brain metabolism have been applied successfully to regional protein synthesis rates (35-37). These methods demonstrate high rates of amino acid incorporation into proteins of the hippocampus, dentate gyrus, piriform cortex, and some thalamic nuclei. Incorporation into proteins of the brain stem and cerebellum are low. The incorporation is sensitive to altered metabolic conditions such as hypoglycemia, especially in those regions vulnerable to pathological damage. The effect of OP compounds on protein synthesis in whole brain is not known; however, evidence indicates significant effects of OPs on neuronal RNA (38) and, therefore, possibly protein synthesis. It is also known that OP compounds inhibit serine esterases other than cholinesterases (39, 40). If proteases of the serine esterase type are involved in
neuronal protein turnover or in the degradation (inactivation) of neuropeptide transmitters, then OPs may significantly alter protein or neuropeptide metabolism.

Method. Protein synthesis in brain occurs by the standard biological polymerization process involving polyribosomal translation of messenger RNAs and incorporation of amino acids from activated aminoacyl-tRNAs. Measurement of the extent of protein synthesis in brain, as determined by the incorporation of plasma-derived amino acids, has been previously demonstrated (41, 42) in rat brain by application of the regional autoradiographic method. This method, which is analogous to the 2-deoxyglucose method (32) for regional glucose metabolism, involves intravenous administration of a radioactive amino acid, determination of the history of amino acid radioactivity in the plasma, rapid fixation by freezing the brain at the end of the experimental period, and quantitative autoradiography. The perfused brain is a particularly good model for this regional method because the amino acid content and specific radioactivity of the plasma amino acids are constant and easily determined, and the blood flow rate is controlled and maintained.

Brain leucine is the precursor of leucyl-tRNA, the amino acyl donor of ribosomal protein synthesis, and it is assumed that the specific activity of this protein precursor also quickly reaches equilibrium with the plasma leucine specific activity. Any catabolism of L-[1-14C]leucine is assumed to occur by transamination and subsequent decarboxylation of the α-keto acid, thus liberating 14CO2 and forming nonradioactive metabolites. Regional protein synthesis, as well as free leucine and leucyl-tRNA, can be determined by differential autoradiography.

In these experiments, L-[1-14C]leucine was infused at a constant rate into the arterial perfusate either during a 20-min control perfusion period or during a 20-min period immediately following exposure to OP (soman, 100 μg). The perfusate was not recirculated, and the specific activity of leucine was constant and was determined directly by amino acid analysis of arterial plasma samples.

After a brief control period (~30 min) to establish a steady state, 50-100 μCi of L-[1-14C]leucine was infused at a constant rate into the carotid cannulas over a period of 20 min. The venous perfusate was not recirculated, and, therefore, the arterial perfusate contained constant specific activity of L-[1-14C]leucine. At the end of the 20-min period, the brain was rapidly removed and frozen, and, on the following day, 20-μm thick coronal sections were prepared with a cryostat for autoradiography. After the first autoradiographic exposure, the tissue sections were wash-incubated in 10% trichloroacetic acid (TCA) to remove acid-soluble carbon-14 radioactivity and then exposed again to photographic films for a second autoradiography. The first autoradiograph represents total tissue radioactivity including free L-[1-14C]leucine, 14C-labeled metabolites, and 14C-labeled protein. The second autoradiograph represents only acid-insoluble 14C-labeled protein and, therefore, represents protein synthesis during the 20-min infusion period.

Results. In preliminary experiments performed during Year 2 of the research project, we studied protein synthesis under control conditions and during oligemia (low perfusate flow) in order to develop and validate the method. The experimental conditions for the two regional protein synthesis experiments were identical except that the perfusate flow rate was reduced to 45% (0.30 ml/g.min) during oligemia (Table 3). This flow rate was used because a significant alteration in EEG occurred within 30 sec of attaining it. The EEG activity pattern changed to low frequency with high amplitude. Such an alteration in EEG is presumed to represent an alteration in cerebral metabolism. After 30 min, total accumulation of plasma-derived L-[1-14C]leucine in brain was substantial, and the amount into acid-insoluble material was about 75% under control conditions (Table 3). However, under reduced flow conditions, the fraction of L-[1-14C]leucine that accumulated in acid-insoluble material was reduced to about 40%. Although equal amounts of L-[1-14C]leucine were infused during both control and oligemia experiments, the specific radioactivity of L-[14C]leucine during oligemia was greater because of the reduced perfusate flow rate. Therefore, the total accumulated 14C in brain during oligemia was greater than under control conditions (Table 3). Protein synthesis was significantly reduced in all brain regions during oligemia except in the hippocampus, which may have about the same relative incorporation into acid-insoluble material as controls (Figs. 11, 12).
In experiments recently completed, protein synthesis was studied after OP exposure. Radioactive leucine was transported into the brain through the vascular endothelium, and the specific activity of brain leucine rapidly approached the specific activity of plasma leucine. The examination of regional protein synthesis in control and OP-exposed brain involved perfusion with L-[1-14C]leucine and subsequent autoradiography of thin coronal sections of rapidly frozen brain. The regional incorporation of L-[1-14C]leucine is apparent from the autoradiographs (Figs. 13, 14). The autoradiographic technique clearly shows regions of high protein synthesis in the cortical gray matter, hippocampus (dentate gyrus and CA1-CA4), brain stem, and cerebellar gray matter (Figs. 13, 14).

Evaluation of the results indicate that substantial incorporation of leucine into brain protein of cerebral cortex occurred during the 20-min control experimental period (Table 4). Transport and incorporation were much greater in cortical gray matter than in white matter, and incorporation into different regions of gray matter also appeared to vary. Following OP (soman, 100 μg) exposure, protein synthesis was greatly reduced, and the amount of free L-[1-14C]leucine was slightly increased (Table 5). Quantitatively, leucine incorporation into protein accounts for between 65 and 97% of the total radioactivity in control brains, but only 23-46% of the total radioactivity in OP-exposed brain undergoing seizure (Table 6).

Comment. It is evident from these studies that regional protein synthesis can be investigated using the perfused brain preparation. The relative fraction of radioactivity incorporated into protein (TCA insoluble) material agrees closely with the results obtained for the rat brain in vivo (43). The clarity and definition visible in the autoradiographs permit quantitation and identification of specific regions of high or low protein synthesis.

Under conditions of OP-induced seizure, transport of L-leucine into the brain appears unaltered. However, incorporation of the amino acid into protein was severely impeded, especially in those structures and cell layers that normally conduct protein synthesis at the highest rates. The reason for reduced protein synthesis may be because of a direct OP effect on some component of the protein synthesis process. Alternatively, excessive neuronal discharge and associated energy depletion may result in dissociation of the polyribosomal complexes and diminution of protein synthesis events. This hypothesis is supported by the similar results observed in oligemia situations, during which energy is compromised and gradients are disrupted.

Specific Aim 5. Investigate the blood-brain transport of various metabolites in control and in organophosphate-exposed brain.

Background. The brain endothelial cell, which lines the walls of all cerebral blood vessels and which forms tight junctions to restrict passive diffusion of blood-borne substances, performs the important function of selectively transporting essential substrates and products in and out of the brain. Although OP compounds cause profound changes in cerebral metabolism, it is not known whether they affect the blood-brain transport of metabolites under constant perfusion pressure conditions. In preliminary experiments (8), the unidirectional transport of glucose (glc), choline (Ch), leucine (leu), and glycine (gly) from blood to brain was measured during control periods and after soman exposure. During the influx measurements under high perfusate flow associated with soman exposure, there was an apparent slightly higher transport rate, although the increase was not significant because of the few measurements obtained. Additional measurements were conducted following OP-induced perfusate flow increases. The experiments in this section were designed to determine blood-brain transport (influx velocity, \( v_{in} \)) of glc, Ch, gly, and leu. For more complete investigation of the possible influence of flow rate, cholinergic agonists, and other cholinergic agents on blood-brain transport of glc, Ch, leu, and gly, additional influx measurements were made following exposure to carbachol, arecoline, oxotremorine, and AF64a.

Method. \([3H]\text{glc}, [3H]\text{Ch}, [3H]\text{leu}, \) or \([3H]\text{gly}, \) along with an intravascular reference compound, \([22Na]^+\), which does not enter the brain significantly, was rapidly infused (1 sec) into the arterial blood stream (44). After injecting a labeled metabolite, venous blood samples were collected every second for 30 sec, by which time the radioactivity in the blood had reduced to nearly background levels. The
next compound was injected after 1 min, and venous blood samples were collected again for 30 sec. Radioactivity levels of the test compound and reference marker were measured in all the blood samples by liquid scintillation spectrometry. The maximum difference in radioactivity between the reference marker and test compound was a measure of the maximal influx of the metabolite (Emax). Emax for all the metabolites was determined in control and OP-exposed brains, and the V in values were calculated using the formula V in = - (F/W) ln(1 - Emax), in which E max = extraction maximum, A = arterial concentration (gic, 5 mmol/l; Ch, 5 μmol/l; gly, 0.17 mmol/l; and leu, 0.089 mmol/l), F = plasma flow rate (ml/min), and W is the brain weight (g).

Results. The control V in values during an experiment determined at 50, 60, and 80 min after brain isolation did not vary significantly (data not shown). In the OP-exposed brain, the V in values of metabolites were determined at 10 min and 50 min after injecting 100 μg of soman. The influx of gic, leu, and gly increased significantly during the elevated flow rate period following OP exposure (Tables 7-10), but Ch influx remained constant (Table 10). The increased gic transport also was generally elevated under conditions of high perfusate flow induced by other agents, including carbachol, arecoline, and a combination of carbachol and soman (Table 7). AF64a, an irreversible inhibitor of high-affinity, sodium-dependent Ch transporter of synaptosomes, did not alter the blood-brain transport of any of the 3H-labeled substrates. High perfusate flow did not appear to alter blood-brain transport of leu, gly, or Ch (Tables 8-10).

Comment. Previously, we did not observe any change in the blood-brain transport of metabolites after OP exposure under constant flow conditions (8). In the present studies, under conditions of constant perfusion pressure, cerebral perfusion flow rate increased about 50% during the first 20 min after OP exposure (see Fig. 2). The calculated increase in metabolite influx during this period may be significant. Our results indicate that OP agents do not inhibit or impair the transporter for gic, amino acids, or Ch. In fact, the evidence suggests that the transport capacity for gic and amino acids may be increased. One explanation is that extensive vasodilation may increase or maximize the number of vessels that have blood (and substrates) flowing through them, and, therefore, the surface area or number of transport sites is increased. An alternative explanation is that there is an enhanced activity of the transport system resulting from increased metabolic demands and activity. In either case, any effect of OP is a secondary response, and the cholinesterase inhibitors are not acting directly on the transporter system. It should be emphasized that the transport processes reported here are carrier-mediated systems specific for their specific substrates. Blood-brain barrier breakdown or opening of the blood-brain barrier is a separate phenomenon. Blood-brain barrier breakdown refers to the hypothesized physical opening of gaps or channels between or within the vascular endothelial cells. This event will allow nonspecific extravasation of blood-borne substituents (including high-molecular-weight proteins). It has been hypothesized that the blood-brain barrier opening in vivo may result from a combination of extensive cerebral vasodilation and concomitant hypertension in the first moments of OP intoxication. Transmission of elevated blood pressure (hydrostatic) to the small arterials and capillaries may result in physical rupture of vessel walls and production of focal extravasation.

Specific Aim 6. Examine the cerebral metabolism of acetylcholine, choline, and choline depots (choline-containing lipids) after organophosphate exposure.

Background. Brain Ch plays a central role in the metabolism of at least two classes of brain constituents — as a precursor and degradation product of the neurotransmitter acetylcholine (ACh) and as a component of the membrane lipids phosphatidylcholine (PC) and sphingomyelin (45, 46). Although brain is capable of de novo Ch synthesis (47), this pathway appears minor, and most brain Ch is of hepatic or dietary origin, reaching the brain via the circulation in either free or possibly conjugated form (48, 49). A low-affinity Ch carrier has been described for the blood-brain transport of Ch (50). In brain, Ch is known to be produced from the inactivation and hydrolysis of ACh by AChE, an enzyme sensitive to inhibition by OP compounds. The toxicity of these agents is usually attributed to the accumulation of ACh in the brain and other tissues, which causes overstimulation of cholinergic neurons (2). However, other toxic influences have been reported (2). For example,
Ch levels are greatly elevated by some, but not all OP inhibitors of AChE (51, 52). Similar elevations of Ch are reportedly produced by direct cholinergic agonists such as oxotremorine (53, 54). Although the primary effect of OPs on brain ACh levels is well established, their additional primary and secondary effects on blood-brain transport and cerebral metabolism have not been elucidated. This series of experiments was focused on the effects of soman and sarin on 1) brain ACh and Ch levels, 2) unidirectional influx of blood Ch into the brain, and 3) the cerebral metabolic rate for free Ch (CMRCh) in isolated, perfused canine brain.

Method. The dog brain was isolated as described in METHODS and perfused for a control period (30 to 45 min) to establish a steady state and to obtain baseline data. Administration of either 100 μg of soman or 400 μg of sarin to the perfusate was accomplished by injection directly into an arterial cannula; thus, each brain served as its own control for physiologic and metabolic measurements.

Nonperfused controls. Adult mongrel dogs (10-25 kg) were anesthetized with 3% halothane and 70% N₂ and were maintained under anesthesia with 2% halothane. After the dog was anticoagulated with heparin and euthanized, the brain was removed from the skull and was dissected immediately. Cerebellum, brain stem, hippocampus, and cerebral cortex samples were frozen immediately after collection and stored at -60°C for later analysis. The time required for sample collection before freezing was 2-3 min.

Perfused controls, recirculation. Dog brains were isolated and perfused, as described above. Venous perfusate was reoxygenated, returned to the reservoir, and allowed to recirculate through the pump/oxygenator system. Perfusion was stopped after either 5 or 90 min, the brain was rapidly removed, and samples were collected and stored as described above. Also during the 90-min perfusion experiments, arterial and venous blood samples were collected every 10 min for Ch analysis.

Perfused controls, nonrecirculation. The dog brains were isolated and perfused as described above, except the venous effluent from the brain was not returned to the pump-oxygenator system for recirculation. Perfusion was continued for 40 min, and brain samples were then rapidly collected, as described above, for later analysis.

Soman or sarin exposure, 5 min. The isolated brain was perfused for 30 min under recirculation conditions to establish a steady state, and then a bolus of 100 μg of soman or 400 μg of sarin was injected into the common carotid cannula. Perfusion of the brain was discontinued 5 min after the agent injection, and brain regions were dissected and stored, as described above.

Soman or sarin exposure, 60 min. The isolated brain was perfused for 30 min under recirculation conditions to establish a steady state, and then a bolus of 100 μg of soman or 400 μg of sarin was injected into the common carotid cannula. During the next 60 min, arterial and venous blood samples were collected at 10-min intervals for Ch analysis. At 60 min after OP administration, brain samples were collected, as described above, for later analysis.

Analysis of ACh and Ch. At the time of analysis, frozen brain samples were homogenized with formic acid/acetone (3:17), and blood samples were deproteinized with 0.3 mol/L perchloric acid. Each sample was centrifuged, and the clear supernatant was extracted and analyzed for ACh and Ch as described earlier (55). The CMRCh (nmol/g/min) was calculated by the equation Efflux = (A - V)/F/W, in which A and V are the respective concentrations of Ch in the arterial and venous samples (nmol/ml), F is the blood flow rate (ml/min), and W is the brain weight (g).

Unidirectional Ch influx. The velocity of Ch influx was determined using the indicator dilution method for the perfused dog brain as described previously (44). A 50-μl solution containing 2 μCi of 22Na, the intravascular marker, and 10 μCi of [methyl-3H]choline, the test molecule, was injected into the arterial bloodstream of the common carotid artery. Immediately after the injection, 30 consecutive venous blood samples were collected at 1-sec intervals. Then, a 50-μl aliquot of each sample was decolorized with H₂O₂ and processed for dual-isotope liquid scintillation spectrometry. Data calculation and analysis (44) allowed the determination of the maximal fractional extraction, E, for Ch.
The rate of unidirectional Ch transport into the brain, \( q_n \), was then calculated using the formula \( q_n = EA/F/W \), in which \( A \) is the plasma Ch concentration, \( F \) is the plasma flow rate, and \( W \) is the brain weight.

**Statistics.** The significant differences between controls and multiple comparisons were determined using Dunnett's procedure against two-sided alternatives (56), except in Table 11, for which Student's unpaired, two-tailed t-test was used.

**Results.** In this study, ACh levels in anesthetized dog brain were found to differ among brain regions. The concentrations were from 0.6 to 4.3 nmol/g tissue, with the lowest concentration in the cerebellum and the highest in the cerebral cortex (Table 11). No significant changes were detected in regional ACh concentrations during perfusion up to 90 min. ACh levels were not influenced by either recirculation or nonrecirculation of the perfusate (Table 11).

Ch levels in anesthetized dog brain ranged between 41 and 79 nmol/g tissue, with the lowest in the cerebral cortex. Isolation of the brain caused about a twofold increase in the brain concentration of Ch (Table 11). When the perfusate was recirculated, Ch continued to increase during the perfusion period, and it reached levels between 239 and 295 nmol/g tissue after 90 min (Table 11). When the perfusate was not recirculated, brain Ch remained at the same levels as at the beginning of perfusion in all areas of the brain except cortex, in which a small increase of 9% was detected (Table 11).

The CMRCh (Ch efflux) during a series of nonrecirculation and recirculation experiments was \(-1.1 \pm 0.1 \text{ and } -1.6 \pm 0.4 \text{ nmol/g min, respectively (Table 12). Although the level of perfusate Ch increased severalfold during recirculation experiments, the efflux of brain Ch was constant during the entire perfusion period (data not shown).}

Blood-brain transport of plasma Ch was determined by measuring unidirectional influx of \([3H]4choline. Before OP exposure, transport velocity was \(0.49 \pm 0.07 \text{ nmol/g min, and this value did not change significantly for up to 40 min after either soman or sarin treatment (Table 13). Unidirectional transport of glc, ieu, and gly were also similarly determined and found unaltered by OP exposure (data not shown).}

Inhibition of AChE by administration of soman caused a large increase in ACh levels of between 10- and 50-fold within 5 min in all brain regions sampled except in the cerebellum, where the increase was small (Table 14). After 60 min of soman exposure, the levels of ACh in hippocampus and cerebellum were greater than after 5 min. Acute exposure to sarin (400 \(\mu\)g) also produced a substantial ACh increase in all brain regions (Table 14), although the rise was not as great after 5 min when compared to the concentrations after soman exposure. The ACh levels in cortex and hippocampus remained constant, but brain stem and cerebellum ACh continued to increase, reaching levels comparable to soman-exposed brain after 60 min.

Brain levels of Ch were also affected by OPs. Within 5 min after administration of soman, increases of 120-250% were observed in all brain regions except cerebral cortex, where the increase was \(-70\% (Table 15). Sixty minutes after acute soman exposure, the concentration of Ch decreased in all brain regions (Table 15). Acute exposure to sarin increased brain Ch concentrations after 5 min to levels similar to those for soman-exposed brain (Table 15). Sixty minutes after acute sarin exposure, the concentration of Ch decreased significantly in all brain regions (Table 15).

To assess the effect of OP compounds on Ch efflux from brain during soman or sarin exposure, the CMRCh was determined during a control period before and for 50 min after each treatment. In this group of experiments, the CMRCh was \(-1.58 \pm 0.09 \text{ nmol/g min during control perfusion periods, indicating net efflux of Ch. The efflux rate decreased toward zero (0.32 \pm 0.07 \text{ nmol/g min) after 30 min and returned to 60-70\% of control rates by 60 min after exposure to either soman or sarin (Fig. 15).}

25
Comment. In this study, when dog brain regions were compared, the concentrations of ACh and Ch were observed to differ substantially. Higher concentrations of ACh were observed in the cortex and in the brain stem than were observed in the hippocampus, and the least was detected in the cerebellum. Similar relative variations have been reported for other species (57), although dog brain ACh concentrations appear lower than those in most smaller species (58-62). The consistent levels of ACh in nonperfused and perfused brain of either short (5 min) or long (90 min) duration indicate that ACh metabolism remains in a steady state and is undisturbed by the isolation and perfusion procedure. This is consistent with numerous other observations of metabolism in the perfused brain preparation (63).

The higher Ch concentrations in brain regions of dog compared to rodents may reflect higher steady-state levels in dog, which may be an effect of anesthesia/surgery or may result from Ch formation during the brief (2-3 min) delay in collection and freezing of tissue samples. There is evidence that Ch increases substantially in ischemic or postmortem brain (64, 65). Because of the size of the dog brain, inactivation with microwave irradiation was impractical; however, introduction of an unnecessary variable was avoided by maintaining a consistent sampling protocol.

The CMRCh indicated that Ch production by the perfused brain was about 1.6 nmol/g.min. This net synthesis of unesterified Ch was constant during the perfusion period even when the blood Ch increased about 10-fold during recirculation of perfusate. Arteriojugular differences in Ch were reported previously (64, 66-68); however, because the cerebral blood flow rate was not determined, the CMRCh was not calculated accurately. The biochemical source of this Ch and the regulation of its synthesis are unknown, although it has been suggested that lipid-bound Ch (48), possibly phosphatidylycholine (lysoPC) (49), is the source.

The concentration of brain Ch appears to vary rapidly in accordance with the blood Ch concentration. This equilibration between the brain Ch pool and the blood Ch pool occurs via the Ch carrier of the brain capillary endothelial cell (Fig. 16). Blood-brain transport of Ch by a saturable, specific, and carrier-mediated mechanism has previously been demonstrated in rat (50, 69). A functional Ch influx of 0.49 ± 0.09 nmol/g.min was determined using [3H]Ch under control conditions for the perfused brain. This value is similar to the calculated rate of Ch transport (0.18-0.34 pmol/g.min) into rat forebrain at physiological concentrations of plasma Ch (50). The Ch transporter is inhibited by either of the OP compounds. Thus, it is unlikely that transport involves an essential site at the active binding site, as do the serine esterases that can be inhibited by OPs. 

Aman (70), Cohen and Wurtman (71), and Haubrich et al. (72) proposed that increasing the concentration of Ch will enhance the synthesis and concentration of ACh in brain. In the present study no changes in brain ACh were observed over a wide range of blood and brain levels of Ch. These results support the suggestions of Jope (73) that regulatory mechanisms maintain a constant level of ACh even under increased availability of Ch to the brain. The effects of chronically elevated Ch are not investigated here.

An exposure to soman and sarin rapidly produced increases in both ACh and Ch. The rise in ACh result of the inhibition of AChE by OP compounds and synthesis by Ch acetyltransferase (74). The increase in Ch on a molar basis is considerably greater than the increase in ACh. Because AChE is not inhibited by OP under these experimental conditions (75), the rise in Ch during the first 5 min of soman exposure is calculated to be 12 nmol/g.min and represents the Ch capacity. A similar estimation of the rate of Ch production during the first 5 min of soman exposure yields a minimum rate of 25 nmol/g.min. Total net production of Ch, therefore, is 37.5 calculated by combining the increase in tissue Ch, plus the Ch used to form ACh, plus the Ch produced as a result of Ch-containing brain lipids, or 4) a combination of these.

26
Ch-containing lipids are a probable source of the elevated levels of brain Ch. Studies of brain free fatty acids (FFAs) suggest that brain lipids are rapidly hydrolyzed following acute alterations in cerebral metabolism. Brain FFAs are known to increase severalfold during the first few minutes of ischemia (77). Although this increase in FFA is partly attributed to hydrolysis of the phosphoinositides (78, 79), PC is also a readily available and abundant substrate for lipase activity. The product of PC hydrolysis, lysoPC, would, therefore, be a source of both free Ch and additional FFA by the action of a phosphatase or lysophospholipase. In support of this hypothesis, lysoPC reportedly increases rapidly and undergoes active turnover at the onset of ischemia (80).

The efflux of Ch from brain after OP exposure declines despite the high levels of brain Ch, thus indicating that the tissue Ch pool in equilibration with blood Ch falls and approaches the blood concentration. It further suggests that brain Ch is sequestered in a pool unavailable for transport to blood and is probably intracellular (Fig. 16).

It is proposed that Ch in brain exists in two compartments, the intracellular, \( \text{Ch}_e \), and the extracellular, \( \text{Ch}_o \) (Fig. 16). \( \text{Ch}_e \) is formed by the action of AChE (reaction 5) on Ch released from neurons. \( \text{Ch}_o \) is in steady-state equilibrium with plasma Ch, \( \text{Ch}_p \), via the Ch transporter of the endothelial cell (reaction 1). Net efflux occurs when \( \text{Ch}_e \) is greater than \( \text{Ch}_p \). Ch is the precursor of synapticosomal ACh and is derived from Ch transport (reaction 2) and synthesis from unidentified endogenous sources (reaction 6). When AChE is inhibited (reaction 5), \( \text{Ch}_e \) decreases, net efflux slows, and synthesis of \( \text{Ch}_o \) by reaction 6, is stimulated by regulatory or receptor-mediated processes.

The metabolism of Ch in brain is complex because of Ch involvement in both ACh synthesis and phospholipid metabolism. However, it is evident that the implications of the effects of cholinesterase inhibitors on cholinergic neurotransmissions, on cholinergic mechanisms of cerebral blood flow regulation (81, 82), and on cerebral membrane lipid metabolism are significant.

### Specific Aim 7

Identify the source and mechanism of choline production in organophosphate-exposed brain and determine phospholipase activity, phospholipid content, and the identity of choline-labeled phospholipid products.

**Background.** Ch serves as a direct precursor for ACh, PC, and sphingomyelin in brain. Although brain has been shown to synthesize Ch via a de novo pathway (46), the synthesized Ch accounts for less than 10% of the brain's requirement, with the rest originating from an unknown metabolic source or extracted from blood in a form other than free Ch. However, at any given time, the concentration of Ch in brain is higher than in blood, resulting in a net efflux of Ch from brain to blood (83, 84). Enhanced levels of Ch were observed in ischemic rat brain (65) as well as in the brains of rats treated with OP (52). Our results with isolated canine brain showed that administration of OP (100 \( \mu \)g of soman or 400 \( \mu \)g of sarin) resulted in a two- to fourfold increase in Ch and about a 10-fold increase in Ch levels in all brain regions studied (83). The mechanism for Ch production is not known. Since PC is a major Ch-containing phospholipid in brain, it is reasonable to assume that substantial amounts of Ch can be derived from PC hydrolysis. The OP-induced increase in Ch concentration can occur from the activation of catabolic enzymes on PC (or sphingomyelin) by OP directly or by increased ACh (resulting from AChE inhibition) acting through some regulatory mechanism.

### Possible pathways and enzymes involved in Ch production are illustrated in Fig. 17.

**Phospholipase D** [1] (bracketed numbers refer to the numbers shown in the figure) hydrolyzes PC to phosphatidic acid (PA) and free Ch. Phospholipase A2 or A1 [2] hydrolyzes fatty acid from the sn-2 or sn-1 position, respectively, of PC to form lysoPC. Lyso-phospholipase D [3] may hydrolyze lysoPC to lysoPA and free Ch. Rat brain was shown to contain lyso-phospholipase D which acts on lysopla.omgolagons to produce lysoPA and free base (85, 86). LysoPC can be decarboxylated to glycerophosphocholine (GPC) by lyso-phospholipase [4]. GPC-phosphodiesterase [5] hydrolyzes GPC to glycerophosphate and free Ch. GPC can also be hydrolyzed by GPC-cholinophosphodiesterase [6] to yield phosphocholine. Phospholipase C [7] hydrolyzes PC to produce diacylglyceride and phosphocholine. Alkaline phosphatase [8] hydrolyzes phosphocholine to phosphate and free Ch. Sphingomyelin is another Ch-containing lipid which may also contribute to
Ch production. Sphingomyelinase [9] hydrolyzes sphingomyelin to ceramide and phosphocholine, which, in turn, can be hydrolyzed by alkaline phosphatase [8] to form Ch. Phospholipase D-type action on sphingomyelin is known to produce free Ch in Corynebacterium ovis (87), but it is not known whether an enzyme of this activity and specificity is present in canine brain or mammalian tissues. We have done a partial characterization of phospholipase D in the subcellular preparation of dog brain using [3H]Ch-labeled PC as the substrate, and our procedure and results are presented below.

**Method.** Subcellular fractions from dog brain tissue were prepared essentially according to Whittaker and Barker (88) and modified as described (89). Briefly, the tissue was homogenized in 0.32 M sucrose (10% w/v) with a Potter-Elvehjem homogenizer. The homogenate was centrifuged initially at 1000 x g for 10 min, and the postnuclear supernatant was centrifuged at 22,000 x g for 30 min to obtain a crude membrane pellet which contained myelin, synaptosomes, and mitochondria. The supernatant, containing microsomes, was centrifuged at 100,000 x g for 1 hr to sediment the microsomes. The crude membrane pellet and the microsomes were washed once, and each preparation was resuspended in 0.32 M sucrose and stored at -20°C until use. The protein content was determined according to Lowry et al. (90).

**Phospholipase D assay.** The substrate 1,2-dipalmitoyl-sn-glycero-3-phosphoryl[3H]choline (the specific activity of [3H]PC adjusted to 1 x 10^4 dpm/nmol) in toluene/ethanol (1:1) was aliquoted into incubation tubes. The solvent was evaporated under a nitrogen stream, 5 μl of ethanol followed by buffer was added, and the tubes were vortexed to disperse the substrate. The incubation medium in 0.25 ml contained 132 μM [3H]PC (3.3 x 10^5 dpm), 40 mM HEPES buffer at pH 7.4, 0.1% Triton X-100, and the crude brain membrane preparation (200-500 μg of protein). Incubations were carried out at 37°C for 30 min, with shaking. Reactions were stopped by adding methanol, and lipids were extracted as described by Sligh and Dyer (91). Control values were obtained by stopping the reaction immediately after adding the enzyme or by using boiled enzyme in the reaction mixture. The radioactivity levels in the water-soluble 3H-labeled products (Ch, phosphocholine, and GPC) were measured in the upper phase after separation by thin-layer chromatography (TLC) (silica gel-H) (92) using methanol/0.6% NaCl/conc. ammonia (50:50:5). More than 90% of the radioactivity was recovered in the Ch fraction, and radioactivity released into this upper phase indicated phospholipase D activity.

In other experiments, the brain microsomal preparation was used as the enzyme source. Dibutylphthalate (DPP), an OP similar to sarin, was used to examine the effect of DPP on phospholipase D in these dog brain preparations. Experimental details are given in Table 16.

To examine the effects of detergents on phospholipase D, different concentrations of sodium deoxycholate, sodium oleate, sodium linoleate, 3[(3-cholamidopropyl)dimethylammonio]-propane sulfonate (CHAPS), octylglucopyranoside, and Triton X-100 were added to the incubations. Experimental details are given in Table 17.

**Results.** Levels of phospholipase D activity in the subcellular fractions of control dog brain cortex are listed in Table 18. The activity was higher in the microsomal fraction when compared with the homogenate or the crude membrane fraction. Surprisingly, DPP did not affect phospholipase D activity (Table 10). This observation, however, is consistent with a recent report that DPP administration to rats did not increase brain Ch levels (52). The effects of detergents on phospholipase D are shown in Table 17. The data are expressed as percentages of control with the control activity (in the absence of detergents) considered to be 100%. Sodium deoxycholate, sodium oleate, and sodium linoleate were inhibitory at all concentrations studied (0.2 mg/ml to 2.0 mg/ml). CHAPS had marginal effects. Octylglucopyranoside was slightly stimulatory up to a concentration of 0.4 mg/ml, and higher concentrations were inhibitory. Triton X-100 showed concentration-dependent stimulation up to 2 mg/ml. Since Triton X-100 was most effective among the detergents tested, several different concentrations were used to determine an optimal concentration, and the results are shown in Fig. 18. The activity increased with increasing concentration, reaching a maximal stimulation of about 400% of control at 2 mg/ml before decreasing. Since many hydrolytic enzymes exhibit metal-ion dependency, it was of interest to examine the effects of metal ions on phospholipase D activity. For this purpose, the effects of CaCl2, MgCl2,
ZnCl₂, and the metal chelator EDTA were examined (Table 18). It appeared that the enzyme did not require any metal ion for its action. Even the addition of EDTA at a concentration of 4 mM had no effect. In fact, Ca²⁺ and Mg²⁺ were slightly inhibitory between concentrations of 1 and 4 mM, whereas Zn²⁺ was highly inhibitory, causing a loss of more than 90% of the activity at the 4 mM concentration.

Comment. Phospholipase D activity in mammalian tissues appears to be latent, and detergent exposure is an important treatment to allow expression of the enzymatic activity (93). Transphosphatidylation activity of phospholipase D from rat brain microsomes was enhanced severalfold by fatty acids (93). In our experiments, both sodium oleate and sodium linoleate were found to be ineffective in activating phospholipase D. However, Triton X-100 caused a fourfold increase in phospholipase D activity in dog brain microsomes.

It is concluded that a major pathway for the formation of free choline in brain is the action of phospholipase D on membranous phosphatidylcholine. Further, it appears that this enzyme is not a target for inactivator OP agents such as sarin. These studies have been reported previously (94, 95), and further investigations of the regulation of phospholipase D following inhibition of AChE are reported in Specific Aim 9 and 13 below.

Specific Aim 8. Determine the kinetics of labeling of choline in phospholipids of various cellular fractions. Determine the regional blood-brain transport of the fatty acid palmitate (C16) and determine the kinetics of fatty acid incorporation into choline-containing brain phospholipids.

Background. We have previously hypothesized that the dynamic steady-state level of brain Ch is dependent on the neuronal uptake of Ch from degraded ACh, the activity of the enzyme Ch acetyltransferase, and the action of phospholipases (i.e., phospholipase D) on choline-containing lipids such as PC (83). In the steady state, the rate of PC synthesis must equal the rate of PC breakdown. The following studies were undertaken to investigate the synthesis of Ch lipids in the intact brain.

The initial objective of this study was to examine the metabolism of Ch-containing lipids under control conditions and during OP-induced seizure using radioactive Ch infused into the arterial perfusate. In preliminary experiments, [³H]Ch was infused over a 15- to 30-min period, and the incorporation of [³H]Ch into brain tissue and brain lipids was determined. Although [³H]Ch was readily transported into brain, there was essentially no detectable radioactivity in PC, sphingomyelin, or in other phospholipids. This is probably the result of the low specific activity of the available radioactive Ch, a slow rate of Ch incorporation into phospholipids, or a combination of both. Consequently, to investigate phospholipid metabolism under control conditions and after OP exposure, the long-chain fatty acids palmitate (C16) and oleate (C18:1) were selected as alternative substrates for lipid biosynthesis. These fatty acids are both known to be incorporated into cellular phospholipids. Palmitate is commonly present at the sn-1 position of glycerophosphate, and the unsaturated oleate is commonly found in the sn-2 position. Based on preliminary infusion experiments, ³H-labeled fatty acids appeared to be useful for examining OP effects on blood-brain transport of these compounds, as well as cerebral metabolism of phospholipids during OP-induced seizure, and the following studies were undertaken.

Method. Perfusion experiments were conducted in which the brain was allowed to reach equilibrium with the perfusate and to establish a metabolic steady state during an initial 30-min control period. The influx rate constants, Kₐ, for blood to brain transport of palmitic acid, a 16-carbon saturated fatty acid, and oleic acid, an 18-carbon unsaturated fatty acid, were determined.

[³H]Palmitic acid or [³H]oleic acid (1.2 mCl, New England Nuclear, Wilmington, DE) in ethanol was dried under nitrogen, resuspended in 250 µl of saline or plasma and infused at a constant rate into the arterial cannulae over a 5-min period. The brain was then rapidly removed, and tissue samples were collected from specific brain regions for digestion and determination of radioactivity levels by
liquid scintillation spectrometry. Additional tissue samples were collected, extracted with chloroform/methanol solvent, and subjected to TLC and quantitative phospholipid analysis. Isolated phospholipid fractions (free fatty acid, PC, phosphatidylinositol [PI], phosphatidylserine [PS], phosphatidylethanolamine [PE], and sphingomyelin) from the TLC were also analyzed for radioactivity and incorporation of [3H]palmitate or [3H]oleate.

Blood-brain transport of [3H]palmitate was evaluated by the integral method, as described previously (96). The influx rate constant, Kin, is calculated from the relationship $C'_{\text{brain}} = K_{\text{in}} \int_{0}^{T} C'_{\text{plasma}} dt$, in which $C'_{\text{brain}}$ is the radioactivity (dpm/mg) in brain tissue, $C'_{\text{plasma}}$ is the radioactivity (dpm/ml) in arterial plasma, and $T$ is the time of infusion (sec). Because the radioactivity in brain is measured, and the time and amount of infused radioactivity are known, the influx constant, $K_{\text{in}}$, is readily calculated. For calculation of net transport of palmitate and oleate, the relationship $v_{\text{net}} = 60(K_{\text{in}})(S)$, in which $S$ is the plasma palmitate or oleate concentration, was employed. The perfusate concentrations of unesterified long-chain fatty acids were determined by extraction, derivatization (methyl ester), and gas chromatography.

**Results.** The permeability of the brain vasculature to palmitate and oleate was relatively low (Table 19). White matter was the least permeable (smallest $K_{\text{in}}$ values) to palmitate, and midbrain and hippocampal regions had influx constants approximately twice the values for white matter. Cortical regions of the cerebrum and cerebellum had the highest influx constants, which were about four times the white matter values.

Transport of oleic acid into brain was significantly greater than palmitic acid transport in all areas of the brain examined (Tables 19, 20). In cerebral cortex, the $K_{\text{in}}$ values were four to five times greater for oleate than palmitate. The $K_{\text{in}}$ values of oleate and palmitate transport into the pituitary, a structure lacking a typical blood-brain barrier, were similar and were significantly greater than those in the other brain regions.

The concentrations of fatty acids in the perfusate (Table 21) were found to vary over a fivefold range and to be similar to those for the same fatty acids in plasma from fasted humans (97). The combination of palmitate and oleate represent about one-half of the total fatty acids. Because the concentrations of perfusate palmitate and oleate are about equal (80 µM), the net uptake of palmitate and oleate are about 0.4 nmol/g-min and 1.5 nmol/g-min, respectively.

When soman (100 µg) was administered acutely to the perfused brain by bolus injection into the carotid cannulae, an immediate increase occurred in CBF (~60%), and a grand mal-like seizure occurred after ~4 min. Blood-brain transport of palmitate but not oleate determined under those conditions increased two- to threefold over transport under control conditions (Tables 19, 20).

The metabolic fates of the free fatty acids after they entered the brain were determined by regional analysis of brain lipids (Tables 22, 23). In control experiments, 40-60% of the radioactive palmitic acid was recovered in PC (Table 22). The free fatty acid fraction contained 25-35% of the total radioactivity, and sphingomyelin labeling consisted of 12-20% of the total. Small and similar incorporations into PI, PS, and PE were detected. These results were similar in all of the eight structures examined except white matter (data not shown) in which all free fatty acid incorporations were low, a result consistent with the low blood-brain transport rates for white matter.

After soman exposure, the pattern of [3H]palmitate labeling was drastically changed. The total radioactivity of the extracted lipids significantly increased and resulted from a two- to eightfold increase in the free fatty acid fraction. This increase was at the expense of incorporation into all the other lipids, which consistently had lower amounts of [3H]palmitate (Table 23).

Metabolism of [3H]oleic acid was markedly different. The majority of [3H]oleate was recovered in the free fatty acid fraction (Table 24). Among the phospholipids, incorporation into PC was greatest, with incorporation into PE and PI about one-half and one-fourth that of PC, respectively. Only small...
amounts were incorporated into sphingomyelin and PS. Similar results were observed in the various brain structures, with white matter having low incorporations (data not shown).

During soman-induced seizure, the amount of \[^{3}H\]oleate found in the phospholipids decreased by 50% or more. This result is similar to that observed for \[^{3}H\]palmitate (Table 25). Levels of \[^{3}H\]oleate in the free fatty acid pool did not change.

Positional analysis of the labeled PC showed that palmitate was predominantly incorporated into the sn-1 position and oleate into the sn-2 position. These results are in agreement with the natural distribution of saturated and unsaturated fatty acids in brain phospholipids (Fig. 19).

PC metabolism was also investigated using \[^{3}H\]Ch as a labeled precursor similarly to the fatty acid incorporation experiments. It was anticipated that Ch would be taken up by the brain and be incorporated into PC. This would then make it possible to study the metabolism of labeled PC and the effect of soman exposure on its metabolism. However, infusion of labeled Ch for 5 min did not result in extensive incorporation into PC. A repeat of the experiment yielded the same result. It is concluded that the incorporation of Ch into PC is relatively small or the specific activity of the intracellular pool of cholinesterase is too low to detect incorporation.

Comment. These studies demonstrate that phospholipid metabolism in brain is dynamic and surprisingly active—a finding that is in contrast to the notion that membranes and their lipids are substantially inert. These results also indicate that the metabolism, but not transport, of free fatty acid is drastically altered by soman exposure and during soman-induced seizure. The data further suggest that the rate of phospholipid synthesis is decreased or the rate of phospholipid degradation is increased or both. In addition, our results suggest possible effects of OP on carrier-mediated transport systems at the blood-brain interface. These effects may be the result of an increase in the surface area of the vasculature, resulting from extensive vasodilation.

These results parallel the findings of protein synthesis (Specific Aim 4, above), another major energy-requiring process that was greatly diminished by OP-induced seizure.

Specific Aim 9. Examine the effects of organophosphorus compounds on labeling of phosphatidylcholine and on receptor-mediated choline turnover.

Background. AChE inhibitors have been shown to cause rapid accumulation of ACh in brain because of their ability to block the hydrolysis of ACh to Ch and acetate. Unexpectedly, it has been observed that brain Ch levels also increase simultaneously (52-54, 83). The elevated Ch has been proposed to originate from hydrolysis of PC, a Ch-containing lipid, and may result directly from the effect of AChE inhibitors on PC hydrolysis or indirectly via ACh through muscarinic receptor stimulation of PC hydrolysis. It has been suspected that some AChE inhibitors may also interact with certain phospholipases to affect their activities and cause changes in Ch levels in brain. In this study, we investigated the direct effects of soman, physostigmine, and DIFP on the hydrolysis of PC by canine cerebral cortex synaptosomes.

Method. Experiments were conducted to examine the effects of anticholinesterase compounds on PC metabolism and the effects on receptor-mediated Ch release from Ch-containing lipids. Brains were isolated and perfused for a control period of 35-45 min to establish a steady state and to obtain baseline data. Administration of 100 µg of soman to the brain vasculature was accomplished by injection directly into the arterial cannulae. Perfusion of the brain was discontinued 15 min after the injection, brain cerebral cortex tissue was dissected, and subcellular microsomal and synaptosomal fractions were prepared essentially according to the following procedure.

Preparation of canine cerebral cortex synaptosomal fractions. The subcellular fractions from dog cerebral cortex were prepared according to Whittaker and Barker (88) and modified as described (89). Briefly, fresh dog cerebral cortex was minced and homogenized (10% w/v) with a Potter-Elvehjem
homogenizer in 0.32 M sucrose containing 1 mM EGTA. The homogenate was centrifuged initially at 1000 x g for 10 min, and the postnuclear supernatant was centrifuged at 22,000 x g for 30 min to obtain a crude membrane pellet that contained myelin, synaptosomes, and mitochondria. The crude membrane fraction was resuspended in 0.32 M sucrose and centrifuged with a Beckman SW-27 rotor at 53,000 x g for 1 hr on a discontinuous sucrose density gradient of 0.32 M, 0.85 M, and 1.2 M. The crude synaptosomal fraction was collected between the 0.85 and 1.2 M sucrose layer. The fraction containing the synaptosomes was diluted to a final sucrose concentration of 0.32 M and layered on top of a discontinuous sucrose density gradient of 0.32 M, 0.85 M, and 1.2 M. After centrifugation at 75,000 x g for 30 min, the material at the interface of the 0.85 and 1.2 M sucrose layers was collected, diluted with 0.32 M sucrose, and centrifuged at 14,500 x g for 20 min to give the synaptosomal pellet. The pellet was then washed several times and resuspended in 0.32 M sucrose and stored at -20°C until use. The protein content was determined according to Lowry et al. (90).

Measurement of the choline-containing products of phosphatidylcholine hydrolysis. The exogenous substrate 1,2-dipalmitoyl-sn-glycerol-3-phosphoryl[3H]choline ([3H]-PC) (S.A. = 1 x 10⁴ dpm/nmol) was used (95). Each incubation mixture in 0.25 ml contained 32 mM [3H]-PC (8.0 x 10⁴ dpm), 40 mM HEPES buffer at pH 7.0, 0.1 mM MgCl₂, and 0.4% Triton X-100. The reaction was initiated by the addition of cerebral cortex synaptosomes (200-300 μg of protein) as the enzyme source and incubated at 37°C, with shaking for 30 min. Reactions were stopped by adding methanol containing 1% acetic acid, and lipids were extracted. The radioactive Ch and phosphorylcholine in the upper phase were separated with a Dowex-1 anion-exchange column or separated by TLC (silica gel-H) using methanol/0.6% NaCl/concentrated ammonia (50:50:5) (98). The radioactivity levels of the Ch fractions were measured using liquid scintillation spectrometry. The amount of [3H]Ch released that was separated from phosphorylcholine represents the hydrolytic activity of phospholipase D. To eliminate [3H]Ch as a product of the hydrolysis of phosphoryl[3H]choline that may be produced by PC phospholipase C action, 5.0 mM cold phosphorylcholine or 5.0 mM p-nitrophenylphosphate, competitive inhibitors of alkaline phosphatase (95, 98), was present in all incubation mixtures. The radioactivity in the Ch fraction was consistently higher than 90% of the total radioactivity recovered in the aqueous phase after lipid extraction. On the other hand, less than 10% of the radioactivity was recovered in the phosphorylcholine fraction, and only a trace amount of radioactivity was recovered in the glycerophosphorylcholine fraction. The enzyme activity was linear with time and protein concentrations used in our experiments.

The direct effects of physostigmine, another AChE inhibitor, on PC hydrolysis by synaptosomes prepared from untreated dog brains were investigated using the same assay conditions as were used in the studies with soman.

To study the potential coupling between muscarinic receptors and phospholipase D, synaptosomes isolated from canine cerebral cortex were used. The hydrolytic activity of PC phospholipase D in the synaptosomes was measured using a radiochemical assay with 1,2-dipalmitoyl-sn-glycerol-3-phosphoryl[3H]choline as the exogenous substrate. To examine the possible involvement of the G protein(s) in regulating PC phospholipase D activity, guanine nucleotide analogues were added to the incubation mixtures.

Results. Organophosphate studies. When the amounts of [3H]Ch and phospho[3H]choline released by synaptosomes prepared from two isolated dog brains that were perfused and treated with 100 μg of soman were compared with those of controls, a slightly higher (about 20% above the control value) but not statistically significant (p > 0.05, n = 4) amounts of radioactivity were released during the 30-min incubation time (Fig. 20). However, when various concentrations of soman (0.008 mg/ml - 0.16 mg/ml) were added to the incubation mixtures to examine the direct effects of OP on hydrolysis of PC by synaptosomes prepared from control dog brains, statistically significant (p < 0.05, n = 3) slight increases in [3H]Ch and phospho[3H]choline were observed (Fig. 21). The maximal stimulation reached 125% of the control value at 0.12 mg/ml; at the higher soman concentration of 0.16 mg/ml, PC hydrolysis was not affected.

Another organophosphate compound, DFP, was also used to examine the effects on PC hydrolysis by the control synaptosomal preparations. Under these conditions, DFP at concentrations between 0.005 mg/ml and 0.2 mg/ml did not affect PC breakdown (p > 0.05, n = 3, data not shown).
Physostigmine studies. The direct effects of physostigmine, another AChE inhibitor, on PC hydrolysis by control synaptosomes were investigated under the same assay conditions as were used in the soman studies. Physostigmine, similar to soman, also showed the statistically significant ($p < 0.05, n = 3$) but small stimulations at concentration ranges between 0.02 and 0.2 mg/ml when it was added to the reaction mixtures (Fig. 22). At concentrations higher than 0.2 mg/ml, physostigmine appeared to be ineffective.

Comment. Our previous studies (83) of the metabolism and blood-brain transport of Ch in perfused canine brain suggest that the production of Ch after organophosphate administration may involve hydrolysis of Ch-containing phospholipids. Brain Ch plays a central role in the metabolism of at least two classes of brain constituents: as a precursor and degradation product of the neurotransmitter ACh and as a component of the membrane lipids PC and sphingomyelin. We postulated that the dynamic interrelationship between the choline in ACh and Ch in membrane PC is highly regulated and balanced (92). A significant imbalance could arise as a consequence of chronic administration of AChE inhibitors that block the formation of Ch within synapses and thus reduce the amounts of Ch entering presynaptic terminals via high-affinity Ch uptake. PC is not only an important reservoir of Ch for ACh biosynthesis, but also is an integral part of the phospholipid component of neuronal membranes, comprising 30-60% of the total phospholipids. Since PC is a major Ch-containing phospholipid in brain, it can be postulated that substantial amounts of Ch can be derived from PC hydrolysis. Further, the increased Ch may result from the direct effects of AChE inhibitors on PC phospholipase D and/or phospholipase C or, indirectly, via cholinergic receptor-mediated PC hydrolysis. In studies of chicken heart, muscarinic stimulation enhanced the hydrolysis of Ch phospholipids and resulted in elevated Ch and phosphatidic acid (PA) levels (99). It was presumed that these results occurred via activation of phospholipase D (99). However, the biochemical mechanisms of action involved with Ch levels being increased by AChE inhibitors and cholinergic agonists were not understood until recently. Our findings (100) have demonstrated that a muscarinic ACh receptor regulates PC phospholipase D via the G protein(s) in canine cerebral cortex synaptosomes. It clearly suggests that the ability of AChE inhibitors to mobilize large amounts of Ch in brain is related to their effects on accumulation of ACh. This accumulation, in turn, results in a stimulation of a muscarinic ACh receptor, which causes the breakdown of membrane PC and a rapid elevation of Ch levels.

Our results here provide evidence that some AChE inhibitors, including physostigmine and soman, have slight stimulatory effects on the release of Ch and phosphocholine from PC, presumably via phospholipase D and phospholipase C mechanisms; however, DFP has no effect. Our studies with soman show that the concentration capable of inducing seizure and rapid elevation of Ch levels in perfused brain is 100-fold lower than the concentration capable of causing a statistically significant, but only slight, stimulation in in vitro incubation reactions. Therefore, we conclude that direct effects of AChE inhibitors on PC phospholipase D and phospholipase C do not play significant roles in elevating brain Ch levels, but may only partially, if at all, contribute to prolonged and slow elevation of Ch. Our results, from another aspect, support the hypothesis that a muscarinic ACh receptor-regulated PC phospholipase D plays a key role in rapid elevation of brain Ch levels after administration of AChE inhibitors.

Specific Aim 10. Determine changes in catecholamines and other neurotransmitters in organophosphate-exposed brain.

Background. Although it has been reported that exposure of animals to various convulsive and anticonvulsive drugs alters brain catecholamines levels, the roles of the adrenergic or dopaminergic systems in the etiology of seizure are not fully understood. Feldberg and Sherwood (101) and Jones and Roberts (102) found that intracerebral injection of norepinephrine (NE) into the brain accompanied anticonvulsant activity. Conversely, an intraventricular injection of 6-hydroxydopamine, which caused marked reduction in brain NE and dopamine (DA) levels, significantly lowered the seizure threshold (103). Banister and Singh (104), however, did not observe any change in the seizure threshold in rats whose NE level was reduced 50% by $\alpha$-methyl-p-tyrosine ($\alpha$-MPT). Several investigators have shown that monoamine oxidase (MAO) inhibitors, which would increase brain NE
levels, protected rats against the development of seizure (105-107). Contrarily, other workers did not
detect such anticonvulsant activity of MAO inhibitors (108, 109). Beta-adrenergic-blocking agents
are reported to have anticonvulsive effects (110), although Faiman et al. (111) found that propranolol
failed to protect rats from OP-induced seizure. Despite the impressive evidence that brain NE
participates in inhibitory functions essential for normal resistance to seizure, its role in the
development of seizure is unclear.

Altering DA levels in the brain, either by DA or L-DOPA injections, also did not alter the seizure
susceptibility (112-114). Apomorphine, which specifically activates DA receptors in the CNS, was
found to elevate the threshold for electroshock seizure (115). Similar to NE, the role of DA in seizure
etiology remains unclear.

To investigate the mechanisms that underlie the development of seizures and vasodilation during
OP intoxication further, the catecholamines, a major class of CNS neurotransmitters, were examined
in the perfused canine brain model. The primary aim was to determine whether significant changes in
catecholamines occurred in response to acute OP exposure. As a followup study, the β-adrenergic
blocker propranolol and the dopaminergic antagonist pimozide were included in the perfusate to
ascertain if either of these types of receptors were involved in eliciting the OP responses despite the
absence of gross alteration in the concentrations of their natural agonists, NE and DA. In addition to
measurement of the catecholamines, the vascular and metabolic effects of these two antagonists are
reported below in Specific Aim 12.

Method. Biogenic amines were determined using high performance liquid chromatography with
electrochemical detection (HPLC-EC) analysis. In preliminary experiments, we found that direct
injection of perchloric acid extracts into the HPLC analytical system results in the elution of several
unidentified compounds at or near the solvent front and prior to elution of most biogenic amine
compounds of interest. These earlier eluting substances reportedly can be eliminated by purifying
and concentrating the biogenic amines with adsorption and elution from activated alumina columns.
An evaluation was performed on this method of alumina purification before HPLC analysis. Our
results indicated that although these chromatograms showed fewer peaks and higher values for NE
and DA, other compounds such as serotonin (5-HT), 5-hydroxyindole-3-acetic acid (5-HIAA), and
homovanillic acid (HVA) were lost during the process. The recoveries were also inconsistent.
Therefore, it was decided to proceed with the method in which the perchloric acid-extracted tissue
samples are injected directly onto the chromatography column without passage through an alumina
column.

Perfusion experiments were conducted to collect tissue samples for analyses of catecholamines
and other neurotransmitters. The canine brain was isolated as described in METHODS and perfused
for a control period of approximately 30 min to allow establishment of a steady state. Sarin (400 μg)
or soman (100 μg) was administered by direct injection into the common carotid cannulae. In separate
experiments, propranolol (0.06 μM) or pimozide (2 μM) was added to the perfusate after a 30-min
control period, and soman was injected ~15 min after propranolol or pimozide treatment. Ten to sixty
minutes later, brain tissue was dissected from six different regions (cerebellum, frontal cortex, parietal
cortex, brain stem, hippocampus, and hypothalamus) and immediately frozen in liquid nitrogen. The
frozen samples were stored at -70°C until the biogenic amines were extracted from tissue (200 mg)
with 1.0 ml of cold 0.05 M perchloric acid, and 100 μl were injected directly into the HPLC-EC system
for analysis of NE, DA, 5-HT, HVA, and 5-HIAA. Dihydroxybenzylamine was used as the internal
standard.

Results. Analysis of brain biogenic amines in perfused control brains revealed distinct regional
variations in the respective compounds (Table 26). The hypothalamus and brain stem generally had
lower catecholamine concentrations than the cerebellum or cortex, findings that are in general
agreement with those reported for other species both qualitatively and quantitatively. The somewhat
large variation in the data (large standard errors) is also reported by other workers and is often
attributed to dissection, sampling, or individual test differences. Standard errors were not calculated
for any of the experimental groups except the control because of the lack of sufficient numbers (n =
2) of valid data.
One hour after soman-induced seizure, the levels of DA appeared to be lower and NE higher in nearly all brain regions. No changes or trends were apparent for 5-HT, 5-HIAA, or HVA.

The presence of pimozide (DA receptor antagonist) appeared to diminish the soman-induced depletion of DA, whereas propranolol had no effect on this catecholamine (Table 26). Propranolol (β-blocker), however, tended to blunt the soman enhancement of NE. Neither antagonist appeared to affect the levels of 5-HT, 5-HIAA, or HVA.

Comment. Based on the analyses of biogenic amines in control brains, it is concluded that the perfusion model contains normal levels of the compounds measured. Soman exposure appears to cause depletion of DA, an effect that is antagonized by pimozide. This observation may suggest that a dopaminergic receptor is involved in either DA release or metabolism. DA depletion may be a result of its conversion to NE by DA hydroxylase. This is supported by the fact that NE is increased after soman exposure. A β-adrenergic receptor may be involved in this process because propranolol antagonized the response. Because of the lack of sufficient sampling size, no firm conclusions can be drawn.

Specific Aim 11. Examine the effects of α-methyl-p-tyrosine on cerebral blood flow, brain electrical activity, cerebral metabolism, and turnover of biogenic amines in control and in organophosphate-exposed brain.

Background. Catecholamines represent a major family of brain neurotransmitters and are derived by sequential metabolic steps from the amino acid L-tyrosine. It has been proposed that OP compounds such as soman or sarin may act by affecting biogenic amines or the respective functions that they regulate (e.g., cerebral blood flow, metabolism, etc., 116, 117). The compound α-MPT is a strong inhibitor of tyrosine hydroxylase, a rate-limiting enzyme early in the pathway of biosynthesis of DA, NE, and epinephrine. If OP agents alter the turnover of any of these catecholamines (increased or decreased degradation), then the catecholamine concentration should be significantly different in the presence and absence of the inhibitor (α-MPT). This was the hypothesis to be tested.

Method. Perfusion experiments were conducted to investigate the role of catecholamines in OP toxicity. Specifically, the involvement of DA was examined by depleting the brain DA with the inhibition of its synthesis by α-MPT. Analysis of catecholamines was with HPLC-EC.

Brains were isolated and perfused for an approximate 30-min control period. Then, α-MPT (300 mg/l) was added to the perfusate, and perfusion was continued for 60 min. This 60-min perfusion was conducted either in the absence of soman or following the administration of soman (100 μg) at the same time as the α-MPT. During this period, the brain electrical activity was constantly monitored by EEG, and blood samples were collected every 10 min and analyzed for metabolism rates. Following the OP exposure period, tissue samples from six brain regions (brain stem, cerebellum, cerebral cortex, motor cortex, hippocampus, and hypothalamus) were rapidly dissected and immediately frozen in liquid nitrogen. The frozen samples were stored at -70°C until the biogenic amines were extracted from tissue (200 mg) with 1.0 ml of cold 0.05 M perchloric acid. A 100-μl sample was then injected directly into the HPLC-EC system for analysis of NE, DA, 5-HT, HVA, and 5-HIAA. Dihydroxybenzylamine was used as the internal standard.

Results. Addition of α-MPT to the perfusate did not alter brain electrical activity or brain metabolism during the control period (Fig. 23A). This compound also was not vasoactive during the experimental period, indicated by an unaltered CVR (data not shown). Administration of soman after pretreatment with α-MPT produced the characteristic OP-induced effects, i.e., immediate vasodilation and increases in brain metabolism with the occurrence of seizure (Fig. 23B). The results of HPLC analysis (Table 27) indicated that the dog brain was rapidly depleted of DA when circulated with perfusate
containing α-MPT. The depletion was extensive, approaching the limits of detection (<4 ng/g of tissue) in cerebellum, cerebral cortex, and hippocampus, and about half the control values in brain stem and hypothalamus. The results also revealed no apparent differences, as determined by statistical analysis of variance, between depletion during control conditions or after OP exposure.

The response to α-MPT observed in these experiments was more rapid than previously observed during in vivo experiments in rats (109) and buttresses the previous evidence that α-MPT effectively blocks DA synthesis in brain. The results indicate that DA degradation in brain occurs at an average rate of at least 38 ± 12 (S.E.M.) ng/g/hr. The evidence also suggested that depletion of DA does not significantly alter the levels of NE, a major product of DA metabolism during the time frame of this study.

Comment. It is concluded that the inhibitor α-MPT quickly penetrates the blood-brain barrier and inhibits the formation of DA by blocking tyrosine hydroxylase. Mechanisms that involve DA utilization continue to be active during α-MPT exposure and result in DA depletion. However, depletion of DA did not significantly alter OP-induced vasodilation, OP-induced changes in brain metabolism, or the OP-induced seizure. No observable differences occurred between control and OP-exposed brain catecholamine levels. Thus, it does not appear that OP agents affect either the steady-state levels or the turnover of the measured biogenic amines.

Specific Aim 12. Examine the effects of receptor family antagonists on cerebral blood flow, brain electrical activity, and cerebral metabolism in control and in organophosphate-exposed brain.

Background. OPs are known to produce irreversible inhibition of AChE, which results in accumulation of ACh at the synaptic cleft. An excess of ACh overstimulates cholinergic receptors and disrupts neurotransmission, thus leading to toxic manifestation. The existence of cholinergic innervation and regulation of brain circulation has been extensively documented (81, 118). Using the isolated, perfused canine brain (3), Drewes and Singh (76) showed that OPs induce vasodilation and seizure, implicating cholinergic involvement in these events. Oxotremorine, another cholinergic agonist, did cause vasodilation, but did not produce fully developed seizure (119). Experiments with atropine (120) and scopolamine, both cholinergic muscarinic antagonists, resulted in the prevention of OP-induced seizure. Also, scopolamine blocked oxotremorine-induced vasodilation, but not OP-induced vasodilation. These results indicate involvement of independent or additional mechanisms in OP-induced vasodilation and OP-induced seizure.

Extensive studies on animals revealed the existence of adrenergic innervation parallel to cholinergic innervation and emphasized the significant role adrenergic innervation plays in cerebral vasomotor regulation (121). There is pharmacological evidence that this close relationship allows for an interaction mechanism by which the cholinergic nerves, through nicotinic receptors on the adjacent adrenergic fibers, can inhibit the release of NE and thereby promote a vasodilatory response during cholinergic nerve activation (122). This effect of NE is mediated through α-adrenergic receptors. It has been reported in another series of experiments that stimulation of noradrenergic neurons causes vasodilation of the cerebral arteries (123, 124). Lowe and Gilboe (125) observed that injection of NE into isolated, perfused brain caused vasodilation. Winquist et al. (126) noted that NE caused a relaxation in the porcine cerebral vessel in vitro and that the relaxation response to NE was blocked by β-adrenergic antagonists. These results indicate that NE exerts its effect on cerebral arteries by a β-adrenergic mechanism. DA is also reported to cause vasodilation and to increase CBF. McCulloch and Harper observed that stimulating dopaminergic receptors with apomorphine increased the CBF (127). Pimozide, a DA receptor blocking agent, prevented the apomorphine-induced increase in CBF (127). The existence of mast cells, located along the pial and intracerebral vessels (128), implicate the possible involvement of histamine in cerebral vasomotor regulation. Studies indicated that both H1 and H2 receptors are present in brain, with H2 receptors mainly responsible for vasomotor control.
In the following series of brain perfusion experiments, several antagonists were evaluated as potential agents to prevent OP-induced vasodilation and OP-induced alterations in metabolism. Additional experiments were conducted to test the vasoactive response of the cerebrovasculature to histamine and to characterize the response with the H2 antagonist cimetidine.

**Method.** *Neurotransmitter antagonists.* The mechanisms of OP-induced vasodilation and seizure genesis were investigated using the isolated, perfused canine brain preparation (3, 4). Brain tissues were isolated and prepared, and physiologic and metabolic measurements were determined as described in METHODS.

Previous experiments (for extensive review, see ref. 129) with cholinergic antagonists atropine and scopolamine and with cholinergic agonists oxotremorine and arecoline have established the involvement of a cholinergic muscarinic mechanism in OP-induced seizure, but not in OP-induced vasodilation. To evaluate the possible involvement of other transmitter mechanisms in these events, experiments were conducted with specific antagonists: scopolamine (cholinergic muscarinic antagonist, 1.6 μM), mecamylamine (nicotinic ganglionic blocker, 60 μM), propranolol (β-adrenergic blocker, 0.06 μM), pimozide (dopaminergic receptor blocker, 2 μM), and cimetidine (histaminergic H2 antagonist, 0.1 mM). These substances were used because of their potency, specificity, and their ability to penetrate the blood-brain barrier. They were dissolved in saline, and concentrations were calculated to be molar concentrations in the perfusate.

After a 30- to 45-min control perfusion period, specific antagonists were added to the perfusate, and arterial and venous blood samples were collected at regular intervals. Samples were analyzed to measure CMRs. Fifteen minutes after the antagonist was added, soman (100 μg) was injected directly into an arterial cannula, and blood flow was adjusted to maintain constant pressure. EEG was monitored to assess OP-induced effects on brain electrical activity after the respective pretreatments.

**Histaminergic mechanisms.** After a 30-min control period, 50-μl aliquots of histamine solution in a concentration range of 10^-6 M to 10^-1 M were injected via a carotid cannula. Injections were made after the vasodilatory response (CVR) returned to the control value. Cimetidine (10^-5 or 10^-4 M) was added to the perfusate in two experiments, and the series of histamine injections was repeated. The cerebrovascular response was calculated for each concentration point.

**Results.** Addition of scopolamine to the perfusate did not produce detectable changes in CVR or in brain metabolism, but did change brain electrical activity. Even though scopolamine alone did not prevent vasodilation induced by injection of OP, the effect was brief when compared to the duration of vasodilation induced by the addition of OP alone or addition of OP after the other antagonists (Fig. 24). Injection of OP produced an immediate decrease in perfusion pressure, characterized by a 25% decrease in CVR, and the pressure began to increase 5 min later (Fig. 24). Except for transitional disturbances in brain electrical activity, the EEG pattern retained scopolamine-induced characteristics throughout the experiment.

Addition of mecamylamine, pimozide, propranolol, or cimetidine to the perfusate had no effect on CVR (Fig. 24), brain metabolism (Fig. 25A-C), or brain electrical activity. Perfusion pressure was unchanged, CMRs for glucose, O2, and CO2 remained essentially the same as during the control period, and the EEG was unchanged. None of these antagonists, however, prevented the characteristic responses to soman exposure. Administration of soman was followed by an immediate decrease in perfusion pressure, manifested by a 25-40% decrease in CVR that remained low for 15 min, and seizure genesis occurred in all cases within 4-5 min. With the occurrence of seizure, the CMRs of glucose, O2 and CO2 increased 30 to 60% (data not shown).

In our experiments, histamine had a dose-dependent vasodilatory effect. This response was inhibited by cimetidine, a specific H2 antagonist, at submolar concentrations (data not shown).

**Comment.** Our observations excluded a cholinergic muscarinic mechanism as the sole factor in OP-induced vasodilation and suggest some additional mechanism(s) in this event. The initial (<1 min) event in OP-induced vasodilation may have different components from the later (>5 min) phase of
induced vasodilation. Even though pretreatment with scopolamine was not enough to prevent the occurrence of OP-induced vasodilation, a faster recovery of CVR during these experiments was evident (Fig. 24), which supports a cholinergic mechanism for a portion of the response. The observed vasodilation had the characteristics of OP-induced vasodilation and did not change in intensity or duration. Although histaminergic mechanisms appear not to be involved in OP-induced vasodilation, histamine was a potent vasoactive substance when administered to the cerebrovasculature. The response appears to be mediated via an H2 type histidine receptor.

The results of our experiments indicate that OP-induced vasodilation and seizure may be uncoupled, i.e., occur by separate, independent mechanisms. In addition, our studies exclude simple involvement of cholinergic muscarinic, cholinergic nicotinic, dopaminergic, adrenergic, or histaminergic mechanisms in OP-induced vasodilation. The cholinergic muscarinic mechanism plays some role in this vasodilation, but only as a part of a more complex process. Studies of involvement of the endothelium-derived relaxing factor (EDRF) may give some additional insight into the mechanism(s) of OP action.

In a parallel study we examined the possible role of NE using α-MPT (inhibitor of NE biosynthesis). These studies are reported in detail in Specific Aim 11.

Specific Aim 13. Examine the effects of a nicotinic agonist on receptor-mediated release of choline from phospholipids. Test the hypothesis that the muscarinic receptor-regulated phosphatidylocholine phospholipase D and phosphatidic acid phosphatase pathway is important in signal transduction for generation of diacylglycerol from phosphatidylocholine in brain.

Background. Diacylglycerol (DAG), an intracellular second messenger, plays an important role in cell signal transduction by activating protein kinase C that, in turn, phosphorylates a range of cellular proteins (129, 130). The well-established pathway for generation of DAG is via receptor-mediated stimulation of inositol phospholipid breakdown by specific phospholipase C action (132, 133). Recently, this classical scheme involving inositol phospholipids as the sole source of DAG has been challenged (134-136). Mounting evidence indicates that an important alternative mechanism for the agonist-induced generation of DAG may be through breakdown of PC (98, 137-141). The formation of DAG may occur either directly via PC phospholipase C or by the action of PC phospholipase D to yield PA that is further dephosphorylated to DAG by PA phosphatase. However, the actual biochemical mechanisms for agonist-stimulated DAG generation from PC have yet to be characterized and may indeed vary from receptor to receptor in different types of cell systems.

Our recent findings (100) revealed that a muscarinic ACh receptor regulates PC phospholipase D via a guanine-nucleotide-binding protein (G protein) in canine cerebral cortex synaptosomes and indicated that this muscarinic receptor-regulated PC phospholipase D is responsible for the rapid formation of Ch and PA. Since PA phosphatase is abundant in synaptic membranes (142), it can be inferred that PA formed by the phospholipase D activity on membrane PC might serve as a substrate for the PA phosphatase activity present in the synaptic membranes. Therefore, we postulate that muscarinic receptor-regulated PC phospholipase D and PA phosphatase comprise an important signal-transduction pathway for generation of Ch and DAG from PC in brain.

Method. Preparation of [3H]PA. The [3H]PA was prepared from 1-palmitoyl-2-[9,10-3H]palmitoyl-L-3-phosphocholine (Amersham Corp.) by action of phospholipase D from Streptomyces chromofuscus (Sigma). Incubation buffer contained 1 mM MgCl2, 0.5 mM CaCl2, 0.1% Triton X-100, and 40 mM HEPES, pH 7.4. Reactions were carried out for 60 min at 30°C, with shaking. Lipids were extracted as described (100) after the reactions were stopped. [3H]PA was separated on Silica Gel G plates using the upper phase from a mixture of ethyl acetate/2,2,4-trimethylpentane/acetic acid/water (9:5;2:10) (143). PA was localized by brief exposure to iodine vapor. To allow the iodine to evaporate, plates were held at room temperature for 30 min before elution of [3H]PA by methanol. The specific radioactivity of [3H]PA was 57 Ci/mmol.
PA Phosphatase assay. Synaptic membranes of cerebral cortex were prepared as described previously (100). Incubation mixtures (0.25 ml) contained 1 mM MgCl₂, [³H]PA (4 x 10⁶ dpm), 40 mM HEPES at pH 7.4, 0.4 mM CaCl₂, and 0.04% Triton X-100. In inhibitor testing studies, unlabeled PA was combined with [³H]PA, or various concentrations of propranolol were added. Reaction mixtures were ultrasonicated on ice for 10 sec and then incubated for 20 min at 37°C, with shaking. Reactions were stopped with methanol containing 1% acetic acid, and the lipids were extracted (98) and separated on Silica Gel 60 using hexane/diethyl ether/acetic acid (65:35:4) (144). Lipids were localized by exposure to iodine vapors, the specific area of DAG was scraped into vials, and the radioactivity levels were determined using liquid scintillation spectrometry. The PA phosphatase activity was not measurably altered by the presence of detergent (0.04% Triton X-100).

Measurement of radioactive PC breakdown. Radioactive PC (1-palmitoyl-2-[9,10-³H]palmitoyl-L-3-phosphocholine) was used as the exogenous synaptic membrane substrate for phospholipases. Incubation mixtures (0.25 ml) contained 0.25 μCi of PC (exogenous PC specific activity: 57 Ci/mol), 40 mM HEPES at pH 7.4, 1 mM MgCl₂, 0.4 mM CaCl₂, 0.04% Triton X-100, 0.5 μM GTP·S, 150 μg of synaptic protein, and the indicated concentration of ACh or muscarine. Incubation and lipid extraction procedures were the same as described above. For PA analysis, the extracted lipids were separated on Silica Gel 60 using ethyl acetate/2,2,4-trimethylpentane/acetic acid (45:25:10) (145) or on Silica Gel H plates (with 1% potassium oxalate) developed in a solvent system of chloroform/methanol/10 N HCl (87:13:0.5). DAG was separated as described above. Individual lipids were localized by exposure to iodine vapors, the specific areas were scraped into vials, and the radioactivity levels were determined using liquid scintillation spectrometry. [³H]Phosphorylcholine and [³H]Ch produced from another radioactive-labeled PC (1.2 dipalmitoyl-sn-glycerol-3-phospho[³H]choline) were separated and determined as described (100). The activity of phospholipase C using either of the two radioactive substrates was not measurably affected by 0.04% Triton X-100.

Results. To test our hypothesis, initial experiments were conducted to determine the presence and characteristics of PA phosphatase in synaptic membranes isolated from canine cerebral cortex. [³H]PA was used as the exogenous substrate to measure the conversion of [³H]PA to [³H]DAG as an indicator of PA phosphatase activity. The activity was linear with incubation time (up to 40 min) and the synaptosomal protein concentrations (up to 400 μg of protein) used in our experiments (Fig. 26A and B). Several compounds were tested for their ability to inhibit PA phosphatase. The amphiphilic cationic drug DL-propranolol, reported to be a PA phosphatase inhibitor (128), was examined. A concentration-dependent inhibition was observed (Fig. 26C). Propranolol, at a concentration of 3 mM, cause an inhibition greater than 90%. This amphiphilic cationic compound was postulated to interact with membrane PA by its positively charged substituted amino group (146), thus causing inhibition of PA phosphatase. However, propranolol is known also to be a nonselective β-adrenergic blocker. Although exogenous norepinephrine (NE) was absent from our assay system, we tested the effects of NE on PA phosphatase activity. With our experimental conditions, addition of NE had no effect on the conversion of [³H]PA to [³H]DAG. This result indicates further that inhibition of PA phosphatase by propranolol is unlikely to be related to its β-blocking activity. This β-blocking-independent inhibitory effect on PA phosphatase was also reported by several other groups (147-149). Another compound we tested was unlabeled exogenous PA (cold PA), and this compound caused a decrease in [³H]DAG formation (Fig. 26D). As previously suggested, this apparent inhibition of PA phosphatase activity is the result of competition between cold PA and [³H]PA as substrate for the enzyme (138). These two compounds, propranolol and cold PA, are useful tools for characterizing the mechanism of DAG generation.

To examine PA and/or DAG generation by cholinergic agonists, the following experiments were performed. When radioactive-labeled PC was used as the exogenous substrate for synaptic membrane phospholipases, the addition of cholinergic agonists ACh or muscarine in the presence of 0.5 mM GTP·S, caused a concentration-dependent stimulation of [³H]PA formation (Fig. 27A). At the same time, a significant increase in [³H]DAG was observed (Fig. 27B). The accumulation of [³H]DAG may result either from direct PC phospholipase C action or from the combined actions of PC phospholipase D and PA phosphatase. To distinguish these possible biochemical mechanisms, we first measured the time course of [³H]PA and [³H]DAG generation from [³H]PC after 1 mM ACh stimulation (Fig. 27C). [³H]PA rapidly accumulated within 15 sec, whereas [³H]DAG formation
showed a transient lag period before becoming elevated and then exceeding the amount of \([3H]PA.\) Second, the amounts of \([3H]phosphocholine and [3H]Ch produced by synaptic membranes were measured by using another radioactive-labeled PC, 1,2 dipalmitoyl-sn-glycerol-3-phospho-
[3H]choline, as the exogenous substrate (100). Muscarine caused a concentration-dependent accumulation of \([3H]Ch,\) but not \([3H]phosphocholine (Fig. 27D).\) These results indicate that the generation of \([3H]DAG\) by cholinergic agonists is not a result of the direct action of PC phospholipase C, but is most likely derived from the PC phospholipase D—PA phosphatase pathway. The possibility that accumulation of \([3H]PA\) could be from phosphorylation of \([3H]DAG\) by a DAG kinase activity is excluded because in our experiments no DAG kinase activity was detected in the absence of exogenous ATP.

Additional experiments were conducted to support this PC phospholipase D—PA phosphatase pathway mechanism. In our previous study, zinc was shown to be a potent inhibitor of PC phospholipase D in canine brain (95, 100). In the current study, muscarine-induced accumulations of both \([3H]PA\) and \([3H]DAG\) were significantly inhibited by 2 mM zinc (Fig. 28). Another compound, p-chloromercuribenzoate (pCMB), has been shown to be a potent inhibitor of phospholipase D in brain and plant tissues (150, 151). Therefore, the effect of pCMB on muscarine-induced accumulation of \([3H]PA\) and \([3H]DAG\) was also examined. Once again, no accumulation of \([3H]PA\) or \([3H]DAG\) was observed (Fig. 28). Zinc, a heavy metal ion, and pCMB, a sulfhydryl residue-blocking reagent, may be nonspecific phospholipase D inhibitors and may also inhibit PC phospholipase C activity in the synaptic membranes. However, neither zinc nor pCMB had any effect on basal phospholipase C activity (Z. Qian and L. R. Drewes, unpublished observations). Thus, inhibition by zinc and pCMB appears to be relatively selective for PC phospholipase D over PC phospholipase C. The inhibitory effects of zinc and pCMB on accumulations of \([3H]PA\) and \([3H]DAG\) suggest that when PC phospholipase D is inhibited, generation of \([3H]PA\) is prevented and no \([3H]PA\) is available for dephosphorylation by PA phosphatase to form \([3H]DAG.\)

To validate the phospholipase D—PA phosphatase pathway further, muscarine was added to the incubation mixtures to stimulate breakdown of \([3H]PC\) in the presence of a PA phosphatase inhibitor, propranolol, or cold PA (Fig. 28). Muscarine caused significant additional accumulations of \([3H]PA.\) However, \([3H]DAG\) did not accumulate, and even decreased, when compared with the control. These results show that \([3H]PA\) produced by muscarine-stimulated PC phospholipase D cannot be further degraded to \([3H]DAG\) because the conversion of \([3H]PA\) to \([3H]DAG\) is blocked by propranolol or cold PA.

Comment. Our above results provide strong evidence that a muscarinic ACh receptor-regulated PC phospholipase D—PA phosphatase pathway does exist in the synaptic membranes of canine cerebral cortex and indeed is responsible for the accumulation of DAG in the CNS after ACh stimulation (152). PC is the major lipid component of all eukaryotic cells and comprises 30 to 60% of membrane phospholipids, including the synaptic membranes in brain. Furthermore, a large quantity of protein kinase C is also associated with synaptic membranes (153). It is reasonable to postulate that DAG generated in synaptic membranes by our newly discovered pathway plays an important role in activation of protein kinase C in brain. Since the fatty acid composition of DAG from PC often differs from that of the inositol phospholipids, the question of whether different species of DAG regulate different subspecies of protein kinase C in brain has yet to be resolved.

Specific Aim 14. Examine the efficacy of scopolamine and valproate as protective agents against cerebral damage caused by organophosphate-induced seizure.

Background. Acute exposure to OP agents produces neurological seizure and respiratory arrest. Neuropathological damage is readily detectable within 1 hr of exposure (119, 154), progresses for 24-48 hr, and is permanently established and evident weeks following exposure. The lesions detected by light and electron microscopy following acute OP exposure resemble lesions caused by hypoxia and ischemia and, therefore, may be related to the stimulated energy and metabolic demands of seizure. Some attempts have been made to correlate the pathological damage to the presence or absence of convulsions (155, 156). However, no clear answer has yet emerged to the
question of what damage is a result of seizure and the related cholinergic crises. If brain lesions can be significantly reduced by preventing seizure, then the use of anticonvulsants may be a useful strategy for preventing significant degeneration induced by OP seizure.

Extensive morphological alterations and edema are evident in the isolated perfused dog brain 1 hr following OP exposure and seizure (8, 154). Cholinergic antagonists (e.g., scopolamine and atropine) prevent seizure induction.

Valproic acid (VPA) is an anticonvulsant drug that has been successfully used to treat several forms of seizure (157, 158). VPA is related structurally to γ-aminobutyric acid (GABA), and even though it is thought to have a mechanism of action involving the enhancement of GABA-mediated neurotransmission (159), the precise mechanism is not known. Some researchers have reported that VPA causes a specific dose-related increase in potassium membrane conductance that leads to hyperpolarization of the resting membrane potential (160). No previous report describes the testing of VPA as an anticonvulsant following OP exposure. Experiments were conducted to examine the efficacy of VPA to act as an anticonvulsant to soman.

Method. After a 30-min control perfusion period, VPA was added to the perfusate at concentrations of 0.4–0.7 μM. These concentrations are at the upper range of pharmacological activity for VPA as an anticonvulsant in humans. The VPA was circulated through the perfusion system for 10–60 min, during which time the metabolism rates and brain electrical activity were examined, before the addition of soman (100 μg).

Perfusion experiments were conducted to examine the ability of cholinergic antagonists to protect the brain from OP-induced edema formation, which is thought to be the result of seizure activity. Each brain was perfused for a 30-min control period and for an additional 15 min with perfusate containing the muscarinic antagonist scopolamine (1.3 μM). This amount of scopolamine is sufficient to prevent OP-induced seizure. In one experiment, soman (100 μg) was administered and in another, sarin (400 μg); a third served as a scopolamine-treated control. Approximately 60 min after OP exposure or after 90 min of perfusion for the control experiment, brains were flushed briefly with saline to remove erythrocytes and other blood components. The brains were then perfusion fixed with appropriate preservation solutions, and tissues were prepared for light and electron microscopy.

Results. Addition of VPA to the perfusate did not produce observable changes in brain metabolism or in the diameter of brain vessels, which would have been detected by a change in perfusion pressure and CVR. CMR values and EEG patterns were unchanged from those of the control period. Injection of OP caused immediate vasodilation, but seizure occurrence was inconsistent. In two experiments, seizure was fully developed. In other experiments, EEG changes were nonspecific, ranging from near normal cortical electrical activity to activity exhibiting gradually smaller and smaller amplitudes.

The protective effects of scopolamine against OP-induced seizure are known from previous experiments. To evaluate protection from scopolamine on a cellular level, brains were fixed for light and electron microscopy. The results indicate that shifts in cellular osmolytes and water occurred despite scopolamine's inhibition of extensive neuronal firing (seizure). Although no seizure activity was apparent from the EEG, edema formation was pervasive and other morphological alterations were present. When compared to OP-exposed brain with no protection against seizure, the cellular alterations and edema were qualitatively similar, but appeared quantitatively somewhat less. However, in control brain tissue perfused and administered only the antagonist, significant signs of edema and morphological alterations were observed. Because scopolamine is commonly used clinically, this result was unexpected and may be an anomaly; however, it should not be ruled out until it is repeated.

Comment. It is concluded that under the conditions of these experiments, the anti-epileptic activity of valproate was ineffective in inhibiting soman-induced seizure, although all results were not in agreement. Because VPA was generally ineffective as an anticonvulsant, light and electron microscopy was not performed on VPA-exposed brains.
Results of the experiments with scopolamine suggest that the anti-epileptic effects on OP-induced seizure are not sufficient to prevent the neurological and neuropathological consequences of OP poisoning. Our studies suggest that mechanisms of cellular degeneration leading to necrosis are activated by OP agents in the absence of sustained seizure. Extensive lesioning, however, may be ameliorated by the action of effective anticonvulsants such as cholinergic antagonists. This may be an important observation for suggesting therapeutic strategies because anti-epileptic drugs, although not sufficient for preventing the specific toxic effects of OP poisoning, may be beneficial in substantially reducing the associated pathological consequences.

Specific Aim 15. Examine the effects of HI-6 and pyridostigmine (and physostigmine and neostigmine), alone or in combination with other drugs, in control and in organophosphate-exposed brain.

Background. In the classic treatment for poisoning by OP compounds, atropine is employed to counteract the muscarinic effects of ACh accumulation, and an oxime is used to reactivate the inhibited enzyme. However, with some OP compounds, such as soman, the inhibited enzyme undergoes an "aging" process that makes it resistant to the nucleophilic attack of oximes (161). In case of poisoning by soman and other similar compounds, conventional oximes are not effective treatment because 1) they are poor reactivators of inhibited AChE, 2) they are incapable of reactivating "aged" enzyme, and 3) most of these oximes do not pass the blood-brain barrier (162, 163). The bisquaternary mono-oximes (HS-6 and HI-6) have been shown to be effective against soman intoxication in rats (164). A number of previous studies have indicated that the AChE reactivation by oximes does not correlate well with their protective effects (165, 166). Lundy and Shih (167) proposed that OP-poisoning protection by HI-6 cannot be predicted solely from examining the brain ACh values. They also proposed that central-noncholinergic effects of HI-6 may be important in reducing the effect of OP. HI-6 has been reported to exert ganglionic (168) and antimuscarinic blockade (169).

Several carbamate anticholinesterase compounds have been found to be effective in protecting animals against soman poisoning (170). Since both carbamate and OP compounds inhibit the enzyme AChE by similar mechanisms, addition of the two compounds together would be expected to enhance the toxic action. Koster (171) proposed that carbamates provided protection against OP toxicity if their administration occurred before OP exposure. When carbamate was administered after the OP, however, additional toxic effects were observed (171). The mechanism for this apparent paradox is not known. Berry and Davis (170) and Gordon et al. (172) have shown that protection given by physostigmine and other carbamates against soman poisoning was optimum if the interval between administration of the two drugs was about 30-60 min. They also observed that the dose of carbamate was not critical and protection was essentially constant for doses ranging from half to four times the maximum dose. The duration of the protective action of a single intramuscular injection of carbamates was greater than 2 hr, pyridostigmine being the largest (172). Dimhuber et al. (173) showed that doses of pyridostigmine that produced 50 or 30% inhibition in AChE activity had essentially the same protection against soman poisoning. Harris et al. (174) have shown that the mean ACh concentrations in physostigmine-treated rats were higher than in those animals treated with both physostigmine and soman. In the present studies, the combined effect on OP exposure of a carbamate AChE inhibitor, pyridostigmine (or physostigmine, neostigmine), with a cholinergic antagonist (scopolamine) was investigated. Because pyridostigmine is a charged molecule and does not readily penetrate the blood-brain barrier, the efficacy of opening the barrier by pretreatment with hyperosmolar urea or mannitol was also tested. Finally, HI-6, a potential reactivator of inhibited AChE, was investigated for its ability to ameliorate the CNS response to OP exposure.

Method. After a control period of 30-35 min, we added pyridostigmine (10 mg/l), physostigmine (0.03 mM), neostigmine (0.16 mM), or HI-6 (12.5 mg/l) to the perfusate and observed the EEG patterns, perfusion pressure, blood flow, and cerebral metabolism. Following an additional perfusion period of 10-30 min, OP (100 μg of soman) was rapidly administered via the arterial cannulae. Physostigmine under the above conditions was itself found to be convulsant; therefore, in two experiments the lipid-soluble muscarinic antagonist scopolamine (1.3 μM) preceded the
administration of physostigmine to block the cholinergic convulsant and vasodilatory actions of this reversible cholinesterase inhibitor. In two experiments with pyridostigmine, the brain was treated for 30 sec by infusion of either 1.2 M mannitol in saline or 2 M urea in saline to permeabilize the cerebrovasculature to the carbamate.

Results. Our results indicate that the cholinesterase inhibitors that are unable to penetrate the cerebrovascular endothelial layer are unable to induce vasodilation or substantial EEG and metabolic alterations. Pyridostigmine and HI-6, both very hydrophilic and ionic, are limited to the blood and do not cause vasodilation, induce seizure, or alter metabolism. Furthermore, when the brain vasculature was altered by hyperosmolar agents to allow penetration of pyridostigmine, no major alterations in blood flow, EEG, or metabolism were observed. In contrast, when physostigmine was added to the perfusate, the initial brain electrical activity pattern was altered, and strong vasodilation occurred immediately (Fig. 29). The initial characteristic change noted in the EEG was synchronization of electrical activity or the appearance of waves of low voltage and high frequency. Seizure occurred after ~5 min, and cerebral metabolism increased accordingly (Fig. 30). This pattern was similar to that observed with soman or sarin. However, when scopolamine was pre-administered to the perfusate, no dilation (Fig. 29) or seizure occurred; CMRs were unchanged (Fig. 30). Additional injection of soman during these experiments did not produce further changes in EEG, blood flow (Fig. 29), or metabolism of glucose, O₂, or CO₂ (data not shown).

In the first experiment with neostigmine, we progressively increased the concentration of the inhibitor in the perfusate from 0.02 mM to a final concentration of 0.1 mM. During this experiment, neostigmine did not produce changes in vasodilation or in glucose, O₂, or CO₂ metabolism. The EEG showed gradual changes with a decrease in amplitude and an increase in frequency. The remaining experiments were performed with a final neostigmine concentration of 0.16 mM. This concentration produced slow and sustained vasodilation with the same changes in EEG as previously described, with no effect on brain metabolism. Neostigmine was allowed to circulate for 15 min before soman (100 µg) was injected. OP did not produce additional vasodilation, except in one experiment in which the vasodilation was about 18% greater. The most consistent change was the reduction in the time of seizure genesis from 4-5 min to 2-3 min after OP injection. The development of seizure was followed by the typical increase in brain metabolism.

Administration of HI-6 (12.5 mg/l) into the perfusate during four separate experiments resulted in no changes in physiologic or metabolic parameters of the perfused brain. Brain electrical activity, monitored by EEG, blood flow, and glucose, lactate, and oxygen metabolism were unchanged. Following about 20 min of HI-6 exposure, OP (sarin, 400 µg) was administered, and no detectable difference was observed when compared to the response in the absence of HI-6.

Comment. With regard to the acute effects of the oxime-type cholinesterase inhibitors on the CNS, our results basically corroborate studies indicating that the brain endothelium is a major barrier to the entry and action of these agents. Compounds that are more lipid soluble, such as the tertiary amine physostigmine, are able to act centrally, but lipid-insoluble (water soluble) compounds such as pyridostigmine and HI-6 are not active centrally. However, our results also suggest "opening" the blood-brain barrier with hyperosmolar agents may not be effective for the blood-borne pyridostigmine compound.

In contrast to soman exposure, scopolamine prevented the physostigmine-induced dilation and seizure. Thus, a major distinction between OP agent mechanisms and physostigmine mechanisms was indicated. Neostigmine, as a quaternary ammonium drug, does not cross the blood-brain barrier easily. Although neostigmine, at elevated levels, was able to prevent OP-induced vasodilation, the occurrence of OP-induced seizure was precipitated. Because seizure genesis is dependent upon penetration of certain substances into the brain, a low accumulation of neostigmine (and subsequent elevation of ACh) within the brain tissue was not enough to produce seizure, but was enough to lower the seizure threshold. Under the conditions of our experiments, it appears that HI-6 in the CNS is poor in its protection or rapid reactivation from OP exposure.

The blocking of OP-induced vasodilation by the combination of physostigmine and scopolamine represents, to our knowledge, the first demonstration of the antagonism of this pathophysiological
effect of OP agents. Thus, the distinction between OP agent mechanisms and physostigmine mechanisms suggests the potential usefulness of this regimen for preventing a toxic effect from soman. These observations led to additional hypotheses involving the effect of OP agents on cerebrovascular blood flow regulating factors and are detailed further in Specific Aim 16 below.

Specific Aim 16. Determine the effects of nitric oxide and nitro blue tetrazolium on blood flow, cerebral metabolism, and brain electrical activity in control and in organophosphate-exposed brain.

Background. One of the neuropathologic consequences of OP toxicity is extensive vasodilation of the cerebral vasculature. To prevent or reverse this response by pharmacological means requires a better understanding of the underlying mechanisms. Previous studies (129, 175) have eliminated several potential mechanisms involving neurotransmitters as major contributors to the OP-induced vasodilation. Recent studies of blood flow regulation in cerebral arteries and in arteries from numerous other sources indicate that endothelial cells produce a factor that diffuses to the adjacent smooth muscle cell and causes the smooth muscle cell to relax (176). This so-called EDRF (endothelium-derived relaxing factor) is short lived ($T_{1/2} = 6$ sec), anionic, and hydrophobic (177). Some reports indicate that EDRF is nitric oxide (NO) and is derived from the amino acid arginine (178). To examine the possible role of NO (the putative EDRF) in the cerebral vasculature during soman exposure, NO was first tested as a vasoactive chemical in the perfused brain preparation. The oxidizing agent nitro blue tetrazolium was then tested for its ability to block soman-induced vasorelaxation.

Method. Vasactivity of NO. The canine brain was perfused for a minimum of 30 min to establish control and steady-state conditions. NO (0.001 M NaNO$_2$ in 0.01 N HCl) was then administered by injection into the arterial cannulae, and the perfusion pressure was observed for >5 min to monitor the CVR. The most dilute concentrations of NO were tested first, followed by increasingly higher concentrations. The CVR was allowed to return to constant control levels between NO administrations.

Nitro blue tetrazolium (NBT) experiments. NBT was dissolved in a minimum of 30% ethanol in saline and added slowly with mixing to the perfusate to a final concentration of 0.5 to 1 mM. Perfusion was maintained for 6-8 min before soman (100 g±g) was administered rapidly as a bolus into the arterial perfusate. Perfusion and determination of vascular resistance were continued for 15 min.

Results. NO was a potent and effective vasodilator in the canine cerebrovasculature when injected into the carotid arterial perfusate (data not shown). The response was immediate, concentration dependent, and reversible within approximately 5 min.

Cerebral metabolism and blood flow were minimally affected by NBT in the perfusate. However, when soman was administered with the inhibitor NBT present in the perfusate, the typically rapid vasorelaxation response was completely blocked (Fig. 31).

Comment. These findings indicate that NO has strong vasoactive relaxation properties in the cerebral circulation and corroborates previous reports (177, 179, 180). Furthermore, the data suggest that NO plays an important role in the pathophysiological vasodilation response to OP agents. This is the first such demonstration and suggests that OP-induced, noncholinergic vasodilation occurs by the EDRF pathway and that EDRF may be NO. OPs thus cause vasodilation by stimulating the formation of EDRF (NO). The pathway by which EDRF is formed and the signal transduction mechanism by which EDRF causes smooth muscle relaxation are, therefore, targets for therapeutic drugs aimed at preventing or minimizing the neurotoxicity of OP agents.
Table 1. Regional Cerebral Blood Flow in Perfused Canine Brain and the Effect of Soman Exposure.
Regional blood flow in the perfused canine brain was determined using \(^{[14}C\)iodoantipyrine as described in the Method of Specific Aim 2 and the legend to Fig. 9. The data are averages (± S.E.M.) of five control experiments and four soman (100 \(\mu\)g) exposure experiments. The total CBF in control brain was 0.67 ± 0.02 ml/g-min and in soman-exposed brain was 1.03 ± 0.10 ml/g-min.

<table>
<thead>
<tr>
<th>Region</th>
<th>Control (ml/g-min)</th>
<th>S.E.M.</th>
<th>After Soman (ml/g-min)</th>
<th>S.E.M.</th>
<th>Increase (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pituitary gland</td>
<td>1.01</td>
<td>±0.13</td>
<td>1.11</td>
<td>±0.28</td>
<td>10</td>
</tr>
<tr>
<td>Olfactory</td>
<td>0.77</td>
<td>±0.13</td>
<td>0.84</td>
<td>±0.14</td>
<td>9</td>
</tr>
<tr>
<td>Frontal cortex</td>
<td>1.12</td>
<td>±0.04</td>
<td>1.83</td>
<td>±0.18</td>
<td>64</td>
</tr>
<tr>
<td>Parietal cortex</td>
<td>1.14</td>
<td>±0.11</td>
<td>2.49</td>
<td>±0.26</td>
<td>118</td>
</tr>
<tr>
<td>Temporal cortex</td>
<td>1.04</td>
<td>±0.07</td>
<td>2.04</td>
<td>±0.24</td>
<td>96</td>
</tr>
<tr>
<td>Occipital cortex</td>
<td>0.88</td>
<td>±0.05</td>
<td>1.89</td>
<td>±0.12</td>
<td>115</td>
</tr>
<tr>
<td>Cerebral cortex</td>
<td>0.82</td>
<td>±0.08</td>
<td>1.37</td>
<td>±0.07</td>
<td>67</td>
</tr>
<tr>
<td>Vermis</td>
<td>0.81</td>
<td>±0.10</td>
<td>1.15</td>
<td>±0.08</td>
<td>42</td>
</tr>
<tr>
<td>Pons</td>
<td>0.49</td>
<td>±0.12</td>
<td>0.96</td>
<td>±0.08</td>
<td>96</td>
</tr>
<tr>
<td>Inferior colliculus</td>
<td>0.97</td>
<td>±0.06</td>
<td>1.73</td>
<td>±0.29</td>
<td>78</td>
</tr>
<tr>
<td>Midbrain</td>
<td>0.58</td>
<td>±0.03</td>
<td>1.29</td>
<td>±0.16</td>
<td>123</td>
</tr>
<tr>
<td>Rostral hippocampus</td>
<td>0.45</td>
<td>±0.03</td>
<td>0.70</td>
<td>±0.05</td>
<td>56</td>
</tr>
<tr>
<td>Caudal hippocampus</td>
<td>0.51</td>
<td>±0.03</td>
<td>0.76</td>
<td>±0.05</td>
<td>50</td>
</tr>
<tr>
<td>Thalamus</td>
<td>0.85</td>
<td>±0.10</td>
<td>1.68</td>
<td>±0.41</td>
<td>98</td>
</tr>
<tr>
<td>Caudate nucleus</td>
<td>0.92</td>
<td>±0.05</td>
<td>1.05</td>
<td>±0.08</td>
<td>14</td>
</tr>
<tr>
<td>White matter</td>
<td>0.17</td>
<td>±0.01</td>
<td>0.18</td>
<td>±0.02</td>
<td>4</td>
</tr>
<tr>
<td>Cerebellar white matter</td>
<td>0.32</td>
<td>±0.09</td>
<td>0.62</td>
<td>±0.10</td>
<td>95</td>
</tr>
<tr>
<td>Corpus callosum</td>
<td>0.39</td>
<td>±0.16</td>
<td>0.32</td>
<td>±0.03</td>
<td>-18</td>
</tr>
</tbody>
</table>
Table 2. Effects of Soman on Regional Utilization of Glucose. D-[6-14C]Glucose was infused into the arterial cannulae of control brains or brains with seizure activity induced by injecting 100 μg of soman. Ten minutes after isotope infusion, brains were quickly removed and frozen in liquid nitrogen-cooled isopentane. To measure radioactivity levels, brain sections (~25 μm) from the different regions were prepared and subjected to autoradiography.

<table>
<thead>
<tr>
<th>Brain Region</th>
<th>Control conditions (n = 3)</th>
<th>Seizure conditions (n = 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gyrus cinguli</td>
<td>0.64 ± 0.13</td>
<td>1.32 ± 0.21*</td>
</tr>
<tr>
<td>Striatum</td>
<td>0.78 ± 0.07</td>
<td>1.34 ± 0.34</td>
</tr>
<tr>
<td>Gyrus coronalis</td>
<td>0.68 ± 0.11</td>
<td>1.33 ± 0.13**</td>
</tr>
<tr>
<td>Corpus callosum</td>
<td>0.18 ± 0.05</td>
<td>0.56 ± 0.11*</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>0.46 ± 0.20</td>
<td>0.67 ± 0.14</td>
</tr>
<tr>
<td>Gyrus suprasylvius</td>
<td>0.68 ± 0.14</td>
<td>1.29 ± 0.24**</td>
</tr>
<tr>
<td>Cortex cerebellum</td>
<td>0.51 ± 0.11</td>
<td>1.02 ± 0.25</td>
</tr>
</tbody>
</table>

*p < 0.05 when compared to control values.

**p < 0.1 when compared to control values.
Table 3. L-[1-14C]Leucine Incorporation into Brain. Experiment conditions are as follows: perfusate flow, 0.66 and 0.30 ml/g-min for control conditions and during oligemia, respectively; plasma leucine, 54 nmol/ml; L-[1-14C]leucine infused, 100 μCi; L-[1-14C]leucine specific activity, 1.22 and 2.46 nCi/nmol for control conditions and during oligemia, respectively.

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Oligemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain radioactivity (nCi/g)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>59.5</td>
<td>285.1</td>
</tr>
<tr>
<td>Acid Insoluble</td>
<td>71.2</td>
<td>122.5</td>
</tr>
<tr>
<td>Leucine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Integrated plasma specific activity (μCi/sec/ml)</td>
<td>176</td>
<td>332</td>
</tr>
<tr>
<td>Brain concentration (nmol/mg)</td>
<td>0.15</td>
<td>0.15</td>
</tr>
</tbody>
</table>
Table 4. Uptake of L-[1-14C]Leucine by Perfused Canine Brain Under Control Conditions. L-[1-14C]Leucine (50-100 µCi) was infused into the arterial perfusate at a constant rate for 20 min. The brain vasculature was rapidly cleared (~10 sec) of radioactive perfusate with ice-cold saline before the brain was removed, sliced into five coronal slabs, and frozen. Twenty-micron thick sections were prepared and subjected to a first autoradiography. Following this initial exposure, the sections were washed with hot 5% TCA to remove unincorporated L-[1-14C]leucine and acid-soluble metabolites. The sections were dried and subjected to a second autoradiography. Both films were exposed for 20 days. The first autoradiogram represents protein synthesis plus primary free L-[1-14C]leucine. The second autoradiogram represents regional brain protein synthesis. Optical densities of the cerebral regions were determined, and tissue radioactivities were calculated using appropriate autoradiography standards. Table values are the averages of two separate brain perfusion experiments.

<table>
<thead>
<tr>
<th>Brain Slice Region</th>
<th>Free Leucine (TCA soluble) pCi/mg</th>
<th>Incorporated Leucine (TCA insoluble) pCi/mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anterior</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gray</td>
<td>107</td>
<td>481</td>
</tr>
<tr>
<td>White</td>
<td>75</td>
<td>118</td>
</tr>
<tr>
<td>Midbrain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gray</td>
<td>257</td>
<td>299</td>
</tr>
<tr>
<td>White</td>
<td>21</td>
<td>96</td>
</tr>
<tr>
<td>Posterior</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gray</td>
<td>11</td>
<td>363</td>
</tr>
<tr>
<td>White</td>
<td>43</td>
<td>86</td>
</tr>
</tbody>
</table>
Table 5. Uptake of L-[1-14C]Leucine by Perfused Canine Brain During Soman-induced Seizure. The experimental details are described in Table 4 except that the L-[1-14C]leucine infusion was started 1 min after arterial injection of 100 μg of soman. Optical densities of the cerebral regions were determined, and tissue radioactivities were calculated using appropriate autoradiography standards. Table values are the averages of two separate brain perfusion experiments.

<table>
<thead>
<tr>
<th>Brain Slice Region</th>
<th>Free Leucine (TCA soluble) pCi/mg</th>
<th>Incorporated Leucine (TCA insoluble) pCi/mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anterior</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gray</td>
<td>278</td>
<td>139</td>
</tr>
<tr>
<td>White</td>
<td>96</td>
<td>32</td>
</tr>
<tr>
<td>Midbrain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gray</td>
<td>342</td>
<td>150</td>
</tr>
<tr>
<td>White</td>
<td>107</td>
<td>43</td>
</tr>
<tr>
<td>Posterior</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gray</td>
<td>310</td>
<td>285</td>
</tr>
<tr>
<td>White</td>
<td>86</td>
<td>53</td>
</tr>
</tbody>
</table>
Table 6. Regional Protein Synthesis in Perfused Canine Brain After Soman Exposure. The experimental details are described in Table 4. In the experiments with soman, L-[1\(^{14}\)C]leucine infusion was started 1 min after arterial injection of 100 μg of soman. The percentages of L-[1\(^{14}\)C]leucine incorporated into protein (TCA insoluble) were determined relative to the total L-[1\(^{14}\)C]leucine uptake (total radioactivity) in regions of the cerebral cortex. Two control and two soman exposure experiments were performed, and the values from each are averaged.

<table>
<thead>
<tr>
<th>Brain Slice Region</th>
<th>Control (%)</th>
<th>Soman Exposure (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anterior</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gray</td>
<td>89</td>
<td>32</td>
</tr>
<tr>
<td>White</td>
<td>69</td>
<td>23</td>
</tr>
<tr>
<td>Midbrain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gray</td>
<td>65</td>
<td>30</td>
</tr>
<tr>
<td>White</td>
<td>85</td>
<td>26</td>
</tr>
<tr>
<td>Posterior</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gray</td>
<td>97</td>
<td>46</td>
</tr>
<tr>
<td>White</td>
<td>70</td>
<td>36</td>
</tr>
</tbody>
</table>
Table 7. Unidirectional Influx of Glucose. Dog brains were isolated and perfused as described in METHODS. Indicator dilutions were performed as described previously (44) after soman exposure (100 μg), carbachol treatment (1 μM), carbachol + soman treatment (1 μM and 100 μg, respectively), arecoline treatment (20 μM), or AF64a. Data are mean ± S.E.M. values.

<table>
<thead>
<tr>
<th>Conditions</th>
<th>( V_{in} ) (μmol/g.min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (n = 22)</td>
<td>0.64 ± 0.06</td>
</tr>
<tr>
<td>After soman exposure</td>
<td></td>
</tr>
<tr>
<td>5 min (n = 3)</td>
<td>0.89 ± 0.12</td>
</tr>
<tr>
<td>30 min (n = 3)</td>
<td>1.07 ± 0.33</td>
</tr>
<tr>
<td>After carbachol exposure</td>
<td></td>
</tr>
<tr>
<td>10 min (n = 2)</td>
<td>0.89</td>
</tr>
<tr>
<td>30 min (n = 2)</td>
<td>0.68</td>
</tr>
<tr>
<td>After carbachol + soman exposure</td>
<td></td>
</tr>
<tr>
<td>5 min (n = 1)</td>
<td>1.12</td>
</tr>
<tr>
<td>20 min (n = 1)</td>
<td>1.09</td>
</tr>
<tr>
<td>After arecoline exposure</td>
<td></td>
</tr>
<tr>
<td>10 min (n = 2)</td>
<td>0.59</td>
</tr>
<tr>
<td>30 min (n = 2)</td>
<td>0.40</td>
</tr>
<tr>
<td>During AF64a exposure (n = 1)</td>
<td>0.72</td>
</tr>
</tbody>
</table>
Table 8. Unidirectional Influx of Leucine. Dog brains were isolated and perfused as described in METHODS. Indicator dilutions were performed as described previously (44) after soman exposure (100 µg), carbachol treatment (1 µM), carbachol + soman treatment (1 µM and 100 µg, respectively), arecoline treatment (20 µM), or AF64a. Data are mean ± S.E.M. values.

<table>
<thead>
<tr>
<th>Conditions</th>
<th>( V'_{ln} ) (nmol/g-min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (n = 18)</td>
<td>15.01 ± 0.55</td>
</tr>
<tr>
<td>After soman exposure</td>
<td></td>
</tr>
<tr>
<td>5 min (n = 3)</td>
<td>15.07 ± 3.28</td>
</tr>
<tr>
<td>30 min (n = 3)</td>
<td>23.44 ± 2.48</td>
</tr>
<tr>
<td>After carbachol exposure</td>
<td></td>
</tr>
<tr>
<td>10 min (n = 2)</td>
<td>14.74</td>
</tr>
<tr>
<td>30 min (n = 2)</td>
<td>12.29</td>
</tr>
<tr>
<td>After carbachol + soman exposure</td>
<td></td>
</tr>
<tr>
<td>5 min (n = 1)</td>
<td>13.78</td>
</tr>
<tr>
<td>20 min (n = 1)</td>
<td>12.43</td>
</tr>
<tr>
<td>After arecoline exposure</td>
<td></td>
</tr>
<tr>
<td>10 min (n = 2)</td>
<td>14.71</td>
</tr>
<tr>
<td>30 min (n = 2)</td>
<td>18.94</td>
</tr>
<tr>
<td>During AF64a exposure (n = 1)</td>
<td>12.13</td>
</tr>
</tbody>
</table>
Table 9. Unidirectional influx of Glycine. Dog brains were isolated and perfused as described in METHODS. Indicator dilutions were performed as described previously (44) after soman exposure (100 μg), carbachol treatment (1 μM), carbachol + soman treatment (1 μM and 100 μg, respectively), arecoline treatment (20 μM), or AF64a. Data are mean ± S.E.M. values.

<table>
<thead>
<tr>
<th>Conditions</th>
<th>( v_{1n} ) (nmol/g·min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (n = 18)</td>
<td>4.05 ± 0.84</td>
</tr>
<tr>
<td>After soman exposure</td>
<td></td>
</tr>
<tr>
<td>5 min (n = 2)</td>
<td>11.93</td>
</tr>
<tr>
<td>30 min (n = 3)</td>
<td>12.52 ± 4.17</td>
</tr>
<tr>
<td>After carbachol exposure</td>
<td></td>
</tr>
<tr>
<td>10 min (n = 2)</td>
<td>7.78</td>
</tr>
<tr>
<td>30 min (n = 2)</td>
<td>4.35</td>
</tr>
<tr>
<td>After carbachol + soman exposure</td>
<td></td>
</tr>
<tr>
<td>5 min (n = 1)</td>
<td>5.53</td>
</tr>
<tr>
<td>20 min (n = 1)</td>
<td>3.98</td>
</tr>
<tr>
<td>During AF64a exposure (n = 1)</td>
<td>3.90</td>
</tr>
</tbody>
</table>
Table 10. Unidirectional Influx of Choline. Dog brains were isolated and perfused as described in METHODS. Indicator dilutions were performed as described previously (44) after soman exposure (100 μg), carbachol treatment (1 μM), carbachol + soman treatment (1 μM and 100 μg, respectively), arecoline treatment (20 μM), or AF64a. Data are mean ± S.E.M values.

<table>
<thead>
<tr>
<th>Conditions</th>
<th>$V_{in}$ (nmol/g-min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (n = 22)</td>
<td>0.61 ± 0.13</td>
</tr>
<tr>
<td>After soman exposure</td>
<td></td>
</tr>
<tr>
<td>5 min (n = 3)</td>
<td>0.56 ± 0.07</td>
</tr>
<tr>
<td>30 min (n = 3)</td>
<td>0.61 ± 0.07</td>
</tr>
<tr>
<td>After carbachol exposure</td>
<td></td>
</tr>
<tr>
<td>10 min (n = 2)</td>
<td>0.58</td>
</tr>
<tr>
<td>30 min (n = 2)</td>
<td>0.50</td>
</tr>
<tr>
<td>After carbachol + soman exposure</td>
<td></td>
</tr>
<tr>
<td>5 min (n = 1)</td>
<td>0.50</td>
</tr>
<tr>
<td>20 min (n = 1)</td>
<td>0.43</td>
</tr>
<tr>
<td>After arecoline exposure</td>
<td></td>
</tr>
<tr>
<td>10 min (n = 2)</td>
<td>0.54</td>
</tr>
<tr>
<td>30 min (n = 2)</td>
<td>0.58</td>
</tr>
<tr>
<td>During AF64a exposure (n = 1)</td>
<td>0.56</td>
</tr>
</tbody>
</table>
### Table 11. Levels of Choline (Ch) and Acetylcholine (ACh) (nmol/g) in Tissue From Various Regions of Canine Brain.

<table>
<thead>
<tr>
<th>Region</th>
<th>Nonperfused brain</th>
<th>Perfused brain</th>
<th>Nonrecirculated</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 3)</td>
<td>5 min (n = 2)</td>
<td>90 min (n = 3)</td>
</tr>
<tr>
<td></td>
<td>Ch (nmol/g)</td>
<td>Ch (nmol/g)</td>
<td>Ch (nmol/g)</td>
</tr>
<tr>
<td></td>
<td>41 ± 1.2</td>
<td>168 ± 7</td>
<td>295 ± 71</td>
</tr>
<tr>
<td></td>
<td>4.3 ± 0.4</td>
<td>5.1 ± 0.1</td>
<td>6.6 ± 1.2</td>
</tr>
<tr>
<td>Brain stem</td>
<td>Ch (nmol/g)</td>
<td>79 ± 1</td>
<td>108 ± 2</td>
</tr>
<tr>
<td></td>
<td>4.1 ± 0.1</td>
<td>2.9 ± 0.1</td>
<td>2.8 ± 0.2</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>Ch (nmol/g)</td>
<td>67 ± 3</td>
<td>131 ± 9</td>
</tr>
<tr>
<td></td>
<td>1.2 ± 0.2</td>
<td>1.1 ± 0.2</td>
<td>0.8 ± 0.1</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>Ch (nmol/g)</td>
<td>61 ± 4</td>
<td>101 ± 3</td>
</tr>
<tr>
<td></td>
<td>0.8 ± 0.1</td>
<td>0.4 ± 0.01</td>
<td>0.6 ± 0.1</td>
</tr>
</tbody>
</table>

Data are mean ± S.E.M values.

- "a"p<0.05 when compared with values for 5-min recirculated perfusate.
- "b"p<0.005 when compared with values for 5-min recirculated perfusate.
- "c"p<0.01 when compared with values for 5-min recirculated perfusate.

55
Table 12. Cerebral Metabolism Rates for Choline (CMRCh).

<table>
<thead>
<tr>
<th></th>
<th>Perfusate Ch (nmol/ml)</th>
<th>(A - V)/F/W (nmol/g·min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonrecirculated (n = 4)</td>
<td>2.9 ± 0.2</td>
<td>-1.1 ± 0.1</td>
</tr>
<tr>
<td>Recirculated (n = 5)</td>
<td>4.9 ± 1.1</td>
<td>-1.6 ± 0.4</td>
</tr>
</tbody>
</table>

The CMRCh (nmol/g·min) was calculated by the following equation: efflux = (A - F)/F/W, in which A and V are the respective concentrations of Ch in the arterial and venous samples (nmol/ml), F is the blood flow rate (ml/min), and W is the brain weight (g). Samples for Ch analysis were collected at 5-min intervals over a maximal period of 55 min for nonrecirculation experiments and at 10-min intervals over a 30-min period for recirculation experiments. Data are mean ± S.E.M values.

Table 13. Unidirectional Influx of Choline (Ch).

<table>
<thead>
<tr>
<th>Conditions</th>
<th>(v'_{in}) (nmol/g·min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (n = 9)</td>
<td>0.49 ± 0.07</td>
</tr>
<tr>
<td>After soman exposure</td>
<td></td>
</tr>
<tr>
<td>10 min (n = 5)</td>
<td>0.48 ± 0.07</td>
</tr>
<tr>
<td>40 min (n = 6)</td>
<td>0.42 ± 0.09</td>
</tr>
</tbody>
</table>

Influx velocity was determined by the indicator dilution method (44) before and at two intervals after soman (100 µg) administration. In this method, velocity, \(v'_{in}\), is calculated by the following formula: \(v'_{in} = E \times A \times F/W\), in which E is the maximal extraction, A is the plasma Ch concentration, F is the plasma net flow rate, and W is the brain weight. Data are mean ± S.E.M values. The plasma Ch concentration used for calculation was 4.9 nmol/ml (Table 12). The experiments were conducted with recirculation of perfusate.
Table 14. Effects of Soman and Sarin on Acetylcholine (ACh) Levels (nmol/g) in Various Regions of Isolated, Perfused Canine Brain.

<table>
<thead>
<tr>
<th>Region</th>
<th>Control</th>
<th>Soman 5 min after</th>
<th>Soman 60 min after</th>
<th>Sarin 5 min after</th>
<th>Sarin 60 min after</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cortex</td>
<td>6.6 ± 1.2</td>
<td>67 ± 7 a</td>
<td>40 ± 8 b</td>
<td>22 ± 1 a</td>
<td>25 ± 2 a</td>
</tr>
<tr>
<td>Brain stem</td>
<td>2.8 ± 0.2</td>
<td>54 ± 1 a</td>
<td>46 ± 8 a</td>
<td>18 ± 2 a</td>
<td>56 ± 2 a</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>0.8 ± 0.1</td>
<td>41 ± 5 a</td>
<td>105 ± 7 a</td>
<td>19 ± 1 a</td>
<td>20 ± 1 a</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>0.6 ± 0.1</td>
<td>1.6 ± 0.8</td>
<td>5.3 ± 1.2 b</td>
<td>1.0 ± 0.1</td>
<td>5.0 ± 0.6 a</td>
</tr>
</tbody>
</table>

Data are mean ± S.E.M values for three experiments. Controls are the concentrations in untreated brain perfused for 90 min under recirculation conditions (Table 11).

a p<0.01 when compared with control values.
b p<0.05 when compared with control values.

Table 15. Effects of Soman and Sarin on Choline (Ch) Levels (nmol/g) in Various Regions of Isolated, Perfused Canine Brain.

<table>
<thead>
<tr>
<th>Region</th>
<th>Control</th>
<th>Soman 5 min after</th>
<th>Soman 60 min after</th>
<th>Sarin 5 min after</th>
<th>Sarin 60 min after</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cortex</td>
<td>295 ± 71</td>
<td>500 ± 10</td>
<td>258 ± 67</td>
<td>500 ± 4 a</td>
<td>328 ± 5</td>
</tr>
<tr>
<td>Brain stem</td>
<td>239 ± 6</td>
<td>839 ± 221</td>
<td>718 ± 52</td>
<td>716 ± 10 b</td>
<td>517 ± 9 b</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>284 ± 19</td>
<td>580 ± 15 b</td>
<td>422 ± 29 b</td>
<td>614 ± 9 b</td>
<td>525 ± 7 b</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>274 ± 22</td>
<td>736 ± 25 b</td>
<td>452 ± 29 b</td>
<td>626 ± 9 b</td>
<td>374 ± 9 b</td>
</tr>
</tbody>
</table>

Data are mean ± S.E.M values for three experiments. Controls are the concentrations in untreated brain perfused for 90 min under recirculation conditions (Table 11).

a p<0.01 when compared with control values.
b p<0.05 when compared with control values.
Table 16. Phospholipase D Activity and the Effects of Diisopropylfluorophosphate (DFP) on the Hydrolysis of 1,2 Dipalmitoyl-sn-glycero-3-phosphoryl[\textsuperscript{3}H]choline by Phospholipase D Activity in Subcellular Fractions from Canine Brain.

<table>
<thead>
<tr>
<th>Activity (nmol [\textsuperscript{3}H]choline released/hr/mg of protein)</th>
<th>Control</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A</td>
<td>B</td>
<td>A</td>
<td>B</td>
<td>A</td>
<td>B</td>
<td>A</td>
<td>B</td>
<td>A</td>
<td>B</td>
<td>A</td>
<td>B</td>
<td></td>
</tr>
<tr>
<td>Homogenate</td>
<td>2.25</td>
<td>2.56</td>
<td>2.15</td>
<td>2.83</td>
<td>1.72</td>
<td>1.6</td>
<td>1.57</td>
<td>1.6</td>
<td>3.6</td>
<td>3.46</td>
<td>3.47</td>
<td>3.23</td>
<td></td>
</tr>
<tr>
<td>Crude membrane fraction</td>
<td>1.72</td>
<td>1.6</td>
<td>1.57</td>
<td>1.6</td>
<td>3.6</td>
<td>3.46</td>
<td>3.47</td>
<td>3.23</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microsomes</td>
<td>2.25</td>
<td>2.56</td>
<td>2.15</td>
<td>2.83</td>
<td>1.72</td>
<td>1.6</td>
<td>1.57</td>
<td>1.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A and B are separate experiments with subcellular fractions obtained from two brains. Values are averages of two determinations. The incubation medium in 0.25 ml contained 40 mM HEPES buffer, pH 7.4, 0.1% Triton-X 100, 132 \textmu M \textsuperscript{3}H choline-labeled phosphatidylcholine (3.3 x 10\textsuperscript{5} dpm; specific activity 1 x 10\textsuperscript{4} dpm/nmol) and brain subcellular fractions (200-500 \textmu g protein). Test incubation mixtures contained 50 \textmu g of DIFP in 5 \textmu l of ethanol. Incubation mixtures were held at 37°C with shaking for 30 min. Reactions were stopped, and lipids were extracted and analyzed as described in Specific Aim 7.
Table 17. Effects of Detergents on Hydrolysis of 1,2-Dipalmitoyl-sn-glycero-3-phosphoryl-[\textsuperscript{3}H]choline by Microsomal Phospholipase D.

<table>
<thead>
<tr>
<th>Detergent concentration</th>
<th>0.2 mg/ml</th>
<th>0.4 mg/ml</th>
<th>1.0 mg/ml</th>
<th>2.0 mg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium deoxycholate</td>
<td>55</td>
<td>75</td>
<td>69</td>
<td>27</td>
</tr>
<tr>
<td>Sodium oleate</td>
<td>93</td>
<td>55</td>
<td>45</td>
<td>21</td>
</tr>
<tr>
<td>Sodium linoleate</td>
<td>82</td>
<td>76</td>
<td>75</td>
<td>76</td>
</tr>
<tr>
<td>CHAPS</td>
<td>79</td>
<td>118</td>
<td>95</td>
<td>121</td>
</tr>
<tr>
<td>Octylglucopyranoside</td>
<td>124</td>
<td>159</td>
<td>54</td>
<td>29</td>
</tr>
<tr>
<td>Triton X-100</td>
<td>110</td>
<td>141</td>
<td>287</td>
<td>340</td>
</tr>
</tbody>
</table>

Values are averages of two determinations with the control value considered to be 100%. Incubation medium in 0.25 ml contained 40 mM HEPES buffer, pH 7.4, 132 \(\mu\)M [\textsuperscript{3}H]choline-labeled phosphatidylcholine (3.3 x 10\textsuperscript{5} dpm; specific activity 1 x 10\textsuperscript{4} dpm/nmol), microsomal protein (275 \(\mu\)g protein), and detergents as listed. The incubation period was 30 min at 37\(^\circ\)C with shaking. Reactions were stopped by adding methanol, and lipids were extracted and analyzed as described in Specific Aim 7.
Table 18. Effects of EDTA and Cations on the Hydrolysis of 1,2-Dipalmitoyl-sn-glycero-3-phosphoryl[3H]choline by Microsomal Phospholipase D.

<table>
<thead>
<tr>
<th>Additions</th>
<th>Activity (% of control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No additions (Control)</td>
<td>100</td>
</tr>
<tr>
<td>EDTA</td>
<td></td>
</tr>
<tr>
<td>1 mM</td>
<td>96</td>
</tr>
<tr>
<td>4 mM</td>
<td>97</td>
</tr>
<tr>
<td>Ca2+</td>
<td></td>
</tr>
<tr>
<td>0.5 mM</td>
<td>91</td>
</tr>
<tr>
<td>2 mM</td>
<td>76</td>
</tr>
<tr>
<td>4 mM</td>
<td>68</td>
</tr>
<tr>
<td>Mg2+</td>
<td></td>
</tr>
<tr>
<td>0.5 mM</td>
<td>91</td>
</tr>
<tr>
<td>2 mM</td>
<td>76</td>
</tr>
<tr>
<td>4 mM</td>
<td>73</td>
</tr>
<tr>
<td>Zn2+</td>
<td></td>
</tr>
<tr>
<td>0.5 mM</td>
<td>50</td>
</tr>
<tr>
<td>2 mM</td>
<td>22</td>
</tr>
<tr>
<td>4 mM</td>
<td>6</td>
</tr>
</tbody>
</table>

Values are the averages of two determinations. Incubations were as described in Table 17 and in the presence of 1 mg/ml Triton X-100.
Table 19. Blood-brain Transport of [3H]Palmitic Acid. Approximately 1.2 mCi of [3H]palmitate in ethanol, dried under nitrogen, and resuspended in 250 µl of saline were infused into the carotid cannulae at a constant rate over a 5-min period. The influx constant was determined from the relationship $K_{in} = \frac{C_{br}}{C_{a}} t$, in which $C_{br}$ is the concentration (dpm/mg) of 3H-labeled free fatty acid in brain, $C_{a}$ is the concentration in perfusate plasma (dpm/ml), and $t$ is the time (sec). Values are expressed as ml/g·sec·$10^5$. The $K_{in}$ values are related to permeability x surface area (P x S) products by the following relationship: $K_{in} = F \times \ln(1 - e^{-PxS/F})$, in which $F$ is the perfusate flow rate (mg/g·sec), $P$ is the permeability (sec$^{-1}$), and $S$ is the vascular surface area (cm$^2$/g). However, when P x S is very small, $K_{in} = P \times S$, and, therefore the $K_{in}$ values in Tables 19 and 20 can also be expressed as the P x S product.

<table>
<thead>
<tr>
<th>Brain regions</th>
<th>Control (n = 4)</th>
<th>Soman (n = 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cortex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frontal</td>
<td>7.3 ± 3.4</td>
<td>13 ± 3</td>
</tr>
<tr>
<td>Parietal</td>
<td>7.1 ± 3.0</td>
<td>15 ± 4</td>
</tr>
<tr>
<td>Temporal</td>
<td>5.8 ± 2.5</td>
<td>11 ± 2</td>
</tr>
<tr>
<td>Occipital</td>
<td>9.9 ± 5.3</td>
<td>21 ± 6</td>
</tr>
<tr>
<td>Cerebellar cortex</td>
<td>7.3 ± 3.0</td>
<td>18 ± 3</td>
</tr>
<tr>
<td>Vermis</td>
<td>10.4 ± 6.1</td>
<td>16 ± 3</td>
</tr>
<tr>
<td>Pons</td>
<td>4.7 ± 2.4</td>
<td>9 ± 2</td>
</tr>
<tr>
<td>Colliculus inferior</td>
<td>7.1 ± 2.5</td>
<td>28 ± 10</td>
</tr>
<tr>
<td>Midbrain</td>
<td>5.1 ± 2.2</td>
<td>11 ± 2</td>
</tr>
<tr>
<td>Hippocampus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rostral</td>
<td>4.2 ± 1.5</td>
<td>9 ± 2</td>
</tr>
<tr>
<td>Caudal</td>
<td>4.3 ± 1.8</td>
<td>8 ± 1</td>
</tr>
<tr>
<td>Thalamus</td>
<td>7.7 ± 4.0</td>
<td>30 ± 11</td>
</tr>
<tr>
<td>Caudate nucleus</td>
<td>5.1 ± 2.0</td>
<td>17 ± 9</td>
</tr>
<tr>
<td>White matter</td>
<td>2.1 ± 0.8</td>
<td>6 ± 2</td>
</tr>
<tr>
<td>Pituitary</td>
<td>71 ± 40</td>
<td>101 ± 22</td>
</tr>
</tbody>
</table>

61
Table 20. Blood-brain Transport of $[^3]$H$[^3]$oleic Acid. Approximately 1.2 mCi of $[^3]$H$[^3]$oleate in ethanol, dried under nitrogen and resuspended in 250 μl of saline, were infused into the carotid cannulae at a constant rate over a 5-min period. The influx constant was determined from the relationship $K_{in} = C_{br}^* C_a^* dt$, in which $C_{br}^*$ is the concentration (dpm/mg) of $[^3]$H-labeled free fatty acid in brain, $C_a^*$ is the concentration in perfusate plasma (dpm/ml), and $t$ is the time (sec). Values are expressed as ml/g·sec·10^5. $K_{in}$ values are related to permeability x surface area (P x S) products by the relationship $K_{in} = F \times \ln(1 - e^{-P x S/F})$, in which $F$ is the perfusate flow rate (mg/g·sec), $P$ is the permeability (sec⁻¹), and $S$ is the vascular surface area (cm²/g). However, when $P x S$ is very small, $K_{in} = P x S$, and, therefore the $K_{in}$ values in Tables 19 and 20 can also be expressed as the $P x S$ product.

<table>
<thead>
<tr>
<th>Brain regions</th>
<th>Control</th>
<th>Soman</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 3)</td>
<td>(n = 3)</td>
</tr>
<tr>
<td>Cortex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frontal</td>
<td>32 ± 7</td>
<td>28 ± 16</td>
</tr>
<tr>
<td>Parietal</td>
<td>43 ± 14</td>
<td>25 ± 12</td>
</tr>
<tr>
<td>Temporal</td>
<td>20 ± 2</td>
<td>23 ± 7</td>
</tr>
<tr>
<td>Occipital</td>
<td>20 ± 4</td>
<td>37 ± 28</td>
</tr>
<tr>
<td>Cerebellar cortex</td>
<td>19 ± 1</td>
<td>34 ± 26</td>
</tr>
<tr>
<td>Vermis</td>
<td>17 ± 2</td>
<td>28 ± 17</td>
</tr>
<tr>
<td>Pons</td>
<td>9 ± 0</td>
<td>15 ± 3</td>
</tr>
<tr>
<td>Colliculus inferior</td>
<td>31 ± 11</td>
<td>51 ± 38</td>
</tr>
<tr>
<td>Midbrain</td>
<td>37 ± 26</td>
<td>27 ± 21</td>
</tr>
<tr>
<td>Hippocampus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rostral</td>
<td>15 ± 5</td>
<td>15 ± 6</td>
</tr>
<tr>
<td>Caudal</td>
<td>18 ± 6</td>
<td>25 ± 12</td>
</tr>
<tr>
<td>Thalamus</td>
<td>24 ± 6</td>
<td>30 ± 12</td>
</tr>
<tr>
<td>Caudate nucleus</td>
<td>15 ± 4</td>
<td>27 ± 11</td>
</tr>
<tr>
<td>White matter</td>
<td>12 ± 2</td>
<td>4 ± 1</td>
</tr>
<tr>
<td>Pituitary</td>
<td>71 ± 8</td>
<td>96 ± 27</td>
</tr>
</tbody>
</table>
Table 21. Free Fatty Acid Concentrations in Perfusate. Plasma lipids were extracted, and free fatty acids were separated along with C17:0 fatty acid as the internal standard. The fatty acids were converted to methyl esters by reaction with diazomethane and were analyzed by gas liquid chromatography. Values are expressed as means ± S.D., n = 12.

<table>
<thead>
<tr>
<th>Fatty acid</th>
<th>Concentration (μM)</th>
<th>Percent of total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palmitic (16:0)</td>
<td>80 ± 18</td>
<td>25.8</td>
</tr>
<tr>
<td>Palmitoleic (16:1)</td>
<td>16 ± 9</td>
<td>5.2</td>
</tr>
<tr>
<td>Stearic (18:0)</td>
<td>41 ± 12</td>
<td>13.2</td>
</tr>
<tr>
<td>Oleic (18:1)</td>
<td>83 ± 30</td>
<td>26.0</td>
</tr>
<tr>
<td>Linoleic (18:2)</td>
<td>55 ± 30</td>
<td>17.7</td>
</tr>
<tr>
<td>Linolenic (18:3)</td>
<td>20 ± 11</td>
<td>6.5</td>
</tr>
<tr>
<td>Arachidonic (20:4)</td>
<td>15 ± 10</td>
<td>4.8</td>
</tr>
</tbody>
</table>
Table 22. [$^3$H]Palmitate Incorporated into Lipids.
Control values are means ± S.E.M. from three experiments.

<table>
<thead>
<tr>
<th>Lipids</th>
<th>Cortex</th>
<th>Thalamus</th>
<th>Hypothalamus</th>
<th>Caudate</th>
<th>Hippocampus</th>
<th>Brain stem</th>
<th>Cerebellum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sphingomyelin</td>
<td>4.6 ± 0.1</td>
<td>2.7 ± 0.1</td>
<td>5.2 ± 1.7</td>
<td>7.5 ± 3.2</td>
<td>3.7 ± 0.9</td>
<td>6.5 ± 1.8</td>
<td>3.5 ± 0.5</td>
</tr>
<tr>
<td>Phosphatidylcholine</td>
<td>15.0 ± 1.1</td>
<td>9.6 ± 0.5</td>
<td>15.0 ± 4.2</td>
<td>14.2 ± 1.9</td>
<td>8.8 ± 0.7</td>
<td>17.0 ± 4.1</td>
<td>14.0 ± 2.9</td>
</tr>
<tr>
<td>Phosphatidylinositol</td>
<td>1.1 ± 0.1</td>
<td>0.8 ± 0.0</td>
<td>1.1 ± 0.3</td>
<td>1.8 ± 0.7</td>
<td>0.8 ± 0.1</td>
<td>0.9 ± 0.1</td>
<td>1.2 ± 0.1</td>
</tr>
<tr>
<td>Phosphatidylserine</td>
<td>0.8 ± 0.1</td>
<td>0.3 ± 0.0</td>
<td>0.7 ± 0.1</td>
<td>1.2 ± 0.6</td>
<td>0.3 ± 0.1</td>
<td>0.6 ± 0.0</td>
<td>0.8 ± 0.3</td>
</tr>
<tr>
<td>Phosphatidylethanolamine</td>
<td>1.1 ± 0.1</td>
<td>1.0 ± 1.1</td>
<td>1.0 ± 0.2</td>
<td>1.4 ± 0.8</td>
<td>1.0 ± 0.4</td>
<td>1.3 ± 0.1</td>
<td>1.4 ± 0.7</td>
</tr>
<tr>
<td>Others, incl. fatty acids</td>
<td>12 ± 1</td>
<td>8 ± 0.5</td>
<td>6 ± 0.2</td>
<td>8 ± 4</td>
<td>6 ± 0.8</td>
<td>6 ± 0.2</td>
<td>13 ± 3</td>
</tr>
</tbody>
</table>

Table 23. Effects of Soman on [$^3$H]Palmitate Incorporated into Lipids.
Values after soman (100 μg) exposure are means ± S.E.M. from three experiments.

<table>
<thead>
<tr>
<th>Lipids</th>
<th>Cortex</th>
<th>Thalamus</th>
<th>Hypothalamus</th>
<th>Caudate</th>
<th>Hippocampus</th>
<th>Brain stem</th>
<th>Cerebellum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sphingomyelin</td>
<td>0.9 ± 0.2a</td>
<td>0.5 ± 0.2a</td>
<td>0.6 ± 0.2b</td>
<td>0.4 ± 0.1b</td>
<td>0.4 ± 0.1a</td>
<td>0.8 ± 0.2a</td>
<td></td>
</tr>
<tr>
<td>Phosphatidylcholine</td>
<td>6.4 ± 1.9a</td>
<td>6.8 ± 1.1</td>
<td>6.9 ± 0.7</td>
<td>6.6 ± 1.0b</td>
<td>4.7 ± 1.1b</td>
<td>7.3 ± 2.3</td>
<td>14.0 ± 5.2</td>
</tr>
<tr>
<td>Phosphatidylinositol</td>
<td>1.4 ± 0.2</td>
<td>0.9 ± 0.2</td>
<td>1.9 ± 0.2</td>
<td>0.9 ± 0.1</td>
<td>0.7 ± 0.1</td>
<td>0.8 ± 0.2</td>
<td>2.3 ± 0.5</td>
</tr>
<tr>
<td>Phosphatidylserine</td>
<td>0.3 ± 0.2</td>
<td>0.1 ± 0.1</td>
<td>0.3 ± 0.2</td>
<td>ND</td>
<td>ND</td>
<td>0.3 ± 0.1</td>
<td>0.2 ± 0.1</td>
</tr>
<tr>
<td>Phosphatidylethanolamine</td>
<td>1.1 ± 0.4</td>
<td>1.4 ± 0.4</td>
<td>1.6 ± 0.4</td>
<td>0.8 ± 0.4</td>
<td>0.8 ± 0.3</td>
<td>1.4 ± 0.6</td>
<td>2.9 ± 0.3</td>
</tr>
<tr>
<td>Others, incl. fatty acids</td>
<td>38 ± 2a</td>
<td>35 ± 10b</td>
<td>26 ± 1a</td>
<td>42 ± 13</td>
<td>20 ± 7</td>
<td>25 ± 7b</td>
<td>39 ± 12</td>
</tr>
</tbody>
</table>

$^ap < 0.01$
$^bp < 0.05$
ND = not detected
### Table 24. [3H]Oleate Incorporated Into Lipids.
Control values are means ± S.E.M. from three experiments.

<table>
<thead>
<tr>
<th>Lipids</th>
<th>Cortex</th>
<th>Thalamus</th>
<th>Hypothalamus</th>
<th>Caudate</th>
<th>Hippocampus</th>
<th>Brain stem</th>
<th>Cerebellum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sphingomyelin</td>
<td>0.8 ± 0.2</td>
<td>1.0 ± 0.5</td>
<td>0.3 ± 0</td>
<td>0.4 ± 0.2</td>
<td>0.2 ± 0.2</td>
<td>0.3 ± 0</td>
<td>0.7 ± 0</td>
</tr>
<tr>
<td>Phosphatidylcholine</td>
<td>11.0 ± 0.2</td>
<td>9.6 ± 1.2</td>
<td>6.9 ± 0.4</td>
<td>9.5 ± 0.3</td>
<td>6.4 ± 1.0</td>
<td>5.2 ± 0.6</td>
<td>9.6 ± 1.3</td>
</tr>
<tr>
<td>Phosphatidylinositol</td>
<td>2.3 ± 0.5</td>
<td>1.8 ± 0.2</td>
<td>1.2 ± 0.3</td>
<td>1.8 ± 0.3</td>
<td>1.3 ± 0.3</td>
<td>0.7 ± 0</td>
<td>2.2 ± 0.4</td>
</tr>
<tr>
<td>Phosphatidylserine</td>
<td>0.7 ± 0.3</td>
<td>0.5 ± 0.3</td>
<td>0.4 ± 0.1</td>
<td>0.8 ± 0.3</td>
<td>0.2 ± 0.2</td>
<td>0.2 ± 0.1</td>
<td>0.4 ± 0.1</td>
</tr>
<tr>
<td>Phosphatidylethanolamine</td>
<td>5.5 ± 0.2</td>
<td>5.0 ± 0.9</td>
<td>3.2 ± 0.1</td>
<td>3.3 ± 0.1</td>
<td>2.3 ± 0.2</td>
<td>2.3 ± 0.4</td>
<td>4.5 ± 0.5</td>
</tr>
<tr>
<td>Others, incl. fatty acids</td>
<td>165 ± 45</td>
<td>101 ± 52</td>
<td>78 ± 22</td>
<td>152 ± 74</td>
<td>49 ± 17</td>
<td>39 ± 2</td>
<td>213 ± 185</td>
</tr>
</tbody>
</table>

### Table 25. Effects of Soman on [3H]Oleate Incorporated into Lipids.
Values after soman (100 μg) exposure are means ± S.E.M. from four experiments.

<table>
<thead>
<tr>
<th>Lipids</th>
<th>Cortex</th>
<th>Thalamus</th>
<th>Hypothalamus</th>
<th>Caudate</th>
<th>Hippocampus</th>
<th>Brain stem</th>
<th>Cerebellum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sphingomyelin</td>
<td>0.3 ± 0.3</td>
<td>0.1 ± 0.1</td>
<td>0.2 ± 0.2</td>
<td>0.1 ± 0.1</td>
<td>0.1 ± 0.1</td>
<td>0.1 ± 0.1b</td>
<td>0.2 ± 0.1</td>
</tr>
<tr>
<td>Phosphatidylcholine</td>
<td>3.6 ± 0.5a</td>
<td>4.8 ± 1.2b</td>
<td>4.3 ± 0.9</td>
<td>3.8 ± 0.7a</td>
<td>2.3 ± 0.4b</td>
<td>3.4 ± 0.4</td>
<td>6.3 ± 0.9</td>
</tr>
<tr>
<td>Phosphatidylinositol</td>
<td>1.1 ± 0.1</td>
<td>1.1 ± 0.4</td>
<td>1.0 ± 0.2</td>
<td>1.1 ± 0.3</td>
<td>0.5 ± 0.2</td>
<td>0.6 ± 0.2</td>
<td>1.5 ± 0.1</td>
</tr>
<tr>
<td>Phosphatidylserine</td>
<td>0.1 ± 0.1</td>
<td>0.3 ± 0.3</td>
<td>0.1 ± 0.1</td>
<td>0.1 ± 0.1</td>
<td>ND</td>
<td>0.1 ± 0.1</td>
<td>0.3 ± 0.1</td>
</tr>
<tr>
<td>Phosphatidylethanolamine</td>
<td>1.2 ± 0.1a</td>
<td>1.9 ± 0.7b</td>
<td>1.8 ± 0.3a</td>
<td>1.0 ± 0.3a</td>
<td>0.4 ± 0.2a</td>
<td>1.5 ± 0.2</td>
<td>2.5 ± 0.3b</td>
</tr>
<tr>
<td>Others, incl. fatty acids</td>
<td>92 ± 58</td>
<td>135 ± 100</td>
<td>79 ± 69</td>
<td>147</td>
<td>31 ± 14</td>
<td>30 ± 18</td>
<td>97 ± 77</td>
</tr>
</tbody>
</table>

*ap < 0.01
bp < 0.05
ND = not detected
Table 26. Biogenic Amine Levels in Canine Brain. Soman (100 μg) was injected after a 30-min control period. In separate experiments, propranolol (0.06 mM) or pimozide (2 μM) was added to the perfusate after a 30-min control period, and soman (100 μg) was injected after propranolol or pimozide treatment. Tissue samples from various regions of canine brain were dissected and analyzed by HPLC. Values are expressed as means (ng/g of tissue) ± S.E.M., with n = 8 for controls and n = 2 for soman, propranolol + soman, and pimozide + soman.

<table>
<thead>
<tr>
<th>Drpamine</th>
<th>Perfused controls</th>
<th>Soman</th>
<th>Propranolol + Soman</th>
<th>Pimozide + Soman</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain stem</td>
<td>87 ± 34</td>
<td>35</td>
<td>29</td>
<td>169</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>18 ± 4</td>
<td>&lt; 4</td>
<td>&lt; 4</td>
<td>&lt; 4</td>
</tr>
<tr>
<td>Cortex</td>
<td>22 ± 3</td>
<td>&lt; 4</td>
<td>&lt; 4</td>
<td>21</td>
</tr>
<tr>
<td>Motor cortex</td>
<td>43 ± 5</td>
<td>27</td>
<td>19</td>
<td>45</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>29 ± 9</td>
<td>&lt; 4</td>
<td>&lt; 4</td>
<td>&lt; 4</td>
</tr>
<tr>
<td>Hypothalamus</td>
<td>320 ± 77</td>
<td>129</td>
<td>178</td>
<td>367</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Noradrenaline</th>
<th>Perfused controls</th>
<th>Soman</th>
<th>Propranolol + Soman</th>
<th>Pimozide + Soman</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain stem</td>
<td>349 ± 53</td>
<td>507</td>
<td>285</td>
<td>582</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>92 ± 12</td>
<td>608</td>
<td>112</td>
<td>298</td>
</tr>
<tr>
<td>Cortex</td>
<td>146 ± 18</td>
<td>572</td>
<td>168</td>
<td>320</td>
</tr>
<tr>
<td>Motor cortex</td>
<td>194 ± 11</td>
<td>586</td>
<td>209</td>
<td>333</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>182 ± 9</td>
<td>460</td>
<td>167</td>
<td>210</td>
</tr>
<tr>
<td>Hypothalamus</td>
<td>1837 ± 459</td>
<td>838</td>
<td>388</td>
<td>783</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Serotonin</th>
<th>Perfused controls</th>
<th>Soman</th>
<th>Propranolol + Soman</th>
<th>Pimozide + Soman</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain stem</td>
<td>441 ± 107</td>
<td>203</td>
<td>293</td>
<td>366</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>8 ± 2</td>
<td>&lt; 4</td>
<td>8</td>
<td>10</td>
</tr>
<tr>
<td>Cortex</td>
<td>102 ± 17</td>
<td>82</td>
<td>64</td>
<td>96</td>
</tr>
<tr>
<td>Motor cortex</td>
<td>176 ± 37</td>
<td>152</td>
<td>93</td>
<td>137</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>394 ± 76</td>
<td>214</td>
<td>212</td>
<td>340</td>
</tr>
<tr>
<td>Hypothalamus</td>
<td>1180 ± 169</td>
<td>803</td>
<td>553</td>
<td>901</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5-Hydroxyindole-3-acetic acid</th>
<th>Perfused controls</th>
<th>Soman</th>
<th>Propranolol + Soman</th>
<th>Pimozide + Soman</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain stem</td>
<td>1712 ± 380</td>
<td>623</td>
<td>889</td>
<td>1850</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>44 ± 9</td>
<td>25</td>
<td>107</td>
<td>24</td>
</tr>
<tr>
<td>Cortex</td>
<td>101 ± 23</td>
<td>58</td>
<td>39</td>
<td>56</td>
</tr>
<tr>
<td>Motor cortex</td>
<td>77 ± 10</td>
<td>66</td>
<td>37</td>
<td>68</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>732 ± 248</td>
<td>242</td>
<td>148</td>
<td>309</td>
</tr>
<tr>
<td>Hypothalamus</td>
<td>1412 ± 217</td>
<td>1076</td>
<td>549</td>
<td>753</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Homovanillic acid</th>
<th>Perfused controls</th>
<th>Soman</th>
<th>Propranolol + Soman</th>
<th>Pimozide + Soman</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain stem</td>
<td>1282 ± 491</td>
<td>346</td>
<td>313</td>
<td>1407</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>86 ± 19</td>
<td>128</td>
<td>174</td>
<td>66</td>
</tr>
<tr>
<td>Cortex</td>
<td>66 ± 15</td>
<td>76</td>
<td>34</td>
<td>54</td>
</tr>
<tr>
<td>Motor cortex</td>
<td>183 ± 37</td>
<td>220</td>
<td>112</td>
<td>227</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>596 ± 124</td>
<td>429</td>
<td>236</td>
<td>430</td>
</tr>
<tr>
<td>Hypothalamus</td>
<td>2210 ± 402</td>
<td>2255</td>
<td>986</td>
<td>2068</td>
</tr>
</tbody>
</table>
Table 27. Biogenic Amine and Metabolite Levels in Canine Brain. α-Methyl-p-tyrosine (α-MPT, 300
mg/l) was added to the perfusate after a 30-min control period. Soman (100 µg) was injected
immediately after α-MPT treatment in the test experiments. Tissue samples from various
regions of canine brain were dissected and analyzed with HPLC. Values are expressed as
means (ng/g of tissue) ± S.E.M., with n = 8 for untreated controls, n = 5 for α-MPT-treated
samples, and n = 4 for α-MPT- and soman-treated samples.

<table>
<thead>
<tr>
<th>Dopamine</th>
<th>Perfused controls</th>
<th>α-MPT</th>
<th>α-MPT + Soman</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain stem</td>
<td>87 ± 34</td>
<td>35 ± 13</td>
<td>59 ± 50</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>18 ± 4</td>
<td>&lt;4</td>
<td>&lt;4</td>
</tr>
<tr>
<td>Cortex</td>
<td>22 ± 3</td>
<td>8 ± 9</td>
<td>&lt;4</td>
</tr>
<tr>
<td>Motor cortex</td>
<td>43 ± 5</td>
<td>16 ± 9</td>
<td>4 ± 4</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>29 ± 9</td>
<td>3 ± 4</td>
<td>15 ± 6</td>
</tr>
<tr>
<td>Hypothalamus</td>
<td>320 ± 77</td>
<td>152 ± 56</td>
<td>227 ± 107</td>
</tr>
<tr>
<td>Norepinephrine</td>
<td>Perfused controls</td>
<td>α-MPT</td>
<td>α-MPT + Soman</td>
</tr>
<tr>
<td>Brain stem</td>
<td>349 ± 53</td>
<td>708 ± 199</td>
<td>544 ± 112</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>92 ± 12</td>
<td>551 ± 190</td>
<td>443 ± 78</td>
</tr>
<tr>
<td>Cortex</td>
<td>146 ± 18</td>
<td>458 ± 172</td>
<td>364 ± 114</td>
</tr>
<tr>
<td>Motor cortex</td>
<td>194 ± 11</td>
<td>418 ± 178</td>
<td>403 ± 92</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>162 ± 9</td>
<td>342 ± 142</td>
<td>292 ± 109</td>
</tr>
<tr>
<td>Hypothalamus</td>
<td>1637 ± 77</td>
<td>793 ± 184</td>
<td>659 ± 112</td>
</tr>
<tr>
<td>Serotonin</td>
<td>Perfused controls</td>
<td>α-MPT</td>
<td>α-MPT + Soman</td>
</tr>
<tr>
<td>Brain stem</td>
<td>441 ± 107</td>
<td>957 ± 332</td>
<td>1167 ± 322</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>8 ± 2</td>
<td>25 ± 10</td>
<td>84 ± 57</td>
</tr>
<tr>
<td>Cortex</td>
<td>102 ± 17</td>
<td>100 ± 21</td>
<td>92 ± 9</td>
</tr>
<tr>
<td>Motor cortex</td>
<td>176 ± 37</td>
<td>125 ± 29</td>
<td>152 ± 36</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>394 ± 76</td>
<td>290 ± 58</td>
<td>477 ± 103</td>
</tr>
<tr>
<td>Hypothalamus</td>
<td>1180 ± 169</td>
<td>1066 ± 145</td>
<td>1061 ± 163</td>
</tr>
</tbody>
</table>
| 5-Hydroxyindole-3-
| acetic acid       | Perfused controls | α-MPT | α-MPT + Soman |
| Brain stem        | 1712 ± 380        | 1900 ± 601 | 2622 ± 514 |
| Cerebellum        | 44 ± 9            | 35 ± 14  | 55 ± 15     |
| Cortex            | 101 ± 23          | 69 ± 13   | 97 ± 15     |
| Motor cortex      | 77 ± 10           | 46 ± 11   | 87 ± 10     |
| Hippocampus       | 732 ± 248         | 239 ± 40  | 357 ± 28    |
| Hypothalamus      | 1412 ± 217        | 1119 ± 238 | 1318 ± 194 |
| Homovanillic acid | Perfused controls | α-MPT | α-MPT + Soman |
| Brain stem        | 1282 ± 491        | 1378 ± 296 | 1721 ± 466 |
| Cerebellum        | 86 ± 19           | 92 ± 39   | 97 ± 21     |
| Cortex            | 66 ± 15           | 97 ± 38   | 70 ± 12     |
| Motor cortex      | 183 ± 37          | 205 ± 48  | 217 ± 14    |
| Hippocampus       | 596 ± 124         | 323 ± 103  | 430 ± 95    |
| Hypothalamus      | 2210 ± 402        | 2293 ± 95  | 2941 ± 428  |
Fig. 1. Diagram of Brain Perfusion System. Artist's sketch of the side view of the isolated brain within the skull is shown in the upper right corner. Perfusate enters via the carotid arteries at the base of the skull. Venous blood returns to the perfusion system via a cannula inserted into the confluence of venous sinuses. Electrodes for EEG monitoring are attached to the bone. Perfusate in the reservoir is continuously oxygenated and filtered.
Fig. 2. Cerebral Vascular Resistance (CVR) and Cerebral Blood Flow (CBF) in Perfused Brain Under Constant Pressure Conditions After OP Treatment. The CVR and CBF are plotted as functions of time after arterial injection of either A) 100 μg of soman or B) 400 μg of sarin. The CVR or CBF at the time of injection is considered to be 100% of the control for each preparation. CVR is the ratio of pressure to flow. Data are expressed as means ± SEM. Average CVR before OP exposure was 169 ± 7 torr·g·min/ml, n = 5. The average CBF before OP exposure was 50.9 ± 1.6 ml/min, n = 5.
Fig. 3. Cerebral Glucose Metabolism (CMR-G) Under Constant Pressure Conditions After OP Exposure. The CMR-G, expressed as a percent of the CMR-G before OP exposure, is plotted as a function of time after administration of A) soman, 100 μg or B) sarin, 400 μg. The vertical bars represent standard errors. Data are means with n = 5. The average glucose consumption before OP exposure was 37.6 ± 2 μmol/100 g-min.
Fig. 4. Cerebral Oxygen Metabolism (CMR-O$_2$) Under Constant Pressure Conditions After OP Exposure. The CMR-O$_2$, expressed as a percent of the CMR-O$_2$ before OP exposure, is plotted as a function of time after administration of A) soman, 100 µg or B) sarin, 400 µg. The vertical bars represent standard errors. Data are means with n = 5, and the average O$_2$ consumption before OP exposure was 205 ± 14 µmol/100 g·min.
Fig. 5. Cerebral Carbon Dioxide Production (CMR-CO₂) Under Constant Pressure Conditions After OP Exposure. The CMR-CO₂, expressed as a percent of the CMR-CO₂ before OP exposure, is plotted as a function of time after administration of A) soman, 100 μg or B) sarin, 400 μg. The vertical bars represent standard errors. Data are means with n = 5, and the average CO₂ production before OP was -273 ± 15 μmol/100 g·min.
Fig. 6. Lactate Efflux from Brain Under Constant Pressure Conditions After OP Exposure. The cerebral metabolic rate for lactate (CMR-L) was determined for perfused brain before OP exposure and at pre-determined intervals for 1 hr after arterial injection of A) soman, 100 µg or B) sarin, 400 µg. Vertical bars represent standard errors. Data are means with n = 5, and the average lactate efflux before OP exposure was 4.6 ± 2.4 µmol/100 g min.
Fig. 7. EEG and Soman Exposure During Constant Pressure Conditions. The EEG was recorded from two electrodes placed over the parietal cortex about 2.5 cm apart. Soman (100 µg) was administered as described in Specific Aim 1. Appropriate scales are shown for each tracing.
Fig. 8. EEG and Sarin Exposure During Constant Pressure Conditions. The EEG was recorded from two electrodes placed over the parietal cortex about 2.5 cm apart. Sarin (400 μg) was administered as described in Specific Aim 1. Appropriate scales are shown for each tracing.
Fig. 9. Regional Cerebral Blood Flow in the Isolated Canine Brain as Determined by \[^{14}C\]lodoantipyrine Infusion and Autoradiography. \[^{14}C\]lodoantipyrine (25 μCi) was infused over a period of 30 sec into the arterial perfusate. Flow was stopped instantly, and the brain was rapidly removed from the cranium, cut into ~1-cm thick slabs, and frozen. Coronal sections (20 μm) were then cut with a cryostat, dried, and subjected to autoradiography. Tissue samples (20-60 mg) from selected brain regions were also collected, weighed, and digested; the radioactivity levels were determined by scintillation spectrometry. Regional CBF was calculated as described in the Method section of Specific Aim 2. The autoradiograms are representative of five control experiments. Four experiments were conducted with soman (data not shown).
Fig. 10. Regional Glucose Metabolism in the Isolated Canine Brain. A) Autoradiograph of coronal brain section from the medial region after infusion of [6-\textsuperscript{14}C]D-glucose as described in the Specific Aim 3. B) Autoradiograph of cerebellar region.
Fig. 11. Relative Protein Synthesis in Brain Regions. Brain sections were washed with TCA to remove free L-[1-14C]leucine and then exposed to photosensitive film. Autoradiographic images obtained represent incorporation of L-[1-14C]leucine into brain proteins.

Fig. 12. Effects of Oligemia on Relative Protein Synthesis in Brain Regions. Oligemia was produced by reducing the pump flow until the EEG tracing showed significant changes in amplitude and frequency, corresponding to a 55% decrease in brain blood flow. Fractional radioactivity is acid insoluble radioactivity expressed as the percent of total radioactivity before TCA washout.
Fig. 13. Autoradiography of L-[1-14C]leucine Uptake and Protein Synthesis in Brain Under Control Perfusion Conditions. Total radioactivity represents the total of free acid-soluble L-[1-14C]leucine and L-[1-14C]leucine incorporated into proteins. After TCA wash, the remaining radioactivity represents synthesized 14C protein. Coronal brain sections from frontal brain, medial brain, and cerebellum were prepared and subjected to autoradiography. Experimental details are described in Specific Aim 4.
Fig. 14. Autoradiography of L-[1-14C]leucine Uptake and Protein Synthesis in Brain Following OP (Soman, 100 µg) Exposure. Total radioactivity represents the total of free acid-soluble L-[1-14C]leucine and L-[1-14C]leucine incorporated into proteins. After TCA wash, the remaining radioactivity represents synthesized 14C protein. Coronal brain sections from frontal brain, medial brain, and cerebellum were prepared and subjected to autoradiography. Experimental details are described in Specific Aim 4.
Fig. 15. Ch Efflux from A) Soman- and B) Sarin-treated Perfused Canine Brain. Arterial and venous perfusate samples were collected and analyzed for Ch content using a gas chromatography-mass spectrometry method. Ch efflux was then calculated from the arteriovenous difference as described in Specific Aim 6. The data for each treatment are from three experiments, and the vertical bars represent the S.E.M. values.
Fig. 16. Brain Ch Metabolism. Ch metabolism in brain involves at least six biochemical reactions. Equilibration of plasma Ch (Chp) and extracellular Ch (Che) occurs via the Ch transporter (reaction 1) of the endothelial cell. Transport into neurons (reaction 2) occurs by a carrier-mediated process. ACh synthesis by Ch acetyltransferase (reaction 3), ACh release (reaction 4), and degradation by AChE (reaction 5) are illustrated. Synthesis of intracellular Ch (Chi) may also occur from endogenous substrates (reaction 6).
Fig. 17. Possible Pathways and Enzymes Involved in Choline Production. The numbers in the figure refer to enzymes as follows: 1, phospholipase D; 2, phospholipase A₂ or A₁; 3, lysophospholipase D; 4, lysophospholipase; 5, glycerophosphocholine phosphodiesterase; 6, glycerophosphocholine-cholinephosphodiesterase; 7, phospholipase C; 8, alkaline phosphatase; 9, sphingomyelinase.
Fig. 18. Effects of Triton X-100 on the Hydrolytic Activity of Dog Brain Microsomal Phospholipase D. Incubations were carried out as described in Table 17. Triton X-100 was added to the reaction mixtures before the addition of enzyme. Data are the averages of two determinations, and control activity in the absence of Triton X-100 is considered to be 100%.
Fig. 19. Positional Distribution of Labeled Fatty Acids Incorporated into Phosphatidylcholine. Phosphatidylcholine from the lipid extracts was isolated using thin-layer chromatography (TLC) and was subjected to phospholipase A2 (*Ophiophagus hannah*) hydrolysis. The radioactivity levels associated with lysoPC (sn-1) and the free fatty acid released (sn-2) were determined after separation by TLC (silica gel H). The solvent for TLC was chloroform:methanol:water (65:35:5).
Fig. 20. Comparison of the Amounts of Choline (Ch) and Phosphocholine Released by Cerebral Cortex Synaptosomes Prepared from Control Dog Brains with the Amounts Released by Synaptosomes from Organophosphate-treated Brains. The perfusion experiments and assay procedures were carried out as described in Specific Aim 9. Values are the means ± S.D. of four separate experiments conducted in triplicate.
Fig. 21. Effects of *In Vitro* Addition of Soman on Choline (Ch) and Phosphocholine Release by Control Cerebral Cortex Synaptosomes. Various amounts of soman were added to incubation mixtures. The assay procedure was conducted as described in Specific Aim 9. Values are the means ± S.D. of three separate experiments conducted with four replicates.
Fig. 22. Effects of Physostigmine on Choline (Ch) and Phosphocholine Release by Synaptosomes. Various amounts of physostigmine were added to incubation mixtures as described in Specific Aim 9. Values are the means ± S.D. of three separate experiments conducted in triplicate.
Fig. 23. Effects of α-Methyl-p-tyrosine on Cerebral Metabolism Rates (CMRs). Isolated brains were perfused for a 30-min control period. Then α-methyl-p-tyrosine (300 mg/L) was added to the perfusate and is indicated in the figure as 0 min. A) without OP and B) with soman treatment (100 μg). Standard error a, b, c <10% in A) n=5 and <12% in B) n=4. Key: CMR-Glucose (--○--); CMR-O_{2} (---); uMR-CO_{2} (----).
Fig. 24. Effects of Soman on Cerebrovascular Resistance (CVR) in Brains Pretreated with Specific Antagonists. Key: scopolamine (-•-); propranolol (-○-); mecamylamine (-□-); pimozide (-○-); cimetidine (-●-). After a 30- to 45-min control period, the specific antagonist was added to the perfusate. Soman (100 μg) was injected 15 min later, and cerebrovascular responses were calculated. The control value (100%) was 180±19 torr·g·min/ml. The data points are means of two experiments for propranolol and cimetidine and three experiments, in which the standard error averaged 8%, for scopolamine, mecamylamine, and pimozide.
Fig. 25. Effects of Soman on Cerebral Metabolism Rates (CMRs) in Brains Pretreated with Specific Antagonists. Key: scopolamine (○); mecamylamine (●); pimozide (□); propranolol (▲); cimetidine (◆). Control values expressed in μmol/100 g·min were A, CMR-Glucose, 33±1; B, CMR-Oxygen, 171±4; and C, CMR-Carbon Dioxide, 247±17. The data points are means of two experiments for propranolol and cimetidine and three experiments, in which standard error averaged 10%, for scopolamine, mecamylamine, and pimozide.
Fig. 26. Properties of PA Phosphatase in Synaptic Membranes of Canine Cerebral Cortex. Results shown are those of typical experiments. A) Time course of the enzyme reaction (150 µg of synaptic protein/reaction mixture); B) DAG formation as a function of synaptic protein concentration curve (20-min incubation); C) Effects of DL-propranolol on PA phosphatase activity (150 µg of protein/reaction mixture, 20-min incubation); D) Inhibition of nonradioactive-labeled exogenous PA on apparent enzyme activity (150 µg of protein/reaction mixture, 20-min incubation).
Fig. 28. Effects of Various Compounds on Muscarinic Stimulation of $[^3]$HPA and $[^3]$HDAG Generation in Synaptic Membranes. Radioactive PC, 1-palmitoyl-2-[(9,10-$[^3]$H)palmitoyl-L-3-phosphorylcholine, was used as the exogenous substrate. The incubation conditions and assay procedures are as described in Specific Aim 13, except that GTP$_y$S was omitted in the control and 0.3 mM muscarine was present in tests 3 to 7. The following compounds were added to the incubation mixtures where indicated: zinc, 2 mM; pCMB, 0.5 mM; DL-propranolol, 3 mM; and unlabeled PA, 0.2 mM. Values are the means ± S.D. of four separate experiments conducted in duplicate.
Brain Vascular Response After Acetylcholinesterase Inhibition. In an experiment with physostigmine alone, the compound was added to the perfusate after a 30-min control period. In two other experiments, scopolamine preceded physostigmine, and soman (100 μg) was added at 45 min.
Fig. 30. Effects of Physostigmine on Cerebral Metabolism Rates (CMRs) in Brains Pretreated with Scopolamine. Scopolamine (1.3 μM) was added to the perfusate before addition of 0.03 mM physostigmine. Results are the averages of two experiments. Key: Physostigmine (○); Physostigmine + Scopolamine (●). Control values (100%) expressed in μmol/100 g-min were A) CMR-Glucose, 43±1; B) CMR-Oxygen, 210±13; and C) CMR-Carbon Dioxide, 330±10.
Fig. 31. Cerebrovascular Resistance (CVR) After Soman Treatment and After Soman Preceded by Nitro Blue Tetrazolium. Data are averages of two control and two test experiments.
REFERENCES


List of Publications

Supported by U. S. Army Medical Research and Development Command
Contract No. DAMD17-82-C-2136 (15 April 1982 - 20 October 1985) and
Contract No. DAMD17-86-C-6036 (21 October 1985 - 20 July 1990)

   transport during altered metabolic states. Oxygen Transport to Tissue-VI (Bruley, D., Bicher, H.

   blood utilizing a sensitive gas chromatography—mass spectrometry method. J. Chromatogr.
   324:163-172.

   brain and blood samples by capillary gas chromatography—mass spectrometry. J. Chromatogr.


5. Singh, A. K., Zeleznikar, R. J., Jr., and Drewes, L. R. (1986) Protection from quinidine or
   physostigmine against in vitro inhibition by sarin of acetylcholinesterase activity. Life Sci.
   38:165-172.


   phosphatidylcholine phospholipase D in canine brain. J. Biol. Chem. 264:21720-21724.

8. Qlan, Z. and Drewes, L. R. (1990) A novel mechanism for acetylcholine to generate

   of microsomal phospholipase D activity of canine cerebral cortex. J. Neurochem. 54:1632-
   1638.

10. Qlan, Z. and Drewes, L. R. (1991) Cross-talk between receptor-regulated phospholipase D and

---

1 Abstracts presented at scientific meetings are not included.
List of Personnel Supported by U. S. Army Medical Research and Development Command
Contract No. DAMD17-86-C-6036 (21 October 1985 - 20 July 1990)

Lester R. Drewes, Ph.D.
Padala V. Reddy, Ph.D.
David Z. Gerhart, Ph.D.
Margaret Broderius, M.A.
Borislav Banjac, M.D.
Steven Olson, B.S.
Zhuo Qian (granted doctorate degree April 1990)
Karrin Helgerson (graduate student one quarter)
Quynh Nguyen (summer worker)
Sandra Geegan (summer worker)
Deborah Pomroy-Petry
Gary Madison
William Bailey
Otmar Kloiber (visiting postdoctoral research associate)
Undergraduate student workers (dishwashing)
DISTRIBUTION LIST

1 copy: Commander
US Army Medical Research and Development Command
ATTN: SGRD-RMI-S
Fort Detrick
Frederick, MD 21702-5012

5 copies: Commander
US Army Medical Research and Development Command
ATTN: SGRD-PLE
Fort Detrick
Frederick, MD 21702-5012

2 copies: Administrator
Defense Technical Information Center
ATTN: DTIC-FDAC
Cameron Station
Alexandria, VA 22314

1 copy: Superintendent
Academy of Health Sciences, US Army
ATTN: AHS-COM
Fort Sam Houston, TX 78234

1 copy: Dean, School of Medicine
Uniformed Services University of the Health Sciences
4301 Jones Bridge Road
Bethesda, MD 20014